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Pain serves as a warning for the body of potential damage from a noxious stimulus 
and allows for appropriate measures to avoid irreversible damage. Physiological 
pain is directly correlated to the noxious stimulus, i.e. if the stimulus persists, the 
pain persists and if the stimulus dissipates, the pain dissipates. Neuropathic pain, 
however, is a maladaptive response to lesions arising from the nervous system fol-
lowing trauma (e.g. accident, surgical), toxicity (e.g. cisplatin) or systemic disease 
(e.g. diabetes mellitus, sarcoidosis). This type of pain is often chronic in nature and 
is no longer correlated to the initial stimulus, i.e. the pain persists after the initial 
stimulus has dissipated or the pain is experienced in an exaggerated form.1 These ex-
aggerated pain perceptions include thermal and mechanical allodynia (a non-painful 
stimulus is perceived as painful, e.g. cold intolerance or the rubbing of clothes) and 
hyperalgesia (a painful stimulus is perceived as more painful).2 Regardless of the 
underlying cause of chronic neuropathic pain, this disease causes great disability in 
everyday life and often results in the inability to maintain a job or in reduced social 
participation.3 In addition, it is a disease that is difficult to treat with conventional 
pain medication and is often empirically treated with antidepressants and antiepi-
leptics4 with variable efficacy and often intolerable side effects. The mechanism of 
the development of neuropathic pain, regardless of the underlying cause, is diverse 
and includes intertwined and converging pathways such as inflammation, loss of 
peripheral nerve fibers, N-methyl-D-aspartate (NMDA) receptor upregulation and 
glia involvement.5 Targeting either of these targets has provided ample evidence of 
neuropathic pain relief or disease modification suggesting involvement of one or 
more of these targets.
Inflammation
The body responds to pathogens or tissue damage with an inflammatory reaction, 
aimed at preventing infection with a pathogen, or the removal of debris after 
damage. Tissue damage to a peripheral nerve induces an inflammatory reaction 
characterized by the release of inflammatory mediators, such as cytokines (e.g. inter-
leukins, tumor necrosis factor α: TNF-α)6-8 that recruit more immune cells or destroy 
damaged cells. These cytokines are released by residing and recruited immune cells 
(e.g. macrophages, T-cells) or support cells (e.g. Schwann cells). Alternatively, many 
systemic diseases such as diabetes mellitus or sarcoidosis induce local or systemic 
inflammatory processes. Local inflammatory reactions after nerve damage have 
their effect in the peripheral nerve by providing an environment of constant noxious 
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stimuli resulting decreased thresholds for signal transduction (i.e. decreased depo-
larization thresholds) resulting in enhanced pain signaling. This barrage of signals 
induces central sensitization in the spinal cord9, lowering the threshold at which 
neurons depolarize, causing an altered perception of pain10. Alternatively peripheral 
nervous system inflammation can result in retrograde transport of TNF-α to the 
central nervous system expanding the inflammatory reaction to the central nervous 
system, resulting in cytokine release in the dorsal horn11. Alternatively the central 
nervous system can become inflamed either by retrograde transport of cytokines, 
like TNF-α, or local inflammatory reaction12 by resident nervous system immune cells 
(i.e. microglia) or support cells (i.e. astrocytes)13, which will be discussed in the fol-
lowing paragraphs.
Microglia
Microglia are the resident macrophages of the central nervous system and over 
the years, this cell type has been correlated to neuropathic pain states arising from 
various types of lesions14 and has become an interesting target for pharmacological 
treatment15 of neuropathic pain. It has been shown that these cells become activated 
by various inflammatory cytokines (TNF-α, interleukins)16 and chemokines (e.g. che-
mokine (C-C motif) ligand 2: CCL2, also known as macrophage chemoattractant pro-
tein 1: MCP-1)17;18, cytokines and chemokines that are released after nerve damage. 
Their phenotype changes from resting (i.e. ramified with a small soma) to activated 
(i.e. amoeboid, retracted rami and a thickened soma)19. Additionally, intracellular 
signaling pathways such as the P38 mitogen activated protein kinase (P38-MAPK)20, 
janus kinase-signal transducer and activator of transcription (JAK-STAT)21 involved in 
the regulation of transcription factors for, for instance the production of cytokines, 
become phosphorilyzed increasing cytokine production and release, creating a self-
sustained inflammatory process contributing to neuropathic pain.
Astrocytes
Astrocytes are the support cells of the central nervous system and make up for the 
blood to central nervous system barrier. After peripheral nerve injury, astrocytes are 
activated in the spinal cord, in response to inflammatory mediators (e.g., TNF-α)22. 
Astrocyte activation may manifest as the phosphorylation of several intracellular 
signaling pathways and proliferation of these cells (i.e. astrogliosis)23. Activation 
of the intracellular signaling pathways results in the production of inflammatory 
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cytokines and chemokines (e.g., interleukin-1β: IL-1β and MCP-1)22. These mediators 
can lead to enhanced pain states by acting at both presynaptic sites on primary af-
ferents and post-synaptic sites on dorsal horn neurons causing increased excitation 
and decreased inhibition of spinal cord nociceptive neurons24.
Loss of peripheral small nerve fibers
Systemic diseases (diabetes mellitus and sarcoidosis), critical illness neuropathy (due 
to sepsis or multi organ failure resulting in prolonged intensive care unit stay) as 
well as pain syndromes such as fibromyalgia are associated with the loss of the 
small sensory fibers in the epidermis of the skin: small fiber neuropathy (SFN) and 
subsequent neuropathic pain25-28. SFN may result from a continuous inflammatory 
state of the peripheral nerves innervating the skin with infiltration of immune cells, 
cytokine production and degeneration of the nerves and thereby contributing to 
sensory deficits, such as dysesthesia or pain.
The N-methyl-d-aspartate receptor
Glutamate is the central nervous system’s major neurotransmitter that acts on the 
NMDA receptor. This receptor consists of two obligatory NR1 subunits that can be 
coupled to either two NR2A through D or two NR3A through B subunits to yield 
a functioning receptor (e.g. NR12/NR2A2 configuration). Activation of the NMDA 
receptor by glutamate results in the removal of the physical magnesium ion block 
that seals the receptor, resulting in an influx of calcium ions, allowing depolariza-
tion of the nerve and signal transduction (reviewed in29). In neuropathic pain states, 
the NMDA receptor becomes upregulated in the dorsal horn, increasing synaptic 
transmission and contributing to exaggerated pain states such as allodynia and 
hyperalgesia30. The NR2A containing NMDA receptors are ubiquitously distributed 
throughout the brain and spinal cord, while the NR2B containing NMDA receptors 
are restricted to areas specific for pain signaling, i.e. laminae I and II of the spinal 
cord dorsal horn and thalamus31. The NR2B receptor subunit has been positively cor-
related to various pain states, including inflammatory32 and neuropathic pain31.
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The innate repair receptor
Erythropoietin (EPO) is involved in the genesis of red blood cells. Hypoxia induces 
stabilization of hypoxia inducible factor 1α (HIF-1α) resulting in the transcription 
of EPO. EPO, in turn, activates the erythropoietin receptor dimer (EPOR2) present 
on hematopoietic cells, resulting in increased survival of erythroblasts. Alternatively, 
erythropoietin possesses anti-inflammatory properties by acting as a natural antago-
nist of TNF-α through a different receptor configuration: EPOR-β-common-receptor 
(EPOR-βcR), termed the innate repair receptor (IRR) (reviewed in33). This βcR consist 
of the β chains of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/
interleukin 3/interleukin 5 receptors, commonly utilized by type 1 cytokines involved 
in the innate and acquired immunity (reviewed in34). Activation of the IRR by endog-
enous or recombinant EPO results in attenuation of the immune response, increased 
survival of tissue, and enhanced regeneration, thus tissue protection and tissue 
repair35-38.
Treatment
Currently, chronic neuropathic pain is treated according to the following algorithm 
with variable results. Current guidelines recommend pharmacological treatment 
with antidepressants (amitryptiline) followed by antiepileptics (carbamazepine and 
gabapentin), opioids (tramadol) or topical capsaicine4. Treatment with these drugs 
is often inadequate resulting in insufficient pain relief and is accompanied by side 
effects that may be severe and intolerable.
Treatment with NMdAR antagonists
Over the past few years, ketamine has gained interest as a pharmacological treat-
ment for chronic neuropathic pain39. A relatively short treatment paradigm induces 
long-term relief of neuropathic pain symptoms in complex regional pain syndrome 
type 1 patients40. The treatment with ketamine, however coincides with undesir-
able and intolerable side effects, such as nausea, dizziness, anxiety and psychosis. 
Ketamine is a non-selective NMDAR antagonist, targeting all the NMDAR subtypes, 
some of which may be involved in the observed side effects. It is unclear, however, 
if ketamine or its active metabolite norketamine is responsible for the pain relief 
and/or induced side effects. NMDA receptor antagonists that are specific for the 
more pain specific NR2B subunit are being developed, one of which is Traxoprodil 




Rationale for treatment with ARA 290
Inflammation is an important part of the mechanism in the onset and maintenance 
of neuropathic pain. Counteracting the inflammatory response with EPO has proven 
to be effective in several types of injury, including injuries to the nervous system. 
However, EPO induces hematopoiesis as an undesired effect to the tissue protective 
and regenerative properties. Therefore, derivatives of EPO that are tissue protective 
but not hematopoietic have been developed42, one of which is the small helix B 
peptide ARA 290. This linear 11-amino acid peptide is a representation of the amino 
acids of EPO interacting with the EPOR and has tissue protective effects equal to EPO, 
but without hematopoietic effects43. Treatment with ARA 290 may be effective in 
treating or preventing neuropathic pain after nerve injury induced neuropathic pain.
Aims
The experiments described in this thesis were designed to investigate:
• The treatment of neuropathic pain with ARA 290
• The treatment of neuropathic pain with NMDAR antagonists ketamine, norket-
amine and Traxoprodil
• The overlapping pathways of ketamine and ARA 290 in the treatment of neuro-
pathic pain
• The feasibility of CCM as an objective measure of small fiber neuropathy in 
sarcoidosis patients with neuropathic pain
• The effect of treatment with ARA 290 on pain and nerve fiber density in patients 
with sarcoidosis and painful small fiber neuropathy




























 1. Costigan M, Scholz J, Woolf CJ: Neuropathic Pain: A Maladaptive Response of the Ner-
vous System to Damage. Annual Review of Neuroscience 2009; 32: 1-32
 2. Baron R, Binder A, Wasner G: Neuropathic pain: diagnosis, pathophysiological mecha-
nisms, and treatment. The Lancet Neurology 2010; 9: 807-19
 3. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D: Survey of chronic pain in Eu-
rope: Prevalence, impact on daily life, and treatment. European Journal of Pain 2006; 10: 
287-333
 4. Attal NA: EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 
revision. European journal of Neurology 2010; 17: 1113-e88
 5. Kuner R: Central mechanisms of pathological pain. Nat Med 2010; 16: 1258-66
 6. Kim CF, Moalem-Taylor G: Detailed characterization of neuro-immune responses follow-
ing neuropathic injury in mice. Brain Research 2011; 1405: 95-108
 7. Liou JT, Liu FC, Mao CC, Lai YS, Day YJ: Inflammation confers dual effects on nociceptive 
processing in chronic neuropathic pain model. Anesthesiology 2011; 114: 660-72
 8. Üçeyler N, Sommer C: Cytokine regulation in animal models of neuropathic pain and in 
human diseases. Neuroscience Letters 2008; 437: 194-8
 9. Ikeda H, Kiritoshi T, Murase K: Contribution of microglia and astrocytes to the central 
sensitization, inflammatory and neuropathic pain in the juvenile rat. Molecular Pain 
2012; 8: 43
 10. Lennertz RC, Kossyreva EA, Smith AK, Stucky CL: TRPA1 Mediates Mechanical Sensitiza-
tion in Nociceptors during Inflammation. PLoS ONE 2012; 7: e43597
 11. Shubayev VI, Myers RR: Axonal transport of TNF-a in painful neuropathy: distribution of 
ligand tracer and TNF receptors. Journal of Neuroimmunology 2001; 114: 48-56
 12. LaCroix-Fralish ML, Tawfik VL, Tanga FY, Spratt KF, DeLeo JA: Differential spinal cord 
gene expression in rodent models of radicular and neuropathic pain. Anesthesiology 
2006; 104: 1283-92
 13. Tenorio G, Kulkarni A, Kerr BJ: Resident glial cell activation in response to perispinal 
inflammation leads to acute changes in nociceptive sensitivity: Implications for the 
generation of neuropathic pain. Pain 2013; 154: 71-81
 14. Colburn RW, Rickman AJ, DeLeo JA: The Effect of Site and Type of Nerve Injury on Spinal 
Glial Activation and Neuropathic Pain Behavior. Experimental Neurology 1999; 157: 
289-304
 15. Aldskogius H: Regulation of microglia - potential new drug targets in the CNS. Expert 
Opinion on Therapeutic Targets 2001; 5: 655-68
 16. Raghavendra V: Complete Freunds adjuvant-induced peripheral inflammation evokes 
glial activation and proinflammatory cytokine expression in the CNS. European journal 
of neuroscience 2004; 20: 467-73
 17. Hinojosa A, Garcia-Bueno B, Leza J, Madrigal J: CCL2/MCP-1 modulation of microglial 
activation and proliferation. Journal of neuroinflammation 2011; 8: 77
 18. Van Steenwinckel J, Reaux-Le Goazigo A, Pommier B, Mauborgne A, Dansereau MA, 
Kitabgi P, Sarret P, Pohl M, Mélik Parsadaniantz S: CCL2 Released from Neuronal Synaptic 
15
Introduction
Vesicles in the Spinal Cord Is a Major Mediator of Local Inflammation and Pain after 
Peripheral Nerve Injury. The Journal of Neuroscience 2011; 31: 5865-75
 19. Streit WJ, Walter SA, Pennell NA: Reactive microgliosis. Progress in Neurobiology 1999; 
57: 563-81
 20. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, 
Catalano R, Ying F, Protter AA, Scott B, Yaksh TL: Activation of p38 mitogen-activated 
protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain 
processing. Journal of Neurochemistry 2003; 86: 1534
 21. Dominguez E, Rivat C, Pommier B, Mauborgne A, Pohl M: JAK/STAT3 pathway is activated 
in spinal cord microglia after peripheral nerve injury and contributes to neuropathic 
pain development in rat. Journal of Neurochemistry 2008; 107: 50-60
 22. Gao YJ, Zhang L, Samad OA, Suter MR, Yasuhiko K, Xu ZZ, Park JY, Lind AL, Ma Q, Ji RR: 
JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitiza-
tion and neuropathic pain. The Journal of Neuroscience 2009; 29: 4096-108
 23. Tsuda M, Kohro Y, Yano T, Tsujikawa T, Kitano J, Tozaki-Saitoh H, Koyanagi S, Ohdo S, Ji 
RR, Salter MW, Inoue K: JAK-STAT3 pathway regulates spinal astrocyte proliferation and 
neuropathic pain maintenance in rats. Brain 2011; 134: 1127-39
 24. Wang W, Wang W, Mei X, Huang J, Wei Y, Wang Y, Wu S, Li Y: Crosstalk between spinal 
astrocytes and neurons in nerve injury-induced neuropathic pain. PLoS ONE 2009; 4: 
e6973
 25. Hoitsma E, Marziniak M, Faber CG, Reulen JPH, Sommer C, De Baets M, Drent M: Small 
fibre neuropathy in sarcoidosis. The Lancet 2002; 359: 2085-6
 26. Khan S, Zhou L: Characterization of non-length-dependent small-fiber sensory neuropa-
thy. Muscle & Nerve 2012; 45: 86-91
 27. Üceyler N, Zeller D, Kahn AK, Kewenig S, Kittel-Schneider S, Schmid A, Casanova-Molla 
J, Reiners K, Sommer C: Small fibre pathology in patients with fibromyalgia syndrome. 
Brain 2013; 136: 1857-67
 28. Latronico N, Filosto M, Fagoni N, Gheza L, Guarneri B, Todeschini A, Lombardi R, Pado-
vani A, Lauria G: Small Nerve Fiber Pathology in Critical Illness. PLoS ONE 2013; 8: e75696
 29. Kalia LV, Kalia SK, Salter MW: NMDA receptors in clinical neurology: excitatory times 
ahead. The Lancet Neurology 2008; 7: 742-55
 30. Labombarda F, Coronel MF, Villar MJ, Nicola AFD, González SL: Neuropathic pain and 
temporal expression of preprodynorphin, protein kinase C and N-methyl-D-aspartate 
receptor subunits after spinal cord injury. Neuroscience Letters 2008; 447: 115-9
 31. Wu LJ, Zhuo M: Targeting the NMDA receptor subunit NR2B for the treatment of neuro-
pathic pain. Neurotherapeutics 2009; 6: 693-702
 32. Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT: Gene knockdown with intrathecal siRNA 
of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene 
Ther 2004; 12: 59-66
 33. Brines M, Cerami A: Emerging biological roles for erythropoietin in the nervous system. 
Nat Rev Neurosci 2005; 6: 484-94
 34. Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, Bonder CS, Lopez AF, 
Parker MW: The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to 
initiation of signaling. Immunological Reviews 2012; 250: 277-302
Chapter 1
16
 35. Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, 
Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P: Erythro-
poietin both protects from and reverses experimental diabetic neuropathy. Proceedings 
of the National Academy of Sciences of the United States of America 2004; 101: 823-8
 36. Brines M, Ghezzi P, Keenan S, Agnello D, De Lanorelle N, Cerami A: Erythropoietin 
crosses the blood-brain barrier to protect against experimental brain injury. Proceedings 
of the National Academy of Sciences USA 2000; 97: 10531-6
 37. Campana WM, Li X, Shubayev VI, Angert M, Cai K, Myers RR: Erythropoietin reduces 
Schwann cell TNF-α, Wallerian degeneration and pain-related behaviors after peripheral 
nerve injury. European journal of Neuroscience 2006; 23: 617-26
 38. Jia H, Feng X, Li W, Hu Y, Zeng Q, Liu J, Xu J: Recombinant Human Erythropoietin Attenu-
ates Spinal Neuroimmune Activation of Neuropathic Pain in Rats. Annals of Clinical and 
Laboratory Science 2009; 39: 84-91
 39. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A: Ketamine for the treatment 
of chronic non-cancer pain. Expert Opinion on Pharmacotherapy 2010; 11: 2417-29
 40. Sigtermans M, van Hilten JJ, Bauer M, Arbous M, Marinus J, Sarton E, Dahan A: Ketamine 
produces effective and long-term pain relief in patients with Complex Regional Pain 
Syndrome Type 1. Pain 2009; 145: 304-11
 41. Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti FS, Nagahisa A: Anti-
nociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. British 
Journal of Pharmacology 1997; 122: 809-12
 42. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, 
Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup 
L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand 
C, Xie Qw, Coleman T, Cerami A, Brines M: Derivatives of erythropoietin that are tissue 
protective but not erythropoietic. Science 2004; 305: 239-42
 43. Non-erythropoietic tissue-protective peptides derived from erythropoietin: 
WO2009094172. Expert Opinion on Therapeutic Patents 2010; 20: 715-23
Chapter 2
Assessment of allodynia relief by tissue-
protective molecules in a rat model of nerve 
injury induced neuropathic pain
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Tissue-protective molecules in neuropathic pain
Introduction
Neuropathic pain is a chronic disease with a mechanism that is diverse and not yet 
completely understood. It is characterized by allodynia (increased sensitivity to a 
non-painful stimulus) and hyperalgesia (increased sensitivity to a painful stimulus) 
of either mechanical (touch or pressure) or thermal (cold or heat) origin1. These pain 
states can become disabling to patients resulting in reduced social participation 
and inability to maintain a job2. Up until now, pharmacological (i.e. treatment with 
opioids, NSAIDS, antidepressants) or non-pharmacological treatment (spinal cord 
stimulation, physiotherapy) of neuropathic pain with has shown limited efficacy. 
The mechanism leading to neuropathic pain includes central and peripheral sen-
sitization, neuronal plasticity and neurogenic inflammation. These elements share 
intrinsic pathways that ultimately lead to altered nociception3,4. In animal experi-
ments erythropoietin (EPO) has shown to cross the blood brain barrier and to be 
neuroprotective5,6. Additionally it has shown to be able to alleviate neuropathic pain 
following nerve injury presumably due to the tissue protective effects of EPO, result-
ing in increased survival of neuronal cells and reduced inflammation of the nervous 
system. In 2003, Campana and Meyers showed that treating rats with recombinant 
human EPO (rhEPO) following L5 spinal nerve crush (SNC) alleviated allodynia and 
decreased the time to recover from SNC, whereas animals in the vehicle treatment 
group showed a higher degree of allodynia and a longer time to reach recovery. This 
effect was supported by the observation that rhEPO prevented apoptosis of dorsal 
root ganglion (DRG) cells and induction of phosphorylated JAK-2, a molecule when 
phosphorylated induces apoptosis7. In addition to the peripheral effects observed, 
rhEPO showed a central effect by protecting neurons in the spinal cord in a rat 
model of neuropathic pain. Following L5 proximal nerve root crush, rhEPO treated 
animals showed less allodynia when compared to vehicle treated animals which was 
accompanied by less apoptosis of neurons in both the ventral and dorsal horns of 
the spinal cord and identification of the EPO receptor (EPOR) and lower levels of 
TNF-α in spinal cord neurons8. A study performed by Keswani et al.9 assessed the role 
of the EPOR and showed neuroprotective effects in both in vitro and in vivo models. 
They showed in vitro that EPO is being produced by neurons and Schwann cells and 
that the EPOR is being expressed predominantly by neurons and was not restricted 
to the soma of the neuron. Additionally they showed beneficial effects of EPO in 
neurotoxicity. In an animal model of nerve damage they showed that EPO mRNA 
was increased in dorsal root ganglia (DRG) as well as in the sciatic nerve, while the 
EPOR mRNA was increased solely in the DRG . Additionally, in acrylamide induced 
neuropathy, EPO protected denervation of the skin, improved motor function in the 
grip strength test and prevented hyperalgesia in the paw withdrawal test. The role 
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of EPO and TNF-α in neuropathic pain states was again explored by Campana et 
al.10 in a chronic constriction injury model (CCI). They showed in animals with nerve 
injury that TNF-α was increased in injured nerves proximal to the injury and that 
rhEPO was able to reduce pain behavior. The induction of TNF-α was counteracted by 
rhEPO resulting in lower levels of the cytokine. Additionally, Jia et al.11 showed that 
treating animals that had received a L5 spinal nerve transection with rhEPO showed 
decreased mechanical and thermal hyperalgesia with respect to control animals. 
This coincided with less microglia activation, decreased pro-inflammatory cytokine 
production (IL-1, 6 and TNF-α), increased anti-inflammatory cytokine production 
(IL-10) and decreased the expression of NF-κB, a signaling molecule important in 
pain processing. Both the expression of the cytokines and NF-κB was shown to be 
dose dependent12. Also EPO derivatives devoid of erythropoietic properties show 
these effects. In a model of neuropathic pain where nucleus pulposus was applied 
to the DRG of animals EPO and asialo-EPO, an EPO derivative without erythropoietic 
properties, decreased mechanical allodynia and decreased levels of phospho-P38, 
a signaling molecule important in pain processing and inflammation, and TNF-α13. 
The EPO-derivative ARA 290, an 11-amino-acid peptide mimicking the 3-dimensional 
structure of B helix of EPO14 has shown to be able to prevent the onset of allodynia in 
animals with nerve injury. In a rat model of neuropathic pain where animals received 
a spared nerve injury (SNI), a short treatment paradigm resulted in a delay of onset 
of allodynia, while the same paradigm complemented with a once per week main-
tenance treatment prevented the onset of allodynia for the duration of 15 weeks. It 
was shown that ARA 290 works through the EPOR-β-common-receptor (EPOR-βcR) 
complex. Mice devoid of the βcR showed no response to ARA 290, whereas wild type 
mice showed reduced levels of allodynia15. EPO and its derivatives show efficacy in 
neuropathic pain making these molecules promising agents as treatment modalities.
Materials
Induction of the neuropathic pain model: spared nerve injury
1. Female Sprague-Dawley rats, 8 weeks old
2. Ethanol 70% and wipes
3. Absorbing under pad
4. Syringe equipped with a 25G needle containing buprenorphin
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9. Gauzes
10. Small cotton swabs
11. 5-0 silk sutures
12. 4-0 nylon sutures
13. Standard pattern forceps, straight (Fine Science Tools, Heidelberg, Germany)
14. Metzenbaum scissors, straight 14.5 cm (Fine Science Tools, Heidelberg, Germany)
15. Bonn micro forceps, smooth 7 cm (Fine Science Tools, Heidelberg, Germany)
16. Vannas spring scissors, straight 4 mm blade (Fine Science Tools, Heidelberg, 
Germany)
17. Student iris scissors, straight 11.5 cm (Fine Science Tools, Heidelberg, Germany)
18. Halsey needle holder, smooth (Fine Science Tools, Heidelberg, Germany)
Assessment of pain: Tactile allodynia
1. Plateau with grid (UGO Basile, Varese, Italy)
2. Perspex cages with lid (UGO Basile, Varese, Italy)
3. Semmes-Weinstein monofilaments (North Coast Medical Inc., San Jose, CA, USA)
Assessment of pain: Cold allodynia
1. Syringe (1 ml)
2. Needle 25G, bent 90°
3. Acetone, analytical grade
Treatment with ARA 290
1. PBS
2. ARA 290 (Araim Pharmaceuticals, Ossining, NY, USA)
3. Syringe, 1 ml equipped with 25G needle
Methods
Induction of the neuropathic pain model: spared nerve injury
1. Sterilize the instruments, for instance with a table top sterilizer.
2. Disinfect the surgical area of the table with 70% ethanol.
3. Place an absorbing under pad on the surgical area and place the surgical tools.
4. Fifteen minutes prior to surgery, administer a single dose of 0.01 to 0.05 mg/kg 
buprenorphin subcutaneously in the scruff of the neck for the relief of acute 
post operative pain.
5. To start surgery, induce and maintain anesthesia (6% induction, 3% maintenance 
in medicinal air mixture).
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6. Place animal on the stomach and shave the leg that is going to be operated on.
7. Disinfect the shaved hind leg and direct and fixate it with a piece of tape towards 
yourself.
8. Draw an imaginary line between the patella and the crest of the ilium and locate 
the center of the line. This is approximately where the trifurcation of the nerve 
is situated (Figure1A).
9. Lift the skin of the hind leg with the standard pattern forceps.
10. Make a small incision with the Metzenbaum scissors perpendicular to the imagi-
nary line 1 cm distally from where the trifurcation is supposed to be.
11. Insert the Metzenbaum scissors horizontally and closed into the small incision 
between the skin and the muscle layer and detach the skin from the underlying 
tissue by opening the scissors and carefully withdrawing it. Repeat this proce-
dure until the skin is sufficiently detached.
12. Make an incision to proximal with a total length of 3-4 cm following the femoral 
bone.
13. Retract the skin to expose the underlying muscles.
14. Locate the margins of the two heads of the biceps femoris muscle, which is 





Figure 1: Surgery for induction of the spared nerve injury. A: Superficial landmarks for orienta-
tion: 1) Crest of ilium, 2) Patella, T) Site of trifurcation, ): Location of first incision. B: Making 
the incision in between the two heads of the biceps femoris muscle with a micro scissor to enter 
the site of the location where the trifurcation is being situated. C: Sciatic nerve and trifurca-
tion: 1) Common peroneal nerve, 2) Tibial nerve, 3) Sural nerve. D: Ligation and transection of 
the common peroneal nerve. Lifting the nerve produces a bridge that allows safe transection 
of the nerve.
23
Tissue-protective molecules in neuropathic pain
15. Carefully lift the medial part of the muscle with the Bonn micro forceps to create 
a small indentation (Figure 1B) .
16. Carefully cut the fascia with the Vannas spring scissors to detach the muscles. 
This allows the exposure of the space where the nerves and vessels are situated.
17. Expose the sciatic nerve and its trifurcation carefully by blunt preparation with 
the standard pattern curved forceps. Insert the forceps in a closed manner and 
allow it to open in order to make space (see Note 2). Be careful not to touch or 
stretch the sciatic nerve, its branches or the vessels that are situated in that area.
18. Identify tibial, common peroneal and caudal cutaneous sural nerve (Figure1C). 
The tibial and common peroneal will be the nerves that are going to be tran-
sected. The cutaneous sural nerve will be spared.
19. Carefully free tibial and common peroneal nerve from their surroundings with a 
cotton swab.
20. Place the curved Moria iris forceps under the tibial nerve and use it to guide a 
5-0 suture to pass under the nerve. Ligate the nerve at approximately 1 cm distal 
from the trifurcation.
21. Repeat the previous step for the common peroneal nerve and ligate with 5-0 
suture at approximately 1 cm distal from the trifurcation.
22. Lift the tibial nerve with the curved Moria forceps closed and allow the forceps 
to open to have the nerve form a bridge of about 4 mm between the two legs 
of the forceps.
23. Cut the nerve approximately 4 mm from the ligature (see Note 3).
24. Lift the tibial nerve and cut away approximately 3 mm of nerve distal from the 
suture.
25. Lift the common peroneal nerve with the curved Moria forceps closed and allow 
the forceps to open to have the nerve form a bridge of about 4 mm between the 
two legs of the forceps.
26. Cut the nerve approximately 4 mm from the ligature (see Note 4).
27. Lift the common peroneal nerve and cut away approximately 3 mm of nerve 
distal from the suture.
28. Carefully displace the proximal nerve stumps with a cotton swab.
29. Restore muscle integrity and suture the fascia with 5-0 silk suture
30. Close skin with four 4-0 nylon sutures.
31. Allow animal to awake and monitor for 30-60 minutes under a heating source 
maintained at 38°C.
32. Transfer the animal to a cage with fresh sawdust, food and water available. 
Animals can be housed 2 per cage.
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Assessment of pain: Tactile allodynia
1. Place the animal in the Perspex cage on the grid and allow to acclimatize for 
10-20 minutes.
2. Stimulate the hind paw with the Semmes-Weinstein mono filaments just lateral 
from the midline. Maintain the filament perpendicular to the paw. Start with 
the filament that applies the lowest amount of force (1,65). Apply at a rate of 
1Hz to a total of 10 stimuli.
3. When a response is observed in the form of an acute withdrawal upon stimula-
tion at any point during stimulation, this is noted and the paw will no further be 
stimulated with the same filament or with a filament of a higher force.
4. When no response is observed, continue with the next filament. Continue 
increasing the filament and repeat until the animal responds. This response is 
noted.
5. Repeat the entire testing sequence to obtain results in duplex.
6. Assessment of pain: Cold allodynia
7. Spray 20 µl of acetone in one fluent application on the plantar surface by using 
the 1 ml syringe with bent needle.
8. Observe the response of the animal and score according to the scoring table 
(Table 1).
9. After 2 minutes rest, repeat the sequence to obtain results in duplex.
Table 1: Scoring for cold allodynia.
Response Score
No response 0
Startle response lasting less than 1 second 1
Clear withdrawal lasting between 1 and 5 seconds 2
Clear withdrawal lasting between 5 and 30 second (with or without licking) 3
Clear withdrawal lasting over 30 seconds (with or without licking and repeated shaking) 4
Treatment with ARA 290
1. Make stock solution of ARA 290 of 1 mg/ml in PBS and store at 4°C.
2. Administer 30 µg/kg ARA 290 or vehicle (PBS) in a total volume of 200 µl intra 
peritoneally (i.p.) with a 1 ml syringe mounted with a 25G needle (Note 4).
Results
Sixteen animals were given the spared nerve injury as previously described and were 
randomly allocated to a treatment group. Eight animals received a sham operation. 
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In short, animals were anesthetized with sevoflurane (6% induction, 3% mainte-
nance) and the trifurcation of the nerve was exposed. No ligation and transection 
was performed and the wound was closed in two layers. Twenty-four hours post 
injury animals received treatment with ARA 290 or vehicle 5 times at 2 day intervals 
followed by once a week maintenance therapy. Within the first two weeks following 
nerve injury, vehicle-treated animals showed rapid development of tactile allodynia 
to the lowest applicable force of 0.004 g. In contrast, i.p. injections with ARA 290 
produced long-term relief of tactile allodynia lasting at least 15 weeks (Figure 2A). 
The allodynic responses differed significantly between treatment groups (repeated 
measures ANOVA, post hoc Holm-Sidak: P < 0.001 versus vehicle-treated animals).
Similarly, cold allodynia developed in animals treated with vehicle following nerve 
lesion with mean scores between 3 and 4 (4 being the maximum score) during the 15 
week study period (Figure 2B). Treatment with ARA 290 was associated with signifi-
cantly less cold allodynia with mean scores between 1.8 and 2.9 (Kruskal-Wallis, post 
hoc Tukey test: P < 0.001 versus vehicle-treated animals).
Notes
1. Anesthesia is induced and maintained with vaporized anesthetic agents (i.e. 
sevoflurane, isoflurane) rather than ketamine, for ketamine and other NMDA 
A B
Figure 2: Effect of ARA 290 on the development of neuropathic pain. Treatment with ARA 290 
results in the prevention of developing: A: tactile allodynia and B: cold allodynia for a period of 
15 weeks. X = treatment with either ARA 290 or vehicle.
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receptor antagonists, the class of drugs ketamine belongs to, have shown to 
reduce neuropathic pain in both humans and animals16,17.
2. Literature describes this procedure to be done by making an incision through the 
muscle18. This induces collateral damage and may cause blood loss. The method 
described in this chapter has been developed to perform the procedure without 
any to minimal blood loss.
3. The most important thing to remember while performing the surgery is to main-
tain a visual on every action in order not to cause additional damage.
4. Treatment is being given after the behavioral tests to minimize influence from 
stress on behavioral tests due to handling the animals during i.p. administration.
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Introduction
Neuropathic pain is a difficult-to-treat chronic pain disorder. It is characterized by al-
lodynia (increased sensitivity to nonpainful stimuli) and hyperalgesia (increased sen-
sitivity to painful stimuli) to mechanical (i.e., touch, pressure) and/or thermal (cold) 
stimuli.1 The mechanisms of neuropathic pain are diverse and not fully understood. 
Key elements include central and peripheral sensitization, neuronal plasticity, and 
neurogenic inflammation.2,3 These elements share intrinsic properties and pathways 
and ultimate behavioral effects on the perception of painful and nonpainful stimuli. 
Management of neuropathic pain is characterized by a trial-and-error approach, 
with interventions including pharmacologic treatment (opioids, antidepressants, 
antiepileptics, nonsteroidal anti-inflammatory drugs, and their combinations), spinal 
cord stimulation, and physiotherapy, often with limited success.
The effects of current pharmacologic approaches are limited with respect to ef-
ficacy, duration of effect, and the occurrence of often-unacceptable side effects.1 
Recent experimental studies examined the effect of exogenous erythropoietin 
in painful peripheral neuropathy models.4-9 The results indicate that exogenous 
erythropoietin facilitates recovery of sensory and motor functions, including a 
reduction of allodynia. Erythropoietin possesses generalized tissue-protective and 
trophic properties that have been demonstrated in various tissues, including neural, 
cardiovascular, and renal tissues.10-14 Erythropoietin produces its tissue-protective 
effects via activation of the erythropoietin receptor (EPOR)-β-common-receptor 
complex (EPOR-βcR complex), which is locally up-regulated after tissue injury.11,15 
Endogenous erythropoietin, produced in injured tissues, is considered a biologic 
antagonist of the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), which 
is produced by immune cells secondary to their activation after an initial tissue in-
sult.11 The tissue-protective effects of erythropoietin are distinct from its effects on 
hematopoiesis. The hematopoietic effect of erythropoietin is mediated through the 
EPOR homodimer (EPOR2) present on erythrocyte precursor cells.
11 The affinity of 
erythropoietin for the EPOR2 is 100 times greater than its affinity for the EPOR-βcR 
complex. Thus, using exogenous erythropoietin for tissue protection requires high 
circulating plasma concentrations. The use of exogenous erythropoietin has several 
disadvantages, including the activation of hematopoiesis and an increased risk of 
cardiovascular complications, including hypertension and thrombosis.16
The robust tissue-protective effects of erythropoietin prompted the development 
of erythropoietin analogs that retain their effect at the EPOR-βcR complex (and 
consequently their tissue-protective effects) but do not interact with the erythro-
poietin receptor homodimer (and thus do not cause erythropoiesis and cardiovas-
cular complications). Various erythropoietin analogs have been produced that are 
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tissue-protective in vivo, including carbamylated erythropoietin and the small helix 
B surface peptide ARA 290.11,17,18 ARA 290 is an 11-amino-acid peptide that mimics 
the tertiary structure of erythropoietin and has been shown to have tissue-protective 
properties without stimulating hematopoiesis.11,17
Because the ability of ARA 290 to treat neuropathic pain after peripheral nerve 
injury remains unknown, the current study was designed to explore the effect of 
ARA 290 on behavioral responses after unilateral nerve injury of the sciatic nerve in 
rats and mice and to determine whether the β-common receptor is involved by using 
mice lacking the β-common-receptor (βcR knockout or βcR-/- mice) and consequently 
lacking the EPOR-βcR complex.
Materials and Methods
Animals
The experimental protocol was approved by the Animal Ethics Committee (Dier-
ethische Commissie) of the Leiden University Medical Center, Leiden, The Nether-
lands, and experiments were performed in accordance with the guidelines of the 
International Association for the Study of Pain.19 The rats used in this study were 
8-week-old female Sprague-Dawley rats (Charles River, Maastricht, The Netherlands) 
weighing 200–260 g. βcR-/- mice used for the experiments, as described previously, 
were obtained from Dr. Nimesh Patel, Ph.D. (Kidney Research United Kingdom 
Career Development Fellow, The William Harvey Research Institute, Centre for 
Translational Medicine & Therapeutics, London, United Kingdom).20 Confirmation 
of βcR-/- was done as described by Robb et al.20 using Southern blot analysis. Control 
strain-matched, wild-type mice (C57/BL6) were obtained from Charles River. The mice 
were 8–12 weeks of age when tested.
Animals were housed two per cage in individually ventilated cages for the duration 
of the entire experimental period under standard laboratory conditions with water 
and food ad libitum and a light–dark cycle (12:12 h; lights on 7:00 AM). At the end 
of the studies, the animals were killed by exsanguination during sevoflurane, 6%, 
anesthesia.
Surgery
Before surgery, animals were tested for baseline nociceptive thresholds as described 
below. Twenty-four rats, 16 βcR-/- mice, and 16 wild-type mice were surgically treated 
to receive an adapted spared nerve injury (SNI).21 Animals were anesthetized with 
sevoflurane (6%) induction and maintenance (3%). A small incision was made in 
the lateral surface of the left hind limb of the animal, exposing the muscles. The 
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trifurcation of the sciatic nerve was revealed by blunt preparation between the two 
heads of the biceps femoris muscle. Next, the tibial and common peroneal nerves 
were tightly ligated with 5–0 silk in rats and 6–0 silk in mice and cut to remove 2–4 
mm of the distal nerve. The sural nerve was left intact. To prevent spontaneous nerve 
reconnection, the transected nerves were displaced. During the surgical procedure, 
great care was taken not to stretch or touch the sciatic or sural nerves. The wound 
was closed in two layers with 4–0 silk in rats and 6–0 silk in mice, and a single dose 
of 0.01 and 0.05 mg/kg buprenorphine was administered in rats and mice, respec-
tively, to relieve postoperative pain. Eight rats, eight βcR-/- mice, and eight wild-type 
mice received a sham operation. To that end, the animals were anesthetized and 
the sciatic nerve was exposed as described. After the exposure, no SNI was induced, 
and the wound was closed in two layers with 4–0 (rats) or 6–0 (mice) silk and a 
single dose of 0.01 (rats) or 0.05 (mice) mg/kg buprenorphine was administered to 
relieve postoperative pain. During the surgical procedure, great care was taken not 
to stretch or touch the exposed nerves.
Study drugs
ARA 290 (Araim Pharmaceuticals, Ossining, NY) was dissolved in phosphate-buffered 
saline (PBS) at pH 7.4 to obtain a stock solution of 1 mg/ml. All animals treated with 
ARA 290 received injections with 30 µg/kg ARA 290 in 200 µl PBS. The peptide was 
stored at 4 °C between uses. Vehicle treatment consisted of 200 µl PBS at pH 7.4. Both 
ARA 290 and vehicle were injected intraperitoneally. The ARA 290 dosages used in 
this study are based on the work of a previous study on the effect of ARA 290 on 
motor function after sciatic nerve compression injury.17
Rat Study design
The 24 rats that received the SNI were allocated randomly to one of the following 
treatment groups. Treatment was initiated 24 h after induction of the SNI. Group 1: 
n = 8; five 30 µg/kg ARA 290 intraperitoneal injections at 2-day intervals, followed by 
once-a-week maintenance therapy of 30 µg/kg ARA 290. Group 2: n = 8; five vehicle 
(PBS) intraperitoneal injections at 2-day intervals, followed by once-a-week main-
tenance therapy of vehicle. Group 3: n = 8; five 30 µg/kg ARA 290 intraperitoneal 
injections at 2-day intervals, with no maintenance therapy.
Mice Study design
The 32 mice that received the SNI were randomly allocated to one of the following 
treatment groups. Treatment was initiated 24 h after induction of the SNI: Groups IA 
and IB: n = 8 βcR-/- and eight wild-type mice; five 30 µg/kg ARA 290 intraperitoneal 
injections at 2-day intervals, followed by once-a-week maintenance therapy of intra-
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peritoneal injections of 30 µg/kg ARA 290. Group IIA and IIB: n = 8 βcR-/- and eight 
wild-type mice; five vehicle (PBS) intraperitoneal injections at 2-day intervals, fol-
lowed by once-a-week maintenance therapy of intraperitoneal injections of vehicle. 
The follow-up was 4 weeks after surgery.
Measurement of Tactile and Cold Allodynia
Allodynia was assessed before surgery (baseline values) and during follow-up at 
1-week intervals on the plantar surfaces of the affected (ipsilateral) and contralat-
eral hind paws. To measure the two types of allodynia, the animals were placed 
in a see-through box on an increased wire mesh floor. Tactile allodynia was tested 
first, followed by testing for cold allodynia. Before testing, the animals were al-
lowed to habituate for at least 10 min. When testing coincided with a treatment 
day, testing was performed before administration of ARA 290 or vehicle. Tactile 
allodynia was tested with the use of different von Frey hairs (Semmes-Weinstein 
Monofilaments, North Coast Medical Inc., San Jose, CA) with increasing stiffness 
(0.004–300 g), causing incremental forces to be exerted on the plantar surface of the 
affected and contralateral hind paws. The hairs were applied 10 times at intervals 
of 1–2 s to slightly different loci within the test area. The hind paw that was not 
surgically treated was tested first. When no response was observed, the ipsilateral 
hind paw was stimulated in a similar fashion. The force necessary to evoke a pain 
reflex by a brisk paw withdrawal was recorded, and no additional filaments were 
applied to the paw that showed a response. The experiment was continued until 
responses from both the ipsilateral and the contralateral paw were obtained. After 
a rest period, cold allodynia was tested. Twenty (rats) or 10 (mice) µl acetone was 
sprayed on the plantar surface of the hind paw, and the response was recorded using 
the following classification: 0 = no withdrawal, 1 = startle response lasting less than 
1 s, 2 = withdrawal lasting between 1 and 5 s, 3 = withdrawal lasting between 5 and 
30 s (with or without paw licking), and 4 = withdrawal lasting longer than 30 s (with 
or without licking and repeated shaking).
Statistical Analysis
A power analysis was based on data from a previous study on the effect of ketamine 
versus vehicle treatment on tactile allodynia in the rat SNI model.22 We calculated a 
group size of at least eight animals was needed to detect a difference between treat-
ments of at least 1 SD between the two groups, with a reliability of 5% and power 
more than 80%. To analyze the effect of treatment with ARA 290 over time on tactile 
allodynia, a two-way repeated measures analysis of variance (ANOVA) was used. The 
tests were followed by a Holm-Sidak test for post hoc comparisons when required. 
The effect of ARA 290 on cold allodynia was tested with nonparametric tests: Kruskal-
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Wallis and post hoc Tukey tests. All statistical analyses were performed with SigmaPlot 
version 11 (Systat Software Inc., Chicago, IL). Hypothesis testing was two-tailed, with P 
values < 0.05 considered significant. Data are expressed as mean ± SEM.
Results
Effect of ARA 290 Maintenance in the Rat
After SNI, animals that received vehicle treatment showed the rapid development 
of tactile allodynia with the lowest applicable force of 0.004 g within 2 weeks after 
surgery. In contrast, intraperitoneal injections of ARA 290 produced long-term relief 
of tactile allodynia lasting at least 15 weeks (Figure 1A). The allodynic responses dif-
fered significantly between treatment groups (main effect: P < 0.001; post hoc: ARA 
290 vs. vehicle P < 0.001, ARA 290 vs. sham P = 0.008). In addition to the development 
of tactile allodynia observed on the ipsilateral side, a decrease of the nociceptive 
threshold was observed in the contralateral paw (i.e., contralateral allodynia). Con-
tralateral allodynia was greater in vehicle-treated than in ARA 290-treated animals 
(Figure 1B, main effect: P < 0.001; post hoc: ARA 290 vs. vehicle P < 0.001, ARA 290 vs. 
A B
Figure 1: Effect of ARA 290 treatment during the 15 weeks after spared nerve injury (SNI) sur-
gery on tactile allodynia. A: Ipsilateral paw. B: Contralateral paw. Thirty µg/kg ARA 290 was 
injected for 5 days at 2-day intervals (first injection within 24 h after surgery), followed by once-
a-week maintenance therapy of 30 µg/kg ARA 290. ARA 290 produces significantly less tactile 
allodynia than does vehicle on ipsilateral (P < 0.001) and contralateral paws (P < 0.001). All treat-
ments were given via the intraperitoneal route. X = treatment with either ARA 290 or vehicle.
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sham P < 0.001). Similarly, in animals treated with vehicle, cold allodynia developed 
rapidly after SNI surgery in the ipsilateral paw, with mean allodynia scores between 
3 and 4 (4 is the maximum score) during the 15-week study period. Treatment with 
ARA 290 was associated with significantly less cold allodynia in the ipsilateral paw, 
with mean scores between 1.8 and 2.9 (Figure 2A, P < 0.001; compared with vehicle-
treated animals by post hoc test). Cold allodynia responses in the contralateral paw 
averaged to approximately 1 in vehicle-treated animals. A small but significant reduc-
tion in cold allodynia was observed during ARA 290 treatment in the contralateral 
paw (Figure 2B, P < 0.05; compared with vehicle-treated animals by post hoc test).
Effect of 2-week versus Maintenance ARA 290 in the Rat
To assess the effect of early ARA 290 treatment, eight animals received five injections 
of 30 µg/kg ARA 290 during the initial 2 weeks after SNI surgery and no additional 
treatment. Animals treated according to this regimen showed a delay in the progres-
sion of tactile allodynia for the duration of follow-up but to a lesser extent than 
that of the group treated with weekly ARA 290 injections (maintenance therapy) 
(P = 0.018, Figure 3A). Regardless of the therapy received, animals displayed compa-
rable nociceptive thresholds in the contralateral paw (Figure 3B).
A B
Figure 2: Effect of ARA 290 treatment during the 15 weeks after spared nerve injury (SNI) 
surgery on cold allodynia. A: Ipsilateral paw. B: Contralateral paw. Thirty µg/kg ARA 290 was 
injected for 5 days at 2-day intervals (first injection within 24 h after surgery), followed by once-
a-week maintenance therapy of 30 µg/kg ARA 290. ARA 290 produces significantly less cold 
allodynia than does vehicle on ipsilateral (P < 0.001) and contralateral paws (P < 0.001). All treat-
ments were given via the intraperitoneal route. X = treatment with either ARA 290 or vehicle.
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Omitting the maintenance therapy resulted in relief of cold allodynia but to a lesser 
extent than occurred after maintenance therapy (Figure 4A, P < 0.001). No difference 
was observed in the contralateral paw (Figure 4B).
Effect of ARA 290 Maintenance in βcR-/- Mice
A treatment effect on tactile allodynia was observed in both genotypes (P < 0.001). 
ARA 290 had no effect on tactile allodynia in βcR-/- mice (ARA 290 vs. vehicle: 
P = 0.963, post hoc test). One week after SNI surgery, withdrawal of the affected paw 
occurred at the lowest possible force, 0.004 g, irrespective of treatment with ARA 
290 or vehicle (Figure 5).
In contrast, wild-type animals did show an effect of ARA 290 treatment, with with-
drawal responses occurring at 0.020 g versus 0.004 g in PBS-treated animals within 
2 weeks after surgery (Figure 5, A and B, P = 0.027 vs. vehicle-treated mice, post hoc 
test).
At the contralateral hind paw allodynia was observed that responded to ARA 
290 treatment in wild-type animals (P = 0.034 vs. vehicle, post hoc test) but not in 
βcR-/- mice (P = 0.941 vs. vehicle, post hoc test) (Figure 5, C and D). In wild-type and 
βcR-/- animals, cold allodynia developed in the ipsilateral (main effect: P < 0.001 in 
A B
Figure 3: Effect of 2 week therapy versus weekly maintenance therapy on tactile allodynia. 
A: Ipsilateral paw. B: Contralateral paw. To guide the eye, data from vehicle-treated animals 
(continuous line) and sham-operated animals (dotted line) are added. Maintenance therapy 
produced less allodynia than 2-week treatment in the ipsilateral paw (P = 0.02), but no differ-
ence was observed in the contralateral paw. All treatments were given via the intraperitoneal 
route. X = treatment with either ARA 290 or vehicle.
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both genotypes) but not contralateral hind paw (main effect: P = 0.068 in βcR-/- and 
0.087 in wild-type mice) (Figure 6). ARA 290 had a significant effect on cold allodynia 
responses in wild-type (Figure 6A, post hoc: ARA 290 vs. vehicle P < 0.05 but not in 
βcR-/- mice (Figure 6B).
discussion
The main findings of our studies are: (1) ARA 290 treatment in the 2 weeks after nerve 
injury produces effective, long-term relief of allodynia in rats; (2) in the same species, 
ARA 290 therapy was most effective when it was maintained at 1-week intervals; and 
(3) an effect of ARA 290 on nociceptive withdrawal responses was absent in mice 
with a homozygous deletion of the β-common-receptor (βcR-/-), whereas reduced 
pain responses were observed in wild-type mice (mice with an intact heterodimer 
receptor). Our finding of a long-term antiallodynic effect of the ARA 290 peptide 
is novel and promising, but additional testing in humans is required to predict the 
effectiveness of ARA 290 in patients with neuropathic pain.
A B
Figure 4: Effect of 2-week therapy versus weekly maintenance therapy on cold allodynia. A: 
Ipsilateral paw. B: Contralateral paw. To guide the eye, data from vehicle-treated animals (con-
tinuous line) and sham-operated animals (dotted line) are added. Maintenance therapy pro-
duced less allodynia than 2-week treatment in the ipsilateral paw (P < 0.001), but no difference 
was observed in the contralateral paw. All treatments were given via the intraperitoneal route. 
X = treatment with either ARA 290 or vehicle.
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ARA 290 is a peptide derived from the erythropoietin molecule. In most tissues, 





Figure 5: Effect of ARA 290 treatment on tactile allodynia measured in the ipsilateral hind 
paw (i.e., paw with nerve injury) and contralateral hind paw. A: Effect of ARA 290 therapy in 
mice with an intact β-common-receptor (wild-type mice), ipsilateral paw. B: Effect of ARA 290 
therapy in mice lacking the β-common-receptor (βcR-/- mice), ipsilateral paw. C: Effect of ARA 
290 therapy in wild-type mice, contralateral paw. D: Effect of ARA 290 therapy in βcR-/- mice, 
contralateral paw. ARA 290 caused a relief of allodynia compared with vehicle in wild-type but 
not βcR-/- animals (wild-type: ipsilateral P = 0.027, contralateral P = 0.034; βcR-/-: ipsilateral P = not 
significant; contralateral P = not significant). All treatments were given via the intraperitoneal 







Figure 6: Effect of ARA 290 treatment on cold allodynia measured in the ipsilateral hind paw 
(i.e., paw with nerve injury) and contralateral hind paw. A: Effect of ARA 290 therapy in mice 
with an intact β-common-receptor (wild-type mice), ipsilateral paw. B: Effect of ARA 290 ther-
apy in mice lacking the β-common receptor (βcR-/- mice), ipsilateral paw. C: Effect of ARA 290 
therapy in wild-type mice, contralateral paw. D: Effect of ARA 290 therapy in βcR-/- mice, contra-
lateral paw. A significant effect was observed in wild-type but not βcR-/- mice at the ipsilateral 
site only (wild-type: ipsilateral P = 0.05, contralateral P = not significant; βcR-/-: ipsilateral P = not 
significant, contralateral P = not significant). All treatments were given via the intraperitoneal 
route. X = treatment with either ARA 290 or vehicle.
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sponse to local injury, counteracting the effects of proinflammatory cytokines.11,23 
Recent animal studies indicate that exogenously administered erythropoietin 
enhances the process of healing and effectively prevents overt tissue damage 
after injury.10-14 For example, Brines et al.12 showed that systemic administration 
of recombinant human erythropoietin (rhEPO, 5,000 units/kg) before or as long 
as 6 h after blunt trauma to the rat brain reduced concussive injury by 50–75%. 
Similarly, rhEPO reduced the infarct size after carotid artery occlusion in the rat.12 
These local tissue-protective effects are not mediated by the hematopoietic EPOR 
dimer but through the EPOR-βcR complex, which is locally up-regulated after tissue 
injury.11,15,17 To activate this receptor, high local concentrations of erythropoietin 
are required because the EPOR-βcR complex exhibits a 100-fold lower affinity for 
erythropoietin than does the hematopoietic EPOR dimer.11 High local concentra-
tions of exogenously administrated erythropoietin are obtained only after high 
doses are injected systemically because tissue production of erythropoietin after 
injury is delayed significantly.11 The use of high-dose exogenous erythropoietin has 
several disadvantages, including the activation of hematopoiesis and increased risk 
of cardiovascular complications (e.g., hypertension, thrombosis). For example, a 
clinical study on the effect of erythropoietin administration (40,000 units once/
week for 4 weeks) to trauma patients admitted to the intensive care unit showed 
that although mortality was reduced by 50%, there was a 40% increased risk of 
thrombosis.16
Several nonhematopoietic erythropoietin analogues have been developed that 
selectively activate the EPOR-βcR complex and that have tissue-protective proper-
ties, such as carbamylated erythropoietin, asialoerythropoietin, and ARA 290.11,17,18,24 
Several preclinical studies have shown these compounds facilitate wound healing, 
limit the infarction volume in a stroke model, reduce collateral damage to surround-
ing tissue adjacent to the injury site in cardiomyopathy, and improve motor function 
after spinal cord compression.11,17,24-27
ARA 290 has been shown to up-regulate EPOR expression in injured tissue.28 In the 
current study, we used ARA 290 to assess its effect on nociceptive responses after 
peripheral nerve injury. ARA 290 caused effective, long-term attenuation of ipsilat-
eral and contralateral tactile and cold allodynia in a SNI model in the rat. The data 
obtained in βcR-/- mice point toward the β-common-receptor as the site of action 
of ARA 290 after nerve injury. Our findings are in agreement with previous obser-
vations on the effect of exogenous erythropoietin in various models of peripheral 
nerve injury (including chronic constriction injury, L5 spinal crush injury, and L5 spinal 
nerve transection).4-9 In all models, erythropoietin effectively reduced pain behavior 
coupled with observations of reduced neuroimmune activation related to the anti-
TNF activity of erythropoietin. In addition, the site of action of ARA 290 is similar to 
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that of erythropoietin (i.e., the EPOR-βcR complex) because the erythropoietin effect 
on motor function after spinal cord injury models is absent in βcR-/- mice.15
The neuroanatomical level of the effect of ARA 290 at the β-common-receptor in 
our experimental pain models remains unknown. We cannot exclude an effect at the 
(peripheral) site of nerve injury or centrally at spinal or supraspinal sites. However, 
a complete and prolonged block of the peripheral nerve by use of local anesthetics 
does not prevent the development of neuropathy, which suggests that central ef-
fects are predominant.29 There is ample evidence that after peripheral nerve injury, 
as induced in our current study, an innate immune response is triggered in the spinal 
cord in which proinflammatory cytokines, including TNF-α, are released.3,5,30-34 This 
neuroinflammatory response is highly self-amplifying, causing collateral damage to 
surrounding tissue and leading to sensitization of primary affected and secondary 
neurons, enhancing allodynia, hyperalgesia, and spontaneous pain. An important 
issue in this respect is the short half-life of ARA 290 (plasma half-life ≈ 2 min in rats 
and rabbits).17 Although this suggests a peripheral rather than a central effect, there 
is ample evidence that ARA 290 passes the blood–brain barrier. For example, ARA 
290 is able to cross the blood–brain barrier to exert its neuroprotective effects in 
ischemic stroke models and passes the blood–retinal barrier, reducing retinal edema 
in diabetic animals.17 Asialoerythropoietin, a nonerythropoietic cytokine with a 
similarly short plasma half-life of 2 min, passes the blood– brain barrier and appears 
promptly in the cerebrospinal fluid after intravenous injection and binds to neurons 
in the hippocampus and cortex in a pattern corresponding to the distribution of the 
EPOR.24 Regardless of the location of action of ARA 290, given its short half-life, it is 
reasonable to assume that ARA 290 initiated a cascade of events involving a series of 
transduction factors, of which activation of the EPOR-βcR complex is the first step (see 
also Brines and Cerami11 Figure 4), that eventually result in the silencing or reduction 
of the inflammatory response. Evidence from such a sequence of events at central 
sites may be inferred from previous studies on rhEPO. Jia et al.8 showed that rhEPO 
attenuates allodynia and reduces the spinal neuroimmune activation induced by L5 
spinal nerve transection with reduced activation of glia cells and reduced production 
of proinflammatory cytokines (TNF-α, interleukin-1β) and NF-κB activation in the 
spinal cord. The same group showed that preemptive rhEPO attenuates mechanical 
and thermal hyperalgesia after L5 spinal nerve transection, as well as the cerebral 
expression of TNF-α, interleukin-1β, and NF-κB activation.9 After dorsal root ganglion 
crush injury, rhEPO reduced local apoptosis and pain behaviors.6 These data indicate 
a neuroprotective and anti-inflammatory role of rhEPO at central sites in a variety of 
neuropathic pain states, causing a significant amelioration of pain behavior. Given 
the observations in rhEPO-treated animals, the fact that AR290 is an erythropoietin 
analog acting at the EPOR- βcR complex, and that it is able to pass the blood–brain 
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barrier, our data may well be explained by an anti-inflammatory and neuroprotective 
effect of ARA 290 at spinal and possibly supraspinal sites. However, we again stress 
that a peripheral effect cannot be excluded. A peripheral effect of rhEPO has been 
observed in an animal model of diabetic neuropathy, where it prevents and reverses 
intraepidermal neuronal loss,4 and in chronic constriction injury, rhEPO facilitates 
the recovery from neuropathic pain and reduces Schwann cell TNF-α expression at 
the nerve injury site.5 Despite a large reduction of allodynia maintained during the 
intensive treatment period, a slow trend toward an increase in pain behavior was 
observed during the weekly ARA 290 dosing paradigm (Figure 3). This observation 
could suggest that because of the biologic half-life of ARA 290 of less than 1 week, 
more frequent dosing could prevent the trend for increased pain. An alternative 
explanation could be that noninflammatory processes slowly develop to foster 
proallodynic responses and gain in importance over time or that the inflammatory 
response becomes more resilient. If true, this suggests that treatment of neuropathic 
pain caused by nerve injury should be aimed at targeting multiple processes, of 
which suppression of the immune response is one that requires early (and continu-
ous) treatment. It is not likely that decreasing the interval between nerve injury and 
the initiation of treatment or using ARA 290 as a preemptive measure results in a 
more effective relief of neuropathic pain because the EPOR-βcR complex is being 
up-regulated secondary to tissue damage.11 Alternatively, more intense treatment 
during the initial phase (e.g., higher doses or injections at a 1-day interval) may be 
more effective in neutralizing the initial hit induced by the peripheral nerve injury.
We observed contralateral development of allodynia in mice and rats that was at-
tenuated by ARA 290 treatment (Figures 1 and 5). These findings indicate the pres-
ence of neuroinflammation in the spinal cord and dorsal root ganglia at the site 
opposite from the severed peripheral nerves and suggest the presence of a more 
generalized inflammatory response in the central nervous system in our SNI animals. 
Indeed, in unilateral nerve damage, a bilateral increase in TNF-α and activated glia 
cells in bilateral homo-and heteronymous dorsal root ganglia is observed in a rat 
model of chronic constriction injury, suggesting a more generalized inflammatory 
response.35,36
In conclusion, our data indicate that the development of allodynia after peripheral 
nerve injury is effectively prevented for the long term by early treatment with ARA 
290. Testing of ARA 290 in patients with chronic pain is required before any conclu-
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Introduction
Neuropathic pain (NP) is a debilitating condition resulting from lesions of the pe-
ripheral or central nervous system with allodynia and hyperalgesia to mechanical or 
thermal stimuli as main symptoms1,2. Treatment of NP is difficult and management 
of symptoms by pharmacological means (opioids, antidepressants or topical agents 
such as capsaicin) or non-pharmacological (physiotherapy) is often not adequate. The 
mechanisms underlying NP are largely driven by peripheral and central inflammation 
leading to peripheral and central sensitization. Peripherally, macrophages and T-cells 
are the main contributors to the inflammatory response3,4. In the central nervous 
system astrocytes and microglia play a crucial role in NP states after peripheral nerve 
injury by showing altered numbers, morphology and activation states5-11. There is 
ample evidence for crosstalk between neurons and glia cells leading to phenomena 
that underlie allodynia and hyperalgesia12. In NP, glia become more abundant and 
activated as a result of the induced release of proliferative molecules, such as frac-
talkine (chemokine (C-X3-C motif) ligand 1; CX3CL1) and C-C motif chemoreceptor 
ligand 2 (CCL2) released by neurons due to increased afferent signaling13-15, and local 
release and retrograde transport of TNF-α16. These glia cells are involved in driving 
and maintaining the inflammatory response, especially in the dorsal horn of the 
spinal cord, by releasing inflammatory mediators, including TNF-α, interleukins 1β 
and 6 and other signaling molecules for periods that may extend over 2 weeks17-20. 
In addition to the observations in experimental animal studies, a case report of a 
patient with longstanding complex regional pain syndrome describes increased acti-
vation of astrocytes and microglia in the spinal cord after autopsy when compared to 
patients without a neuropathic pain condition21. These observations strongly suggest 
that astrocytes and microglia serve as potential targets for treatment of neuropathic 
pain. Indeed, inhibition of activated microglia and astrocytes reduces neuropathic 
pain symptoms in vivo22-24.
We recently showed that the neuroprotective synthetic 11-amino acid erythropoietin 
(EPO) derivative ARA 290 produces effective and long-term pain relief following 
peripheral nerve damage in the rat25,26. ARA 290 produces its effects via activation 
of the β-common-receptor25-27. The β-common-receptor in conjunction with the EPO 
receptor forms a heterocomplex (designated the innate repair receptor, IRR), which 
becomes locally up-regulated following tissue injury28,29. Its activation initiates a local 
anti-inflammatory response, inhibition of death signal and anti-apoptosis, thereby 
preventing overt tissue damage. Additionally, activation of the IRR also promotes tis-
sue repair responses, including neurite outgrowth in the nervous system30. In humans 
we recently showed that chronic ARA 290 administration reduced pain symptoms and 
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improves functionality in patients with chronic neuropathic pain related to small fiber 
neuropathy31. Various animal studies have shown the tissue-protective effects of ARA 
290, all related in part to its anti-inflammatory effects. For example, ARA 290 improves 
survival following myocardial infarction, reduces organ dysfunction in hemorrhagic 
shock and suppresses development of atherosclerosis in hyperlipidemic rabbits32-34.
In this study, we investigated the dose-response effect of ARA 290 on mechanical 
and thermal allodynia in an experimental rat model of chronic neuropathic pain 
(using the spared nerve injury model in which two of the three branches of the 
sciatic nerve are surgically cut). Next, to better understand its mechanism of action, 
we assessed whether ARA 290 has an anti-inflammatory effect at the level of the spi-
nal cord by visualizing spinal astrocyte and microglia using immunohistochemistry. 




The experimental protocol was approved by the Animal Ethics Committee (Diereth-
ische Commissie) of the Leiden University Medical Center, Leiden, The Netherlands 
and the Animal Care and Use Review Office (ACURO) of the United States Army 
Medical Department Medical Research and Materiel Command. All experiments 
were performed in accordance to the guide lines of the International Association for 
the Study of Pain35. Forty-two, eight-week-old, female Sprague-Dawley rats (Charles 
River, Maastricht, The Netherlands) weighing 200 to 260 grams were used in this 
study. Animals were housed two per cage in individually ventilated cages for the 
duration of the entire experimental period under standard laboratory conditions 
with water and food ad libitum and a 12h-12h light/dark cycle. At the end of the 
studies the animals were anesthetized and euthanized by exsanguination under 6% 
sevoflurane anesthesia, perfuse-fixed with 100 ml ice-cold heparinized saline fol-
lowed by 150 ml 4% paraformaldehyde for tissue extraction.
Neuropathic pain model
Chronic neuropathic pain was induced in 34 rats by spared nerve injury (SNI)25. 
Animals were anesthetized with 6% sevoflurane induction and 3% maintenance. 
A small incision was made in the lateral surface of the left thigh of the animal, 
exposing the muscles. The trifurcation of the sciatic nerve was revealed by blunt 
preparation between the two heads of the biceps femoris muscle. Next, the tibial 
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and common peroneal nerves were tightly ligated with 5-0 silk in rats and cut to re-
move 2-4 mm of the distal nerve. The sural nerve was left intact. In order to prevent 
spontaneous nerve reconnection, the transected nerves were displaced. During the 
surgical procedure, great care was taken not to stretch or touch the sciatic or sural 
nerves. The wound was closed in one layer with 4-0 ethilon and a single dose of 0.01 
mg/kg buprenorphine was administered to relieve acute postoperative pain.
Eight animals received a sham operation where the nerve was exposed, but not 
ligated and transected. The wound was closed in one layer with 4-0 ethilon sutures 
and a single dose of 0.01 mg/kg buprenorphine was administered for the relief of 
acute postoperative pain. After surgery, animals were allowed to recover with body 
temperature maintained at 38 °C for 1 h before being transferred to a cage with 
fresh saw dust.
Treatment
The experimental drug ARA 290 was dissolved in phosphate buffered saline (PBS) to 
obtain a stock solution, aliquoted and stored at 4 °C until use. Prior to injection, the 
stock solution of was diluted in PBS to yield the desired dose in 200 µl. Following 
surgery, 34 animals were treated on days 1, 3, 6, 8 and 10 post-surgery. All injections 
were administered intraperitoneally. Nine of the animals were sacrificed after the 
2-week treatment period (Group 1); twenty-five animals were followed for another 
18-weeks following treatment and then sacrificed (Group 2). Group 1 animals were 
randomly allocated to one of the following treatment groups: 0 (= vehicle; PBS), 
10, 30 µg/kg (n = 3/group). Group 2 animals were randomly allocated to one of the 
following treatment groups: 0 (= vehicle; PBS), 3, 10, 30, and 60 µg/kg ARA 290 (n = 5/
group). Three animals in Group 1 and five in Group 2 received sham surgery and 
were not treated (i.e. sham controls).
Neuropathic pain assay
Allodynia was assessed prior to surgery (baseline values), at days 1, 3, 6, 8 and 10 dur-
ing the treatment period, and during follow up from day 14 on at 1-week intervals. 
The test site was the plantar surface of the injured hind paw. The animals were 
placed in a transparent cage on an elevated wire mesh floor and were allowed to 
habituate for at least 10 minutes before testing for mechanical allodynia, followed 
by thermal allodynia after a short interval to allow recovery from the previous test. 
When testing coincided with a treatment day, testing was performed prior to admin-
istration of ARA 290 or vehicle.
Mechanical allodynia was tested with the use of von Frey hairs (Semmes-Weinstein 
Monofilaments, North Coast Medical Inc., San Jose, CA) with increasing stiffness 
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(0.004 – 300 g) causing incremental forces to be exerted on the plantar surface of the 
injured hind paw. The hairs were applied 10 times at a frequency of 1 Hz to slightly 
different loci within the test area to avoid sensitization due to repetition. The force 
necessary to evoke a pain reflex by a brisk paw withdrawal was recorded and no 
further filaments were applied to the paw that showed a response. All measure-
ments were obtained in duplex with a 1-minute interval between the tests and then 
averaged.
Cold allodynia was tested by using the acetone test. Twenty microliters of acetone 
was sprayed on the plantar surface of the hind paw. The response of the animal was 
recorded using the following classification: 0 = no withdrawal, 1 = startle response 
lasting less than 1 s, 2 = withdrawal lasting between 1 and 5 s, 3 = withdrawal lasting 
between 5 and 30 s (with or without paw licking) and 4 = withdrawal lasting longer 
than 30 s (with or without licking and repeated shaking). All measurements were 
obtained in duplex with a 1-min interval between the tests and then averaged.
Immunohistochemistry
After perfuse-fixing the animals, the lumbar spinal cord was extracted and post-fixed 
in 4% paraformaldehyde for 24 h. After post-fixation, the tissues were cryoprotected 
for 72 h in 30% sucrose before embedding them in TissueTek (Sakura FineTek, Alphen 
a/d Rijn, The Netherlands). The extracted lumbar spinal cord was sectioned transver-
sally at a freezing microtome at −20 °C to obtain serially sectioned 20 µm sections. 
Every 10th section was mounted on a Superfrost+ slide (Menzel Gläser, Braunschweig, 
Germany) and stored at −80 °C prior to staining. For immunohistological staining, 
sections for all animals of both time points were stained in one run for each antibody 
to reduce variability between stainings. The sections were retrieved from the freezer 
and allowed to thaw before blocking for 1 h with 10% goat serum (Invitrogen, 
Auckland, New Zealand) with 0.4% Triton X-100 (Sigma-Aldrich, St. Louis, USA). 
Sections were stained overnight at 4 °C for microglia with 1 µg/ml rabbit-anti-Iba-1 
(Wako Chemicals GmbH, Neuss, Germany) or astrocytes with 1:200 rabbit-anti-GFAP 
(Dako, Heverlee, Belgium) in 3% normal goat serum with 0.4% Triton X-100. After 3 
washings in PBS, the slides were incubated for 3 h at room temperature with 1:500 
goat-anti-rabbit-Alexa488 (Invitrogen, Eugene, USA) as a secondary antibody in 3% 
normal goat serum with 0.4% Triton X-100. After incubation, slides were washed 
3 times with PBS and Vectashield (Vector Laboratories Inc., Burlingame, USA) as an 
anti-fading agent was applied. Lastly, the slides were cover slipped and sealed with 
nail polish. Standardized microphotographs of the dorsal horn were taken with 
a Leica M5500 fluorescence microscope (Leica Microsystems, Rijswijk, The Nether-
lands). During photography, the spinal cord segment of the image was determined 
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with a spinal cord histology atlas on the basis of white matter to grey matter ratio, 
ventral horn morphology and dorsal horn morphology and documented for clas-
sification during analysis36. The photomicrographs were analyzed using ImageJ (NIH, 
Bethesda, MD, USA).
Image analysis
First, images were screened for quality by assessing if the dorsal horn was completely 
visible, without folds or significant damage. Images that did not meet these criteria 
were not analyzed (on average 5.3% per group). Next, the remaining 8-bit grey 
scale images were thresholded using the auto threshold function of ImageJ to create 
dichromatic images required for analysis of the percentage covered with immunore-
active cells. This function objectively separates signal from noise and no adjustments 
for background, brightness or contrast were performed. Obtained values were aver-
aged per spinal cord segment for each animal.
Statistics
Allodynia
Behavioral data for effects on tactile and cold allodynia were analyzed by 2-way 
analysis of variance with post hoc Student-Newman-Keuls comparisons for multiple 
testing. The effect of dose-dependency was analyzed by calculating the area under 
the curve with the trapezoid rule and curve fitting the data using a linear function. 
Log-Rank survival curves were created to determine the duration of allodynia relief 
by ARA 290 treatment. End-points were defined as reaching the maximum amount 
of measurable allodynia (reaching the 0.004 g filament or reaching a score of 4 in the 
acetone test). Holm-Sidak post hoc analysis for multiple comparisons was performed.
Microscopy
Spinal cord microscopy data were analyzed per segment by two-way analysis of vari-
ance with post hoc Student-Newman-Keuls comparisons for multiple testing.





ARA 290 reduces mechanical and cold allodynia in a dose-dependent manner
Mechanical allodynia
Following SNI, vehicle-treated animals progressively developed mechanical allodynia 
within 10 days with withdrawal responses to the filament exerting the lowest pos-
sible force (0.004 ± 0.0 grams). Sham operated animals showed no decline in response 
threshold. Regardless of treatment, all SNI groups differed significantly from sham 
operated animals (P < 0.001 for all groups). The two-week treatment with ARA 290 
produced a lasting relief of tactile allodynia (Figure 1A, treatment effect P < 0.001). 
Post hoc analysis revealed significant effects for the 30 and 60 µg/kg groups (30 µg/
kg: P = 0.049 and 60 µg/kg: P < 0.001 versus vehicle). In contrast, the lower doses of 
ARA 290 did not produce significant relief of allodynia (3 µg/kg: P = 0.825 and 10 µg/
kg: P = 0.707 versus vehicle). Comparing efficacy of treatment with ARA 290, a linear 
dose response relationship was observed with an adjusted R2 of 0.56 (Figure 1B). 
Higher doses of ARA 290 resulted in higher AUCs corresponding to animals tolerat-
ing stimulation with filaments that exert a greater force and hence less mechanical 
allodynia. Survival analysis indicates that with higher dosages of ARA 290 relief from 
allodynia persists for longer time periods (Figure 1C, Log-Rank P < 0.001).
Cold allodynia
Following SNI, vehicle-treated animals developed cold allodynia within 7-14 days a 
mean score of 3.2 ± 0.2 (range 3 to 4). Sham operated animals showed no increase in 
response. Regardless of treatment, all SNI groups differed significantly from sham-
operated animals (P < 0.001 for all groups). Animals treated with ARA 290 showed 
a dose-dependent relief of allodynia (Figure 2A, treatment effect P < 0.001). Post 
hoc analysis showed that at all doses allodynia was significantly less compared to 
vehicle (P < 0.001). A linear ARA 290 dose-response relationship was observed with 
an adjusted R2 of 0.78 (Figure 2B). Higher doses of ARA 290 resulted in lower AUCs 
corresponding to animals responding less vigorously to the application of acetone 
and hence less thermal allodynia. Survival analysis indicates that a more persisting 
effect was obtained at higher ARA 290 doses (Figure 2C, Log-Rank P < 0.001).
ARA 290 prevents the increase of Iba-1-immunoreactivity in the dorsal horn
In figure 3, representative overviews are given from the spinal cords of animals after 
2 weeks of survival that received SNI with vehicle (Figure 3A), SNI with 30 µg/kg 
ARA 290 (Figure 3B) or sham surgery without treatment (Figure 3C). There was an 
apparent increased Iba-1-immunoreactivity (Iba-1-IR) on the side of the injury that 
seemed more pronounced in the 0 µg/kg treated group when compared to the 30 
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Figure 1: A: Effect of spared nerve injury and treatment with vehicle or different doses of ARA 
290 on mechanical allodynia. Animals were sham-operated or received spared nerve injury and 
5 doses of vehicle, 3 µg/kg ARA 290, 10 µg/kg ARA 290 (green), 30 µg/kg ARA 290, or 60 µg/kg 
ARA 290 administered on days 1, 3, 6, 8 and 10 post-surgery. B: Correlation of ARA 290 treat-
ment dose and the relief of mechanical allodynia, calculated by the difference in area under 
the curves (AUC) of the mechanical allodynia response on day 1 vs. day 140. The adjusted R2 is 
0.56. C: Survival analysis showing the mechanical allodynia-free proportion of animals in time 
either sham-operated, or receiving spared nerve injury and treated with vehicle or different 





Figure 2: A: Effect of spared nerve injury and treatment with vehicle or different doses of ARA 
290 on cold allodynia scores. Animals were sham-operated (grey) or received spared nerve in-
jury and 5 doses of vehicle, 3 µg/kg ARA 290, 10 µg/kg ARA 290, 30 µg/kg ARA 290, or 60 µg/kg 
ARA 290 administered on days 1, 3, 6, 8 and 10 post-surgery (for each treatment P < 0.0001 com-
pared to vehicle). Scoring of cold allodynia is described in the Methods section. B: Correlation 
of ARA 290 treatment dose and the relief of cold allodynia, calculated by the difference in area 
under the curves (AUC) of the cold allodynia score on day 1 vs. day 140. The adjusted R2 is 0.78. 
C: Survival analysis showing the cold allodynia-free proportion of animals in time either sham-
operated, or receiving spared nerve injury and treated with vehicle or different doses of ARA 
290. Log-Rank P < 0.001.
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µg/kg group. The dorsal horns of animals that received SNI with vehicle (Figure 3D), 
SNI with 30 µg/kg ARA 290 (Figure 3E) or sham surgery without treatment (Figure 3F) 
showed increased iba-1-IR in the dorsal horn which was more pronounced in vehicle-
treated animals. High power magnifications of individual microglia from the dorsal 
horns of animals that received SNI with 0 µg/kg ARA 290 (Figure 3G), SNI with 30 
µg/kg ARA 290 (Figure 3H) or sham surgery without treatment (Figure 3I). Microglia 
from the vehicle-treated group showed an activated phenotype with an amoeboid 
shape and retracted rami, whereas microglia from the 30 µg/kg treatment group and 
sham surgery group showed a resting phenotype with a stretched soma and rami. 
For further analysis, computerized calculation of the amount of immunoreactivity 
was performed.
Representative images of recorded photomicrographs of Iba-1-IR in lumbar dorsal 
horns L1 to L6 of animals at 2 weeks and 20 weeks following SNI surgery and treated 
with the various ARA 290 doses are given in Figures 4A and B with high power 
magnifications of microglia cells presented in the inserts. For group 1 (2 weeks post 
injury), microglia in the L5 segment of the 0 µg/kg treatment group showed an 
activated phenotype, whereas the microglia in other panels show a resting phe-
notype. Iba-1-IR was increased in the L5 segment following vehicle treatment only 
(Figure 5A, P < 0.05 versus sham). Irrespective of treatment, no increase in reactivity 
was observed in any of the other segments. In contrast, in group 2 (20 weeks post 
injury), Iba-1-IR had spread both cranially and caudally to multiple spinal cord seg-
ments in vehicle-treated animals (Figure 4B) with significantly increased Iba-1-IR in 
segments L2 to L5 (p < 0.05 vs. sham). As shown in the inserts of Figure 4B, microglia 
in the L1-L6 segments of the vehicle and 10 µg/kg treatment groups showed an acti-
vated phenotype, whereas the microglia in the 30 µg/kg and sham groups showed a 
resting phenotype. In Groups 1 and 2, treatment with 30 µg/kg ARA 290 prevented 
an increase in Iba-1-IR as shown by the absence of Iba-1-IR in all segments (Figures 
5A and B; 30 µg/kg: ns vs. sham, P < 0.05 vs. vehicle at segments L2 to L4). In Group 
2, treatment with 10 µg/kg of ARA 290 did not decrease Iba-1-IR relative to vehicle-
treated animals (Figure 5B; ns vs. vehicle, P < 0.05 vs. 30 µg/kg at segments L2-L4).
Figure 3 (next page): Representative photomicrographs of Iba-1 immunoreactivity (green) in the 
L5 spinal cord segment of animals 2 weeks after spared nerve injury (SNI). (A-C) Low power 
magnifications, (D-F) detailed images of (A-C) as indicated by the white rectangles, and (G-I) high 
power magnifications of the spinal cord of animals that underwent: A, D and G. SNI and vehicle 
treatment, B, E and H. SNI and treatment with 30 µg/kg ARA 290, C, F and I. sham surgery with-
out treatment. The left-hand side of the photomicrographs represents the ipsilateral side of the 
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SNI does not increase GFAP-immunoreactivity in the dorsal horn
SNI did not induce an astrocytic response in vehicle-treated animals relative to sham 
operated rats for spinal cord segments L1-L6 at either 2 weeks (Figure 6A, Figure 7A) 
or 20 weeks (Figure 6B, Figure 7B) post injury. No effect of treatment was observed.
Figure 4 (previous pages): A: Representative photomicrographs of Iba-1 immunoreactivity 
(green) in the lumbar dorsal horns of animals 2 weeks after spared nerve injury (SNI). Animals 
were either treated with vehicle (upper row), 10 µg/kg ARA 290 (second row) or 30 µg/kg 
ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In 
each column, the Iba-1 immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is 
shown. Inserts show higher magnifications of the photomicrographs.
B: Representative photomicrographs of Iba-1 immunoreactivity (green) in the lumbar dorsal 
horns of animals 20 weeks after spared nerve injury (SNI). Animals were either treated with 
vehicle (upper row), 10 µg/kg ARA 290 (second row) or 30 µg/kg ARA 290 (third row). The 
bottom row represents sham-operated animals without treatment. In each column, the Iba-1 
immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show 
higher magnifications of the photomicrographs.
A B
Figure 5: Quantification graphs showing Iba-1 immunoreactivity (percentage of immunostained 
area) in sections of different lumbar spinal cord levels (L1-L6) from animals 2 weeks (panel A) 
or 20 weeks (panel B) after sham-operation, spared nerve injury and vehicle-treated, spared 
nerve injury and treatment with 10 µg/kg ARA 290, or spared nerve injury and treatment with 
30 µg/kg ARA 290. A: At 2 weeks post injury, Iba-1-IR was increased in the L5 segment following 
vehicle treatment only * P < 0.05 vs. sham. B: At 20 weeks post injury, vehicle * P < 0.05 vs. sham 






















The main findings of this study are: (1) The spared nerve injury model caused a rapid 
and long-lasting neuropathy with mechanical and cold allodynia; (2) ARA 290 pro-
duced dose-dependent relief of both mechanical and cold allodynia; (3) A spreading 
microglia response (i.e. Iba-1-IR and phenotype) was apparent from L5 at week 2 
following nerve damage to L2-6 at week 20; (4) No effect of nerve injury on the 
Figure 6 (previous pages): A: Representative photomicrographs of GFAP immunoreactivity 
(green) in the lumbar dorsal horns of animals 2 weeks after spared nerve injury (SNI). Animals 
were either treated with vehicle (upper row), 10 µg/kg ARA 290 (second row) or 30 µg/kg 
ARA 290 (third row). The bottom row represents sham-operated animals without treatment. In 
each column, the GFAP immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is 
shown. Inserts show higher magnifications of the photomicrographs.
B: Representative photomicrographs of GFAP immunoreactivity (green) in the lumbar dorsal 
horns of animals 20 weeks after spared nerve injury (SNI). Animals were either treated with 
vehicle (upper row), 10 µg/kg ARA 290 (second row) or 30 µg/kg ARA 290 (third row). The 
bottom row represents sham-operated animals without treatment. In each column, the GFAP 
immunoreactivity signal at different lumbar spinal cord levels (L1-L6) is shown. Inserts show 
higher magnifications of the photomicrographs.
A B
Figure 7. Quantification graphs showing GFAP immunoreactivity (percentage of immunos-
tained area) in sections of different lumbar spinal cord levels (L1-L6) from animals 2 weeks 
(panel A) or 20 weeks (panel B) after sham-operation, spared nerve injury and vehicle-treated, 
spared nerve injury and treatment with 10 µg/kg ARA 290, or spared nerve injury and treat-
ment with 30 µg/kg ARA 290. Data are mean ± SEM.
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astrocyte response was observed at weeks 2 and 20 following nerve damage; and (5) 
ARA 290 suppressed Iba-1R in a dose dependent manner.
Neuropathic pain in animals (due to experimental nerve damage) and humans (due 
to sarcoidosis or diabetes mellitus type 2) responds well to treatment with ARA 290, 
in that it produces relief of spontaneous pain (humans) and allodynia (humans and 
animals)25,26,31,37. Studies in mice that lack the β-common-receptor show further that 
ARA 290 is without behavioral effect (i.e. allodynia is not relieved by ARA 290), 
implicating this receptor as site of action of ARA 29025,26.
The β-common-receptor forms a heterocomplex together with EPO receptor and it 
is believed that this receptor complex, which we designate the innate repair recep-
tor (IRR), is the molecular site of action of both EPO and ARA 29027,29,38. Exogenous 
EPO, similar to ARA 290, reverses allodynia and reduces neuronal apoptosis and 
proinflammatory cytokine production, neuronal regeneration and the release of 
anti-inflammatory cytokines28. We do not use EPO in our studies as, in contrast to 
ARA 290, it comes with severe side effects including enhanced hematopoiesis and 
cardiovascular complications (e.g. hypertension, thrombosis, myocardial infarction). 
In common with previous studies25,26, we show here that ARA 290 has effective and 
prolonged (up to 20 weeks) anti-allodynic effects.
There is ample evidence that peripheral nerve injury results in a strong spinal inflam-
matory response17. For example, we previously showed in mice that surgical damage 
to the sciatic nerve causes the increase of expression of pro-inflammatory markers 
including Iba-1 mRNA, GFAP mRNA and CCL2 mRNA, within 7 days following nerve 
damage26. CCL2 plays an important role in the invasion of monocytes from peripheral 
blood as well as resident macrophages towards the spinal cord lesion site following 
peripheral nerve damage. In our current study the inflammatory response follow-
ing SNI was apparent from the increase in Iba-1-IR. The Iba-1-IR response showed a 
marked expansion from level L5 in week 2 following SNI, to 5 adjoining segments, 
L2 to L6, at week 20. In addition to the spreading of Iba-1-IR to multiple segments, 
the intensity of the response also increased over time as shown by a higher degree 
of Iba-1-IR and phenotypic signs of activation. We are the first to show this spreading 
inflammatory response in the spared nerve injury model of neuropathic pain. Similar 
observations were made earlier in experimental models of spinal cord injury and nerve 
root avulsion39,40. Previous reports of glial response following peripheral nerve injury 
showed that the response area is confined to the spinal cord segments innervated by 
the damaged nerve41,42. However, these responses were measured within a 2-week 
time frame. This is in agreement with our observation of lack of spreading at week 
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2. Caudal and cranial expanding inflammation, as observed here, may explain the 
increase in severity of NP symptoms over time and development of symptoms in areas 
of the body not innervated by the damaged nerve43. Similarly, various experimental 
reports indicate that the inflammatory responses may spread to contralateral spinal 
cord areas8,44. In this study we did not quantify contralateral inflammation. Our data 
do suggest that time is an important factor in the spreading of the microglia response.
Iba-1-IR reflects microglia activation in addition to localization and morphology. 
Our data show increased Iba-1-IR after SNI, which is dose-dependently and long-
term reduced by ARA 290 treatment coupled to a dose-dependent and long-term 
reduction of mechanical and cold allodynia. This long-term effect suggests a disease 
modulatory effect of ARA 290. We argue that ARA 290 initiates a cascade of events 
involving several transduction factors of which activation of the IRR is the first step 
that eventually silences or reduces the inflammatory process29,36. Since the activa-
tion or recruitment of microglia is largely mediated through the local production of 
CCL245,46, a possible scenario is that ARA 290 reduces the release of CCL2 via activation 
of the IRR on neuronal and immune cells26. However, both at 2 and 20 weeks after 
SNI and ARA 290 treatment, relief of allodynia was not complete, indicating that 
the central response to peripheral nerve damage involves multiple systems including 
neuroinflammation and probably also up-regulation of excitatory pathways and 
synaptic plastic changes. Of interest is that ARA 290 treatment causes a reduction 
in NMDA mRNA (subunits NR1, NR2A and NR2B) in SNI animals, suggestive of an 
additional role, apart from immune-modulation, for ARA 290 in the treatment of 
neuropathic pain by suppression of excitatory glutamatergic activity26.
In contrast to a markedly increased Iba-1-IR after SNI, no change in GFAP-IR or 
astrocytic phenotype (i.e. activation) was observed in animals with an SNI treated 
with vehicle after 2 and 20 weeks of lesion. This observation stands in contrast with 
reports describing involvement of astrocytes adjacent to microglia in NP5,7,10,47,48. The 
absence of astrocytosis in our SNI model may be explained by a time-limited astro-
cyte response (i.e. < 2 weeks or between 2-20 weeks). The involvement of astrocytes 
following peripheral nerve injury reported in the literature varies with some studies 
showing a relatively short-lived increase in GFAP-IR7, while others show an increase 
in GFAP-IR after 14 days that was still present after 150 days5. Further studies using 
more dense observations over time are required to get a reliable indication of the 
kinetics of the astrocyte response to peripheral nerve damage.
We have argued that the spinal cord is the predominant site of action of ARA 290 
following peripheral nerve damage. Indeed, there is ample evidence that peripheral 
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nerve injury activates an innate immune response activated in the spinal cord5-11. 
Furthermore, a complete block of the peripheral nerve with local anesthetics will not 
prevent central inflammation following peripheral nerve damage but only delays 
the development of pain, suggestive of a predominant central effect49,50. Still, at 
this point we cannot exclude an additional peripheral effect of ARA 290. Indeed, 
EPO specifically reduces axonal TNF-α in Schwann cells after peripheral nerve injury, 
resulting in attenuation of NP symptoms51. Hence, in addition to a central nervous 
system effect, modulation of the peripheral nerve immune response could also be 
part of the mechanism of action of ARA 290, but these specific effects remain to be 
investigated.
Conclusions
In conclusion, in the spared nerve injury model, we show that the erythropoietin-
analogue ARA 290 dose-dependently reduces allodynia coupled to suppression of 
the spinal microglia response, suggestive of a mechanistic link between ARA 290-in-
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Introduction
There is ample evidence for the importance of the excitatory N-methyl-D-aspartate 
(NMDA) glutamate receptor in the development and perseverance of chronic neu-
ropathic pain.1 NMDA receptors consist of multiple subunits: the obligatory NR1 
subunit combines with at least one NR2 subunit.2,3 Multiple NR2 subunits (A-D) have 
been identified. The NR1/NR2A NMDA receptor is ubiquitously distributed through-
out the brain and spinal cord; NR2Bcontaining NMDA receptors are restricted to 
specific areas with importance for pain signaling, including dorsal root ganglia, 
lamina I and II of the dorsal spinal horn, thalamus, hippocampus, and cortex.4 It is, 
therefore, not surprising that there is increasing experimental evidence that NR2B-
containing receptors are involved in chronic pain responses.2,5 Both nonselective and 
NR2B-selective NMDA receptor antagonists induce antinociception in experimental 
chronic pain models.6-9 However, an important difference between the two subsets 
of pharmacologic agents is that, whereas nonselective antagonists cause severe side 
effects, there are suggestions that NR2B selective agents are devoid of such actions.10
Extrapolation of animal data on the link between the NMDA receptor and chronic 
pain has led to the increased popularity of ketamine for the treatment of therapy-
resistant chronic noncancer pain, as may be concluded from the increase in the 
number of case studies and clinical studies on ketamine treatment in neuropathic 
and chronic, noncancer pain.11 Currently, proof for the efficacy of ketamine – or 
any NMDA receptor antagonist in the treatment of neuropathic chronic pain – is, 
however, limited.11 Ketamine is effective when used in combination with opioids in 
the treatment of acute postoperative pain and cancer pain management.11 Ketamine 
is currently the most potent NMDA receptor available for use in humans and is non-
selective (so far no selective NR2B NMDA receptor antagonists have been registered 
for pain treatment). Akin to animal observations, ketamine produces serious side 
effects in humans,11 including nausea, sedation, and psychedelic effects. Ketamine 
is rapidly metabolized into another NMDA receptor antagonist, norketamine.12,13 
Some contribution of norketamine to ketamine effects has been observed,8 but 
the magnitude of this contribution to ketamine analgesia and side effects remains 
unknown.
We agree that there is a need for an NMDA receptor antagonist with a clear separa-
tion of analgesic effects and side effects, most importantly psychedelic side effects.8 
The antinociceptive properties of three NMDA receptor antagonists – ketamine, 
norketamine, and Traxoprodil (a highly selective NR2B NMDA receptor antagonist) 
– were characterized in a model of acute antinociception and a well-established rat 
model of persistent neuropathic pain, the spared nerve injury (SNI) model.14 In ad-
dition, side effects (stereotypical behavior and activity level) and injured paw func-
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tionality were quantified. In contrast with previous studies,6-9 we used a long-term 
infusion paradigm (3 h for 5 consecutive days) administered 7 days after peripheral 
nerve injury. The delay in treatment was chosen to mimic established neuropathic 
pain states in patients by allowing the development of NMDA receptor sensitization 
and plasticity. A long-term infusion was used to mimic the observation in humans 
that prolonged infusion schemes are needed to ensure analgesic effects lasting for 
weeks rather than hours or days.11,15
The aims of the study were to compare ketamine, norketamine, and Traxoprodil with 
respect to: (1) analgesic behavior in acute and chronic pain paradigms, (2) separation 
in effect versus side effect, and (3) functionality of the injured paw after nerve injury. 
We hypothesized that all three NMDA receptors would produce analgesia, with 
Traxoprodil showing an improved utility index (i.e., analgesia with less side effects 
than either ketamine or norketamine). We further hypothesized that as a result of 
the reduction in pain, locomotor function would be improved after treatment with 
all three drugs in the chronic nerve injury model.
Materials and Methods
Female Sprague-Dawley rats (Charles River Nederland BV, Maastricht, Netherlands), 
9 weeks old and weighing approximately 230 g were housed two per cage in indi-
vidually ventilated cages under standard laboratory conditions with water and food 
ad libitum and 12 h light/dark cycles (lights on/off at 7:00 AM/PM). After surgery, 
animals were housed separately. Body weights were determined on the day of test-
ing. All studies were performed during the light phase of the cycle. At the end of the 
studies, animals were euthanized by exsanguination under 6% sevoflurane anesthe-
sia. The experiments were performed after approval of the protocol by the animal 
ethics committee of Leiden University (Dier Ethische Commissie, Leiden University 
Medical Center).
Acute Pain Model
Fifteen rats each received an intravenous cannula in the external jugular vein for 
drug administration under general anesthesia (6% sevoflurane induction, 3.5% 
maintenance). The cannula was subcutaneously directed toward the scalp and fixed 
to the skull. After surgery, animals were allowed to recover for 7 days, after which 
they were randomly allocated to one of three test groups (5 per group). Group 1 
received ketamine (Eurovet Nederland, Bladel, Netherlands) at the following doses: 
0, 1.25, 2.5, 5, 7.5 and 10 mg/kg. Group 2 received norketamine (Tocris Bioscience, 
Bristol, United Kingdom) at the following doses: 0, 2.5, 5, 7.5, 10 and 12.5 mg/kg. 
77
NMDA receptor antagonists and pain relief
Group 3 received Traxoprodil (Pfizer Inc., New York, NY) at the following doses: 0, 
10, 20, 30, 40 mg/kg. Higher doses were not tested because they induced loss of con-
sciousness. Each dose was tested on a separate day. The order of doses was random.
Acute antinociception was assessed by applying an infrared thermal stimulus to the 
plantar surface of the hind paws (Plantar Test, Ugo Basile, Comerio VA, Italy). After 
a period of adaptation, the test drug was infused (dissolved in 200 µl normal saline) 
and paw withdrawal times (PWT) were obtained at regular intervals (5, 10, 15, 25, 
40, and 55 min after infusion). The intensity of the heat stimulus was set to obtain 
baseline PWT at approximately 5 s and a cut-off value of 20 s was used to prevent 
burning of the skin. Each animal received one heat stimulus to each of the hind paws 
per time point. Measurements were averaged for further analysis.
Stereotypical behaviors and activity levels were scored as an indication of the drug’s 
side effects. Stereotypical behaviors were scored on a scale from 0 to 3, with 0 = nor-
mal behavior, 1 = increased explorative (sniffing) behavior, 2 = increased urge to 
move around the cage, and 3 = inability to hold still with weaving/shaking/twitching 
of the head and body. Activity level was scored on a scale from 0 to 3, with 0 = normal 
activity, 1 = mildly impaired activity (i.e., disturbance in paw support), 2 = moderately 
impaired activity (i.e., a tendency to fall over but able to regain an upright posi-
tion after falling), and 3 = severely impaired activity (i.e., inability to maintain paw 
support, falling with an inability to regain the upright position). These scores were 
adapted from Holtman et al.8 and possibly relate to psychedelic side effects observed 
in humans.
Chronic Pain Model
The SNI model was designed according to the model of persistent neuropathic pain 
by Decosterd and Woolf.14 In 32 animals, the skin on lateral surface of the thigh was 
incised under sevoflurane anesthesia (induction 6%, maintenance 3.5%). The sciatic 
nerve, with its three terminal branches (sural, common peroneal, and tibial nerves), 
was exposed by blunt preparation. The common peroneal and the tibial nerves were 
tightly ligated with 5.0 silk sutures and sectioned distal to the ligation, removing 
2–4 mm of distal nerve stump. Great care was taken to avoid any contact with or 
stretching of the intact sural nerve. The nerve stumps were dislocated (more than 
1 cm) to prevent regeneration. Muscle and skin were closed in two layers. The SNI 
model results in early (within 24 h), prolonged (more than 6 months), and robust (all 
animals are responders) behavioral changes. Next, a venous catheter was placed in 
the jugular vein for intravenous drug infusion. The catheter was placed subcutane-
ously at the back of the neck and fixed on the surface of the skull.
After a 1-week rest period, animals were randomly allocated to receive intravenous 
ketamine, norketamine, Traxoprodil, or vehicle. Eight animals were assigned to each 
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study group. Randomization was performed in blocks of four; four successively oper-
ated animals were randomized into one of the four treatment groups. Intravenous 
infusions were given continuously for 3 h for 5 consecutive days: 3 mg/kg/h ketamine 
(9 mg/kg per day for 5 days), 9 mg/kg/h norketamine (27 mg/kg per day for 5 days), 
or 10 mg/kg/h Traxoprodil (30 mg/kg per day for 5 days). Vehicle was normal saline 
(0.9% NaCl) given at a rate of 1 ml/h. Ketamine, norketamine, and Traxoprodil doses 
were based on a pilot study aimed at producing equiefficacy with respect to me-
chanical antiallodynic effect combined with minimal side effects.
In three other animals, a sham operation was performed. Under sevoflurane anes-
thesia, the skin on the lateral surface of the thigh and underlying muscle was incised. 
The sciatic nerve and its three terminal branches were exposed by blunt preparation. 
No nerve ligation was performed. Subsequently, muscle and skin were closed in two 
layers. No treatment was given to these animals.
Postoperatively, the animals were given 0.1 mg/kg buprenorphine and monitored for 
1 h with body temperature maintained at 38 °C. Thereafter, animals were monitored/ 
tested weekly for motor functions, behavior changes (autotomy), body weight, and 
allodynia of the injured paw. The study ended 10 weeks post surgery.
In order to measure mechanical allodynia, the animals were placed in a see-through 
box on a wire mesh floor. With the use of different von Frey hairs (Semmes-Weinstein 
monofilaments, North Coast Medical Inc., San Jose, CA) with increasing stiffness 
(0.004–300 g), incremental forces were exerted on the plantar surface of the affected 
hind paw. The hairs were applied 10 times at intervals of 2–3 s to slightly different 
loci within the test area.7 The force necessary to induce a withdrawal reflex was 
recorded. Peak allodynia was defined as the minimum force that would trigger a 
withdrawal response in the first 10 postoperative weeks.
Next, animals were tested for cold allodynia with an acetone spray test. The stimulus 
was applied by spraying 20 µl acetone on the plantar surface of the affected hind 
paw. Animal response was scored according to the following classification: 0 = no 
withdrawal, 1 = startle response lasting less than 1 s, 2 = withdrawal lasting 1–5 s, 
3 = withdrawal lasting 5–30 s (with or without paw licking), and 4 = withdrawal last-
ing longer than 30 s (with or without licking and repeated shaking).
Using a video-based, illuminated footprint analysis system (CatWalk, Noldus Infor-
mation Technology, Wageningen, Netherlands),16,17 we measured the following gait 
and footprint parameters during a short walk of the animals on a glass plate: area of 
the foot print (surface of paw used during step cycle), stand duration (time spent on 
paw during step cycle), and maximum intensity (maximum exerted pressure on paw 
during step cycle). All data were collected for further analysis, which was performed 
on a blinded data set.
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data and Statistical Analysis
Acute Pain Model
To obtain an estimate of the acute anti-nociceptive potency of the test drugs, PWT 
data (latencies) were fitted to the following model (adapted from Romberg et al.,18 
and Lötsch et al.19):
PWT(d) + PWTB + PWT0 + 5 ∙ [d/X5]
γ
PWT(d) is the peak latency observed after dose d; PWTB, the latency before drug 
infusion; PWT0, peak latency observed after saline; X5, drug dose causing an increase 
in latency of 5 s (i.e., approximate ED50); and γ, a shape parameter. The model was 
fitted to the data with the statistical package NONMEM (Nonlinear Mixed Effects 
Modeling, version VII; ICON Development Solutions, Ellicott City, MD).20
For the two measured side effects, typical behavior and activity level, data were 
analyzed using the following model (adapted from Romberg et al.,18 and Lötsch et 
al.19):
S(d) = S0 + 1.5 ∙ [d/Y1.5]
γ
S(d) is the side effect score at dose d; S0, the score after saline; and Y1.5, the drug 
dose causing an increase in score by 1.5 points. Estimations were performed with 
NONMEM.20 
Chronic Pain Model
Power analysis was based on a pilot study of ketamine versus saline treatment effect 
on mechanical allodynia in the SNI model. Four animals were treated with ketamine, 
three others with saline. At t = 2 weeks (1 week after end of treatment), the mean 
± SD force that caused a withdrawal response in ketamine-treated animals was 0.2 
± 0.17 versus 0.02 ± 0.01 g in saline-treated animals. We calculated group sizes of 
at least eight animals to detect a difference between treatments of at least 1 SD 
between groups, with a reliability of 5% and a power higher than 80%.
Areas under the curve were calculated from postoperative weeks 1–10 using the 
trapezoidal rule (AUC1–10). Among treatments, a comparison on AUC, peak effect, 
and duration of effect was performed using Kruskal-Wallis test and post hoc Tukey 
tests (hypothesis testing was two-tailed). Duration of effect was defined as the time 
at which the effect of an individual animal crossed the 95% CI of saline treatment.
The function of the injured paw was expressed as a percentage of the function of 
the sham animals. Gait analyses were performed in postoperative weeks 1, 3, and 
4. Treatment effects were assessed by Kruskal-Wallis and post hoc Dunn’s tests (hy-
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pothesis testing was two-tailed). The data are expressed as mean ± SEM or median 
± 50% quartile range for side effects (typical behavior and level of activity) unless 
otherwise stated. Statistical analyses were performed with SigmaPlot (version 11; 




All three tested NMDA receptor antagonists produced dose-dependent acute anti-
nociception (Figure 1). Model parameter estimates are PWTB = 5.3 ± 0.2 s, PWT0 = 1.1 
± 0.3 s, ketamine X5 = 7.6 ± 0.9 mg/kg, norketamine X5 = 12.5 ± 1.3 mg/kg, and Traxo-
prodil X5 = 37.9 ± 2.6 mg/kg. Corresponding values for γ are 0.9 ± 0.2, 1.9 ± 0.5, and 
1.7 ± 0.3, respectively.
Stereotypical behavior and activity level scores are given in Figure 2. Both ketamine 
and norketamine produced dose-dependent side effects. Traxoprodil showed no 
signs of side effects across the dose range tested. Accordingly, no quantitative 
analysis was performed on Traxoprodil data. Model parameter estimates were for 
stereotypical behavior (S0 = 0 ± 0 [median ± SEM]): ketamine Y1.5 = 3.7 ± 0.4 mg/kg and 
Figure 1: Dose-response relationship of ketamine, norketamine, and Traxoprodil versus paw 
withdrawal latencies. Percent analgesia was calculated as: (drug latency at dose d - latency 
after saline)/(cutoff latency - latency after saline). Values are presented as mean ± SEM.
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norketamine Y1.5 = 9.4 ± 0.6 mg/kg, with respective values for γ of 0.6 ± 0.1 and 1.3 
± 0.3. For activity level (S0 = 0 ± 0): ketamine Y1.5 = 2.8 ± 0.5 mg/kg and norketamine 
Y1.5 = 9.4 ± 0.4 mg/kg, with respective values for γ of 0.6 ± 0.1 and 2.1 ± 0.3.
Chronic Pain Model
Although, during treatment, side effects were observed for ketamine and norket-
amine, but not for Traxoprodil, no side effects were observed in the 8 weeks after 
treatment. One week after transection of the common peroneal and the tibial nerve, 
animals displayed overt mechanical allodynia with withdrawal responses induced by 
0.004 – 0.02 g filaments versus 8 g in the sham operated group (Figure 3, table 1). 
Five-day treatment with ketamine, norketamine, and Traxoprodil, but not saline, 
resulted in alleviation of mechanical allodynia with maximum relief (peak effect) oc-
curring at postoperative week 2 (ketamine and Traxoprodil) and week 3 (ketamine). 
No difference in efficacy of the three NMDA receptor antagonists on mechanical 
allodynia, at the doses tested, could be detected.
A significant main effect for treatment on AUC1–10 was observed (P < 0.001). The 
AUC1–10s of ketamine, norketamine, and Traxoprodil were significantly larger 
compared with saline, but did not differ among each other. Similarly, a significant 
main effect of treatment on peak antiallodynia was present (P < 0.001, Table 1). At 
peak antiallodynia, animals treated with the NMDA receptor antagonists ketamine 
A B
Figure 2: A: Dose vs. Stereotypical behavior. B: Dose vs. level of activity. Displayed for the three 
test drugs, ketamine, norketamine, and Traxoprodil. Values are presented as mean ± SEM.
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and norketamine responded to a higher force compared with saline-treated rats. 
However, between treatments, no difference was detected. In contrast, peak an-
tiallodynic effect in the animals treated with Traxoprodil did not differ from peak 
effect in saline-treated animals. Duration of antiallodynia was similar between 
A B
C
Figure 3: The effect of ketamine (A), norketamine (B), and Traxoprodil (C) on mechanical al-
lodynia in the spared nerve injury model of the ipsilateral paw. Squares represent data from 
placebo-treated animals; circles, animals treated with N-methyl-D-aspartic acid receptor an-
tagonists; triangles, sham-operated animals. X = treatment day. On the y-axis, the force used 
on injured paw with von Frey filaments to induce withdrawal response. Values are presented 
as mean ± SEM.
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treatments and lasted until postoperative weeks 5.6 ± 0.9 (ketamine), 7.1 ± 0.9 
(norketamine) and 5.4 ± 0.6 (Traxoprodil). Relative potencies (calculated as dose 
ratio at which agents had identical AUC1–10) were 1:2 (ketamine:norketamine) and 
1:8 (ketamine:Traxoprodil).
Allodynia to cold stimulation occurred in week 1 after nerve injury in all animals 
(cold allodynia scores before treatment range between 2.5 and 3.1 in animals with 
SNI vs. 0.7 in sham operated animals, table 1). Ketamine, norketamine, and Traxo-
prodil induced relief of allodynia with peak antiallodynic effect occurring in week 2 
(ketamine and Traxoprodil) and week 3 (norketamine).
A significant main effect for treatment on AUC1–10 was observed (Table 1 and Figure 
4, P < 0.001). The AUC1–10s in animals treated with NMDA receptor antagonists were 
significantly smaller than the AUC1–10 observed in saline-treated animals by 17–27%. 
No differences in AUC1–10s were observed among the three NMDA treatments. Al-
though a significant main effect was observed for a difference in peak antiallodynic 
effect (P = 0.03), post hoc analysis revealed that only norketamine was different from 
saline (Table 1). Duration of antiallodynic effect was similar between treatments and 
lasted until postoperative weeks 4.4 ± 1.1 (ketamine), 5.8 ± 0.7 (norketamine) and 
Table 1: Effect of Ketamine, Norketamine, and Traxoprodil on mechanical and cold allodynia
Ketamine Norket-
amine




















2.7 ± 1.2 *
(0.2 – 5.2)











1.4 ± 0.5 *
(0.5 – 2.3)
























25.4 ± 1.4 *
(22.3 – 28.2)
22.1 ± 1.0 *
(20.1 – 24.1)
















- P = 0.03
All values are mean ± SEM (95% CI).
# Main effect (P-value), Kruskal-Wallis test. * P< 0.05 vs. saline, post hoc Tukey test.





Figure 4: The effect of ketamine (A), norketamine (B), and Traxoprodil (C) on cold allodynia 
in the spared nerve injury model of the ipsilateral paw. The y-axis reflects the 4-point scale 
used to calculate cold-temperature stimulation of the injured paw via acetone spray test: 0 = no 
withdrawal, 1 = startle response lasting less than 1 s, 2 = withdrawal lasting 1–5 s, 3 = withdrawal 
lasting 5–30 s (with or without paw licking), and 4 = withdrawal lasting longer than 30 s (with or 
without licking and repeated shaking). Squares represent data from placebo-treated animals; 
circles, animals treated with N-methyl-D-aspartic acid receptor antagonists; triangles, sham-
operated animals. X = treatment day. Values are presented as mean ± SEM.
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4.8 ± 0.6 (Traxoprodil). Relative potencies (calculated as dose/AUC) were 1:3.4 for 
ketamine:norketamine and ketamine:Traxoprodil.
At postoperative week 1, nerve injured animals displayed severe dysfunction of the 
affected paw (Figure 5). At week 1, the surface of the injured paw used during a step 
cycle (area) was 2.6–9.6% (range) of that of the sham operated animals. Time spent 
on the injured paw during a step cycle (stand) was 19–33%. Pressure on the injured 
paw during a step cycle (intensity) was 32–37%. In the 2 weeks after treatment, 
saline-treated animals displayed a further gradual deterioration of gait-related 
parameters. Significant main effects of treatment were detected for all three tested 
indices (stand, P = 0.02; area, P = 0.03; intensity, P = 0.045). Post hoc analysis revealed 
that neither ketamine nor Traxoprodil treatment had a significant effect on any 
of the measured gait parameters. Only after norketamine treatment improved re-
sponses (relative to saline) were observed for all three indices (all P < 0.05). However, 
these effects were limited in magnitude and duration of effect (Figure 5).
Peak effect occurred at postoperative week 3, showing an improved value versus 
saline (area, 17 ± 2% vs. 3.4 ± 0.9%; stand, 52 ± 7% vs. 27 ± 5%; and intensity, 60 ± 
4% vs. 33 ± 2%). At week 4, however, gait responses had returned to values observed 
before treatment (i.e., week 1).
discussion
Ketamine is the prototypical NMDA receptor antagonist, now in use for nearly 50 
years.21 It is widely applied in the treatment of therapy-resistant chronic pain, as 
an adjuvant to opioids in the perioperative setting, and in cancer pain manage-
ment.11,21 Side effects, occurring at analgesic doses, restrict its use and emphasize 
the need for an NMDA receptor antagonist with an improved therapeutic index.8 
In this experimental study, we characterized and compared the effects of ketamine 
with its active metabolite norketamine and the NR2B-selective NMDA receptor an-
tagonist Traxoprodil. Several important observations were made: (1) All three NMDA 
receptor antagonists were efficacious in a model of acute antinociception and a 
well-established model of chronic neuropathic pain. (2) Ketamine was most potent 
in acute and chronic pain models, followed by norketamine and Traxoprodil. (3) Pain 
relief in the chronic pain model persisted for weeks after treatment termination. (4) 
Side effects (stereotypical behaviors and loss of activity) were present after treat-
ment with ketamine and norketamine. Although norketamine showed an improved 
therapeutic index compared with ketamine, side effects occurred over the entire 
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tween effect and side effects was present for Traxoprodil with, across the dose range 
tested (0 – 40 mg/kg), the absence of any signs of agitation and motor dysfunction. 
(5) After induction of nerve injury, norketamine caused improvement in function of 
the injured paw during the period of pain relief, although the effect was short-lived 
and relatively small. In contrast, no improvement was seen after treatment with 
ketamine or Traxoprodil, despite significant relief of mechanical allodynia.
Potencies for acute pain relief – as determined by parameter X5, the dose causing an 
increase in PWT of 5 s (an approximate ED50) – indicate that ketamine was 1.6 times 
more potent than norketamine and 5 times more potent than Traxoprodil (derived 
from X5 ratios). Side effects were present after the administration of ketamine and 
norketamine. Although norketamine showed an improved therapeutic index (de-
fined as X5/Y1.5, equations 1 and 2) compared with ketamine (agitation, ketamine = 2.1 
vs. norketamine = 1.3; motor dysfunction, ketamine = 2.7 vs. norketamine = 1.3), side 
effects occurred over the entire analgesic dose range for both agents. A clear separa-
tion between effect and side effect was present for Traxoprodil with (across the 0-40 
mg/kg dose range tested) the absence of any signs of stereotypical behavior and loss 
of activity.
Our data indicate that Traxoprodil may be clinically useful in the treatment of acute 
pain, with a superior therapeutic index when compared with ketamine and nor-
ketamine. The observation of absence of side effects is in agreement with other 
studies.10 With respect to motor function, this finding is likely related to the absence 
of NMDA receptors containing the NR2B subunit in the cerebellum.6 The mechanisms 
by which NMDA receptor antagonists produce acute pain relief have been attributed 
to activity at non-NMDA receptors, such as the µ-opioid receptor.22 However, there 
is evidence for the NR2B-containing NMDA receptors located presynaptically on pri-
mary afferent C-fibers in lamina I of the dorsal horn.6 These receptors may modulate 
the presynaptic release of substance P and glutamate and consequently modulate 
acute pain transmission in the spinal cord.6
All three NMDA receptor antagonists produced relief of mechanical and cold al-
lodynia in the SNI model. Relative potencies indicate that, for mechanical allodynia, 
ketamine is twice as potent as norketamine and eight times more potent than Traxo-
prodil. For cold allodynia, ketamine was 3.4 times more potent than norketamine 
and Traxoprodil. For none of the three agents did any side effects (agitation, motor 
dysfunction) occur during the period of testing. We observed that the magnitude 
and duration of relief of mechanical allodynia was more pronounced than that of 
cold allodynia (Figure 4). Previously, Qu et al.,23 showed that pretreatment with 
ifenprodil, a selective NR2B antagonist, induced relief of mechanical allodynia, but 
not thermal hyperalgesia, in a spinal nerve ligation model. These findings suggest 
that the development of different pain expressions or modalities (e.g., mechanical 
Chapter 5
90
vs. cold allodynia) is due to activation of different pain pathways after peripheral 
nerve injury, each with a different (subunit) expression of NMDA receptors and, 
consequently, distinct sensitivities to different NMDA receptor antagonists.23 For 
example, after peripheral nerve injury, sprouting of Aδ-fibers into the superficial 
layers of the dorsal horn is associated with mechanical allodynia but not thermal 
hyperalgesia.23,24
Several studies on the effect of NMDA receptor antagonists on neuropathic pain test 
the preemptive effect of treatment or the effect of treatment in the early stage of 
nerve injury.6,23,25,26 We performed our infusion 1 week after the induction of nerve 
injury. This timing was used to induce an established neuropathic pain state. We 
assumed that 1 week after surgery (the late phase of nerve injury), NMDA receptor 
sensitization had fully developed with established structural changes in the affected 
pain pathways (such as up-regulation of NMDA receptors).9 Our approach mimics 
the situation in neuropathic pain patients, who are often treated weeks or months 
after nerve injury has occurred. We infused the test agents for 5 consecutive days. 
This process was used because, in neuropathic pain patients, long-term or repeti-
tive treatments with NMDA receptor antagonists (rather than short-term infusions) 
produce long-lasting analgesic effects.11 For example, we previously showed that a 
100-h infusion with S(+)-ketamine produced pain relief that lasted up to 12 weeks in 
patients with chronic pain as a result of complex regional pain syndrome type 1.15 In 
patients with neuropathic pain from spinal cord injury or monoradiculopathy, a rela-
tively short 24-h infusion with Traxoprodil produced pain relief during the infusion 
period only.4,5,27 A similar short duration of analgesic effect (8 h) was observed in the 
rat after an intrathecal injection with ifenprodil given 7 days after dorsal root gan-
glion compression.9 We believe that a prolonged analgesic effect is mandatory when 
treating neuropathic pain patients with intravenous NMDA receptor antagonists to 
reduce treatment costs and patient discomfort and increase treatment compliance.
We observed long-term relief of mechanical and cold allodynia lasting 3–6 weeks 
after the initiation of 5-day treatment. Because ketamine exhibits a rapid reduction 
in ketamine and norketamine plasma concentrations on infusion termination, it is 
not expected that any active agent was present in the rat during the test phase 
of our study. Apparently, ketamine initiated a cascade of events (of which the first 
step is NMDA-receptor desensitization) that caused long-term effective and continu-
ing blockade for central trafficking of pronociceptive signals to the thalamus and 
cortex.28,29 In agreement with this theory, Christoph et al.30 showed that the antial-
lodynic effect of NMDA receptor antagonists (more than 3 h with ketamine) outlasts 
the in vivo NMDA receptor antagonism (t1⁄2 = 10–12 min) in rats with chronic nerve 
constriction injury. In addition, a central reset of central glutamatergic brain circuits 
involved in pain transmission may play a role.29 A supraspinal effect of NMDA recep-
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tor antagonists is in agreement with studies that point to a role for NR2B NMDA 
receptors in the forebrain and amygdala in the development and enhancement of 
neuropathic and inflammatory pain.31-33 Our findings indicate that long-term relief 
of neuropathic pain is possible despite a delayed therapy start with all three tested 
NMDA receptors. More prolonged effects may be feasible by adjusting dosing or 
duration of treatment, or by repetition of treatment at 4 –5 week intervals.
Injured paw use during locomotion was tested using Cat-Walk automated quantita-
tive gait analysis,16,17 which has been used previously to quantify tactile allodynia in 
the rat. Vrinten and Hamers16 compared gait analysis using von Frey testing in rats 
with chronic constriction injury of the sciatic nerve. They observed a high degree of 
correlation between gait parameters and von Frey mechanical allodynia. In contrast, 
Gabriel et al.34 were unable to find significant correlations in rats with chronic pain 
induced by intra-articular λ-carrageenan injection in the knee. Mogil et al.,35 using 
a blinded scoring approach, observed differences in dynamic, weight-bearing (gait) 
changes between sham operated mice and mice with spared nerve (but not chronic 
constriction injury). However, in the SNI animals, there was a pharmacologic dissocia-
tion between mechanical allodynia and gait changes. Morphine, gabapentin, and 
EMLA cream (2.5% lidocaine ± 2.5% prilocaine) reversed mechanical allodynia but 
did not affect gait abnormalities of the injured paw. Our data indicate a profound 
and long-lasting effect of SNI damage on the gait parameters of area, stand, and 
intensity. In all animals with SNI, we observed reduced use of the affected paw 
with minimal floor contact during locomotion. We relate the reduced use to the 
perception of mechanical allodynia during contact of the paw with the surface 
(weightbearing allodynia).
We are the first to quantify pharmacologic treatment with NMDA receptor antago-
nists on gait patterns in chronic pain with the CatWalk system. The effect of treat-
ment on gait abnormalities was disappointing. After treatment with norketamine, a 
significant effect on gait-parameters was observed, but the effects were short-lived 
(effect in week 3 only, Figure 5) and relatively small. No improvements were observed 
after treatment with ketamine or Traxoprodil, despite significant relief of mechani-
cal allodynia (measured via von Frey test). The reason for absence of improvement 
of paw abnormalities (or just a limited effect, as seen with norketamine) may be that 
weight-bearing allodynia is less sensitive to pharmacologic intervention and requires 
higher doses. Testing mechanical allodynia with von Frey hairs may be less painful 
and more sensitive to NMDA receptor antagonism. Alternatively, diminished paw 
use and gait changes after nerve injury may not reflect (NMDA receptor–related) 
mechanical allodynia and are therefore not responsive to treatment with NMDA 
receptor antagonists. Both at the spinal and supraspinal level, gait and pain path-
ways are distinct. Gait is controlled by spinal networks under the direct influence of 
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descending pathways originating at the brainstem, which in turn receive afferent 
information from the cerebellum, basal ganglia, and sensorimotor cortex.34 It is rea-
sonable to assume that, after the inflicted nerve injury changes occur in these motor 
pathways (which do not involve NMDA receptor sensitization and up-regulation), 
a permanent inability to use the paw during locomotion occurs, possibly without 
spontaneous pain.35
The current findings are in agreement with our findings in patients with chronic pain 
from complex regional pain syndrome type 1.15,36 After treatment with ketamine, 
spontaneous pain scores improved significantly. However, there was no improvement 
of function-related parameters. We argued that pain relief should coincide with im-
provement of function and use of the affected limb. Our current and previous data 
do not support this argument. It may well be that improvement of locomotor func-
tion and increase in use requires a different treatment approach (e.g., combining 
pharmacotherapy with physical exercise, physiotherapy, and/or surgical intervention 
(nerve reconnection or transplantation)).
Conclusion
All three NMDA receptor antagonists caused dose-dependent antinociception in the 
acute pain model. Likewise, they caused relief of mechanical and cold allodynia for 
3–6 weeks after treatment in a chronic neuropathic pain model. In both pain tests, 
ketamine was most potent, with norketamine 1.5–2 times less potent and Traxopro-
dil 5–8 times less potent than ketamine. In contrast to nonselective NMDA receptor 
antagonists, treatment with Traxoprodil caused no side effects. Although all three 
agents produced long-term relief of mechanical allodynia in nerve-injured animals, 
improved use of the affected paw during locomotion, as tested by computerized 
gait analysis, was limited (norketamine) or absent (ketamine and Traxoprodil). These 
observations make Traxoprodil an attractive alternative to ketamine in the treat-
ment of chronic neuropathic pain. Alternative treatment options are required to 
induce increase limb (paw) use.
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Introduction
Neuropathic pain (NP), arising from lesions affecting the somatosensory system1, is 
often not adequately treated by current pharmacotherapy, such as antidepressants, 
opioids, and topical agents (e.g., lidocaine or capsaicin). It is a common feature fol-
lowing trauma or infectious, autoimmune, metabolic, and neurological diseases2,3, 
and is often accompanied as well by hyperalgesia. Inflammation arising from injury 
plays an important role in the development and maintenance of NP and the periph-
eral and central sensitization phenomena that establish allodynia and hyperalgesia 
depend upon a variety of neuromodulatory processes2. These may include the activa-
tion and up-regulation of dorsal horn excitatory glutamatergic N-methyl-D-aspartate 
receptors (NMDAR), as well as a vigorous inflammatory response within the spinal 
cord initiated and maintained by microglia and reactive astrocytes as well as the 
production of TNF-α, interleukins and CCL2 (reviewed in ref.4).
Recently, evaluation of preclinical models of NP have shown that erythropoietin (EPO) 
is locally produced following peripheral nerve injury and functions as an endogenous 
factor that limits damage and improves nerve function5,6. The tissue protective effects 
are mediated by the EPO receptor-β-common receptor complex7, rather than the EPO 
receptor homodimer (EPOR2) involved in erythropoiesis. This isoform, termed the in-
nate repair receptor (IRR), may additionally form functional complexes with other 
molecules to transduce specific cellular responses (e.g. vascular endothelial growth 
factor receptor-2 or endothelial nitric oxide synthase, reviewed in ref.8). Generally, 
inflammation and tissue injury induce both the expression of the IRR and the produc-
tion of local EPO in a characteristic temporal and spatial pattern (reviewed in ref.9).
Treatment of NP in animal models with exogenous EPO results in relief of allodynia 
and hyperalgesia and attenuates a number of detrimental cellular responses, includ-
ing neuronal apoptosis and pro-inflammatory cytokine production while enhancing 
beneficial cellular responses, including regeneration and anti-inflammatory cytokine 
production. Recently, we have shown that the novel EPO-derivative ARA 290, spe-
cifically interacting with the IRR and not with the EPOR2 thus rendering it without 
hematopoietic side effects, is able to persistently relieve NP10.
Accordingly, recent clinical trials of ARA 290 in patients with neuropathy have shown 
benefit11,12. Similar observations have been made following treatment of patients 
with NP with ketamine, which has shown to have potent and long-lasting analgesic 
effects on NP13-15. However, ketamine is associated with significant side effects that 
limit its use outside of closely monitored medical settings. Ketamine acts at multiple 
receptor systems in addition to antagonism of the NMDAR. Evidence also suggests it 
also possesses anti-inflammatory activities and inhibits the activation of microglia and 
astrocytes which play prominent roles in the development of NP16,17. The similarity of 
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action of ARA 290 and ketamine on NP raised the hypothesis that both compounds 
share a common mechanistic pathway, possibly involving the IRR. To evaluate this 
possibility, we compared the effects of ketamine and ARA 290 on the expression of 
the NMDAR subunits, glia cell markers, and the signaling molecule CCL2 in a NP pain 
model. Further, since receptor gene knock out studies constitute a powerful method 
to establish roles of specific receptor systems in complex biological responses18, we 
also compared the differences in nociception and psychomotor effects, known to 
depend upon NMDAR, and NP behavior elicited by sciatic nerve injury in wild type 
mice and to βcR-/- mice that lack responses activated by the IRR.
Materials and Methods
Ethics
The study protocols were approved by the animal ethics committee of the Leiden 
University Medical Centre and the Animal Care and Use Review Office (ACURO) of the 
United States Army Medical Department Medical Research and Materiel Command. 
All experiments were performed according to the guidelines of the International 
Association for the Study of Pain19.
Animals
Six to eight week-old female C57Bl/6 mice were purchased from Charles River, Maas-
tricht, The Netherlands. β-common-receptor knockout mice (βcR) were obtained 
from The William Harvey Research Institute, London, UK. Confirmation of the geno-
type was done as described by Robb et al. using Southern blot analysis20. All animals 
were housed in groups of 4–5 per individually ventilated cage with water and food 
available at libitum and a 12 h light-dark cycle (lights on/off at 7AM/7PM).
drugs
ARA 290 (Araim Pharmaceuticals, New York, USA) and ketamine (Eurovet, Bladel, 
The Netherlands) were dissolved to yield a 30 µg/kg and 50 mg/kg dose in a 200 ml 
injection volume and were administered intraperitoneally. All drugs were dissolved 
in PBS (vehicle).
In vitro Screening Assay
ARA 290 (10 µg) was evaluated in the ‘‘High Throughput Profile’’ of CEREP, Inc. 
(Poitiers, France) and the N-methyl-D-aspartate binding assay as described at www.
cerep.fr. No significant interaction of ARA 290 with any of the screens was observed 
(data not shown).
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QRT-PCR
To establish a profile of the transcriptional changes of the mRNA of specific cytokines 
and receptors induced by the SNI or and the effect of the investigated drugs on those 
cytokines, QRT-PCR was performed on tissue of the injured sciatic nerve and spinal 
cord. Naive mice (n = 5) served as reference for basal mRNA expression levels. Mice 
that had received SNI, with or without treatment (n = 5/group), were sacrificed 7 
days post lesion. The nucleotide sequences of the PCR primers and their fluorogenic 
probes for the target genes were designed by using the computer program primer 
express (PE Biosystems) and are included in Table 1. Each fluorescent probe has a 
reporter dye (FAM for the target RNA and TET for the 18S RNA control) covalently 
attached at its 5’ end and a quencher dye (TAMRA) attached at its 3’ end. Before 
use, the probes were purified in the PolyPak II cartridge (Glen Research, Sterling, VA) 
following the manufacturer’s instructions. RNA was isolated from the sciatic nerve 
Table 1: QRT-PCR primers and probes used in this study. Primers and probes used for the quan-
tification of mRNA from NMDA receptor subtypes NR1, NR2A and NR2B (Grin); microglia 
marker Iba-1 (AIF-1), astrocyte (GFAP) and CCL2; f, Reporter dye1 (FAM:6-carboxyfluorescein); t, 
Reporter dye 2 (TET:Tetrachloro-6-carboxyfluorescein); q, Quencher dye (TAMRA: 6-carboxytet-
ramethyl-1-rhodamine).
Gene Type Sequence (5’–3’)
Grin1 (NMDAR NR1) Forward GTC CAT CTA CTC TGA CAA GAG
Reverse AAA CCA GAC GCT GGA CTG GT
Probe f TCC ACC TGA GCT TCC TTC GCA CCGq
Grin2a (NMDAR NR2A) Forward ACC TCG CTC TGC TCC AGT TT
Reverse GTT GTG GCA GAT GCC CGT AA
Probe f CAG TGT CTC CAG CTC TTC CAT CTC ACq
Grin2b (NMDAR NR2B) Forward TGG TCT TCT CCA TCA GCA GA
Reverse GTT CAT CAC GGA TTG GCG CT
Probe f ATC TAC AGC TGT ATC CAC GGA GTA GCq
CCL2 Forward CTG GAG CAT CCA CGT GTT G
Reverse TGG GAT CAT CTT GCT GGT GA
Probe f AGC CAG ATG CAG TTA ACG CCC CAC T q
AIF-1 (Iba-1) Forward GCA ATT CCT CGA TGA TCC CA
Reverse ATG TAC TTC ACC TTG AAG GCT
Probe f CAG CAA TGA TGA GGA TCT GCC GTC CAq
GFAP Forward CTC AAG AGG AAC ATC GTG GT
Reverse TGC TCC TGC TTC GAG TCC TT
Probe f TGA CCT CAC CAT CCC GCA TCT CCAq
18S Forward AGA AAC GGC TAC CAC ATC CA
Reverse CTC GAA AGA GTC CTG TAT TGT
Probe tAGG CAG CAG GCG CGC AAA TTA Cq
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and spinal cord from each of 5 mice in the experimental groups outlined above with 
the ABI Prism 6100 Automated Nucleic Acid Workstation according to the manu-
facturer’s protocol. Real-time RT-PCR amplifications were employed as described in 
ref.21. The numbers of copies of the PCR template in the starting sample were calcu-
lated by using the sequence detector software incorporated in the ABI Prism 7300 
Sequence Detector System. Sense RNAs were synthesized from the standard plasmids 
by the manufacturer’s protocols, using a MAXIscript transcription kit (Ambion). The 
concentrations of purified sense RNAs were determined as micrograms per optical 
density unit, and serial dilutions of the sense RNA, using bacterial tRNA as a car-
rier, were used to generate standard curves. When quantification was relative to 
an endogenous control, standard curves were prepared for both the target and the 
endogenous control. We assumed that 18S RNA is present in all tested and control 
samples of tissue RNA at a constant proportion and normalize the amount of total 
RNA in our test samples by comparing their 18S RNA fluorescent signal after PCR 
with that from mouse embryonic stem cell RNA freed from DNA by DNase treatment. 
Relative mRNA levels are expressed as using 18S RNA as reference.
Acute Antinociception
In uninjured animals (n = 5/treatment group), tail withdrawal latencies (TWL) were 
recorded to determine the antinociceceptive effect of the drugs. The water bath 
was heated to 47.5 °C which resulted in a baseline response with a threshold of 9–11 
seconds. The tail of the mouse was immersed in water and the latency to withdraw 
the tail was recorded. A cut-off value of 30 s was used to prevent tissue damage. 
Baselines were recorded prior to injection of the drugs and TWL were recorded 30 
and 60 minutes after injection. TWL were obtained in duplicate with an interval of 
30 seconds in between measurements and averaged.
Side Effects
Side effects induced by drug treatment (n = 5/treatment group) were assessed in 
uninjured animals by using a method adapted from ref.22. Briefly, animals were ob-
served for 60 min post injection at 5-min intervals. Stereotypic behavior was scores 
on a 7-point scale as: −3: anesthesia, −2: sedation, −1: drowsiness, 0: normal, 1: 
moderately increased (increased explorative behavior), 2: increased (increased urge 
to move around the cage), 3: greatly increased (inability to hold still with weaving, 
shaking or twitching of the head and body). Activity level was defined as follows: 
−3: anesthesia, −2: sedation, −1: drowsiness, 0: normal, 1: moderately impaired (dis-
turbances in paw support), 2: impaired (unable to maintain paw support with the 
ability to regain an upright position after falling over), 3: greatly impaired (inability 
to regain an upright position after falling over).
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Spared Nerve Injury
Mice (n = 8/treatment group per genotype) were anesthetized with isoflurane (4% 
induction and 2% maintenance) and were operated to receive a spared nerve injury 
(SNI) as described previously10. In short, a lateral incision on the left thigh was made, 
exposing the muscle. The left sciatic nerve was then exposed by blunt preparation and 
the tibial and common peroneal nerves were ligated with 6–0 silk sutures, transected 
and displaced to prohibit any regeneration. Consecutively, muscle integrity was re-
stored and the wound was closed with 5–0 sutures. In case of sham SNI, animals were 
anesthetized and the sciatic nerve was exposed as described above. After exposure 
no SNI was induced and the wound was closed. Animals were administered a single 
s.c. injection of 0.1 mg/kg buprenorphine for the relief of acute post operative pain 
and were allowed to recover from surgery in a clean cage with body temperature 
maintained at 38 °C and were observed for 1 h before being transferred back to the 
cage with fresh sawdust. The animals were followed up for 7 days or 42 days.
Tactile Allodynia
Assessment of tactile allodynia was performed using Semmes-Weinstein monofila-
ments. Animals were placed in transparent Perspex cages on a grid and allowed to 
habituate to the experimental environment for 5–10 min. After habituation, 
filaments were applied to the ipsilateral hind paw by applying 10 stimulations over 
10 s. Failure to respond led to progression to the next filament exerting a greater 
force. Withdrawal of the stimulated paw led to the recording of the force of the 
corresponding filament. All measurements were done in duplicate with a 30 second 
interval between measurements and averaged.
Statistical Analysis
All behavioral data was analyzed for a treatment effect by two-way repeated mea-
sures analysis of variance (ANOVA) followed by a post hoc Student-Newman-Keuls 
test for multiple comparisons. QRT-PCR data was analyzed by one-way ANOVA fol-
lowed by a post hoc Student-Newman-Keuls test for multiple comparisons when 
distributed normally. In the absence of a normal distribution, as defined by the 
Shapiro-Wilk criterion, or unequal variance, data was analyzed by a Kruskal-Wallis 
one-way ANOVA on ranks followed by a Student-Newman-Keuls test for multiple 
comparisons. P-values < 0.05 were considered significant. Analysis was done with 




Ketamine and ARA 290 Attenuate Neuropathy-related mRNA Changes of the 
Spinal Cord in a Similar Manner
To evaluate changes in gene expression for potentially relevant receptors and in-
flammatory molecules in the development of allodynia, animals were sacrificed on 
day 7 following sciatic nerve injury and real time PCR performed on extracts of the 
spinal cord. SNI with vehicle treatment moderately changed NMDAR subunit mRNA 
expression of NR1 (1.27±0.02 fold, P = 0.183), NR2A (1.83±0.07 fold, P < 0.001) and 
NR2B (1.39±0.16 fold, P = 0.101) when compared to naïve (uninjured and untreated) 
animals at 7 days post injury (Figs. 1A–C).
Treatment with either drug significantly decreased expression of NR1, NR2A and NR2B 
mRNA when compared to injured, vehicle treated animals. For NR1 mRNA, treatment 
resulted in changes in expression of 0.78±0.13 fold (P = 0.042 versus vehicle) and 
0.31±0.05 fold (P = 0.002 versus vehicle) for ketamine and ARA 290, respectively, with 
ARA 290 inducing the greater changes in mRNA levels (P = 0.022 between treatments). 
For NR2A mRNA, changes in expression of 0.94±0.11 fold (P < 0.001 versus vehicle) and 
0.44±0.08 fold (P < 0.001 versus vehicle) were observed for ketamine and ARA 290 
respectively, with ARA 290 inducing the greater changes in mRNA levels (P = 0.007 
between treatments). The mRNA levels of NR2B after treatment were 1.02±0.11 fold 
(P = 0.048 versus vehicle) and 0.45±0.04 fold (P = 0.002 versus vehicle) for ketamine 
and ARA 290 respectively, with ARA 290 inducing the greater changes in mRNA levels 
(P = 0.019 between treatments). The microglial response to SNI followed by vehicle 
treatment (mediated by chemokine (C-C motif) ligand 2 (CCL2), also known as mac-
rophage chemotactic protein 1 (MCP-1)) showed a significant 25.53±1.8 fold increase 
in CCL2 mRNA relative to naïve animals (P < 0.05), which was attenuated by ketamine 
(7.26±0.29 fold, P < 0.05) and ARA 290 (5.27±0.44 fold, P < 0.05), with ARA 290 induc-
ing a greater change in mRNA levels (P < 0.05 between treatments, Figure 2A).
SNI followed by vehicle treatment significantly increased the microglia activation 
marker ionized calcium binding adaptor molecule 1 (Iba-1) mRNA by 4.16±1.06 
fold (P = 0.01 versus naïve). Both treatments significantly decreased Iba-1 mRNA to 
1.41±0.27 fold (P = 0.008 versus vehicle) and 0.96±0.10 fold (P = 0.015 versus vehicle, 
Figure 2B) for ketamine and ARA 290 respectively. Ketamine and ARA 290 were 
equally effective when comparing between treatments (P = 0.839). The increase in 
the astrocyte marker glial fibrillary acidic protein (GFAP) mRNA following SNI and 
vehicle treatment (2.11±0.20 fold, P < 0.001) was significantly reduced by ketamine 
(0.99±0.08 fold, P = 0.001) and ARA 290 (0.51±0.08, P < 0.001, Figure 2C). Treatment 
with ARA 290 induced greater changes in mRNA when comparing between treat-
ments (P = 0.039).
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Ketamine and ARA 290 have divergent Effects on Acute Nociceptive Pain and 
Behavior
Normal mice exhibited a brisk withdrawal response within 9–11 s after tail immer-
sion in heated water of 47.5 °C (Figure 3A). Vehicle treated animals did not show 
alterations in TWL during the follow up period after injection. Ketamine administra-
tion (50 mg/kg intraperitoneally) rapidly induced an acute antinociceptive effect as 
A B
C
Figure 1: Ketamine and ARA 290 reduce mRNA for NDMA receptor subunits in established neu-
ropathy. Real time PCR data show that NMDA receptor subunits 1 (panel A), 2A (panel B), and 
2B (panel C) are all modestly elevated one week following sciatic nerve injury. Administration 
of ketamine significantly reduces mRNA to baseline levels. In contrast, ARA 290 reduced mRNA 
for these receptor subunits to substantially below baseline (naïve). * P < 0.05 versus vehicle, # 
P < 0.05 between ketamine and ARA 290 treatments, ** P < 0.05 versus naïve.
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demonstrated by a marked increase in the withdrawal latency (TWLs of 29.8±0.16 s 
and 24.85±1.26 s for 30 and 60 min post injection respectively, treatment effect 
P < 0.001 versus vehicle, Figure 3A). In contrast, animals administered ARA 290 (30 
µg/kg i.p.) demonstrated no change in latency during the 60 min observation period 
following administration (treatment effect P = 0.977 versus vehicle, Figure 3A). Ad-
ditionally, ketamine administration was associated with side effects characterized by 
the induction of stereotypical behavior and changes in locomotor activity. Follow-
A B
C
Figure 2: Ketamine and ARA 290 reduce inflammatory mediators in the spinal cord following 
sciatic nerve injury. One week post surgery, animals showed a marked elevation of CCL2 (panel 
A), Iba1 (panel B), and GFAP (panel C) compared to naïve controls. Both ketamine and ARA 
290 significantly reduced the mRNA levels of these genes to a similar extent. * P < 0.05 versus 
vehicle, # P < 0.05 between ketamine and ARA 290 treatments, ** P < 0.05 versus naïve.
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A B
C
Figure 3: Ketamine and ARA 290 differ in effects on acute nociceptive pain and side effects. 
A: Ketamine administration increases the latency of tail withdrawal to a thermal stimulus 
(treatment effect, P < 0.001), whereas ARA 290 does not. B: Ketamine treatment had signifi-
cant biphasic effects on stereotypic behavior: after a period of transient sedation, the animals 
showed signs of psychomimetic disturbances that lasted for about 20 minutes (treatment ef-
fect, P < 0.001). ARA 290 did not display these side effects. C: Treatment with ketamine was as-
sociated with a biphasic activation of generalized activity (treatment effect, P < 0.001) causing 
an increase in restlessness and explorative behavior after a period of transient sedation.
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ing ketamine, administration mice displayed a period of transient sedation which 
dissipated within 10 min, followed by a longer excitatory state characterized by 
stereotypical behavior and increased locomotor activity that lasted for 20–25 min 
before subsiding (treatment effects for stereotypical behavior and activity level, 
P < 0.001 and P < 0.001 versus vehicle respectively, Figs. 3B and C). In contradistinc-
tion, no behavioral changes were observed following ARA 290 (treatment effects 
for stereotypical behavior and activity level, P = 0.549 and P = 0.346 versus vehicle 
respectively, Figs. 3B and C).
Ketamine and ARA 290 do not Effect Allodynia in Mice Lacking the β-common 
Receptor
Following sciatic nerve surgical transection in which the sural branch is preserved 
(spared nerve injury; SNI), tactile allodynia developed in both wild type and βcR-/- mice 
within 24 h as demonstrated by significant decreases in the force required to induce 
a withdrawal response following plantar stimulation (Figs. 4A and 5A). To evaluate 
potential effects of ARA 290 and ketamine on the development of allodynia, animals 
were administered drug or vehicle every other day beginning 24 hours following 
surgery, and weekly starting in the second week after surgery. Following injury, 
vehicle treated animals uniformly displayed allodynia, reaching a nadir in the force 
BA
Figure 4: Ketamine and ARA 290 have similar effects on allodynia. A: Treatment with both ket-
amine and ARA 290 prevented the full development of allodynia (treatment effect, P = 0.049 
and P = 0.03, respectively). B: The effects of ketamine on acute nociceptive pain remained un-
changed over time (treatment effect, P < 0.001). Digits represent testing days. X = treatment day.
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required to induce a withdrawal within 7 days at an applicable force of 0.004±0.0 
g. Allodynia was sustained for the duration of the follow up. In C57Bl/6 (wild type; 
WT) mice, treatment with either ARA 290 (30 µg/kg i.p.) or ketamine (50 mg/kg 
i.p.) significantly attenuated the development of tactile allodynia during the first 
week, which was maintained for the duration of the follow up period (treatment 
effect versus vehicle, P = 0.049 and P = 0.03 for ketamine and ARA 290 respectively, 
Figure 4A).
Contrastingly, both ARA 290 and ketamine were ineffective in sciatic nerve transected 
βcR-/- mice, (treatment effect versus vehicle, P = 0.308 and P = 0.730 for ketamine and 
ARA 290, respectively, Figure 5A), although ketamine retained its acute antinocicep-
tive effect (Figs. 4B and 5B) and behavioral effects (data not shown) similar to those 
observed in WT animals.
discussion
The results of these experiments show that (1) nerve injury coincides with changes in 
expression levels of NMDAR subunit mRNA and spinal cord inflammatory mediators 
(CCL-2, Iba-1 and GFAP) after 7 days of NP, which are blunted by both ketamine and 
BA
Figure 5: Relief of allodynia depends upon the β-common-receptor (βcR). A: Both ketamine and 
ARA 290 did not prevent the development of allodynia in βcR-/- mice. B: However, the effect of 
ketamine on nociceptive pain is unchanged in βcR-/- animals (treatment effect, P < 0.001). Digits 
represent testing days. X = treatment day.
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ARA 290; (2) ketamine induces relief of acute nociceptive pain and behavioral side 
effects, whereas ARA 290 lacks these acute effects; (3) ketamine and ARA 290 induce 
relief of allodynia (i.e., analgesia) in a similar manner in wild type mice, but have no 
effect in mice lacking the βc chain. Contrastingly, βcR-/- status had no effect on the 
acute antinociceptive or psychomotor effects of ketamine.
As would be predicted if ketamine and ARA 290 shared a common mechanism of 
action on NP, examination of gene expression in the spinal cord of injured animals 
shows comparable effects of these two agents on NMDA receptor expression and 
spinal cord inflammatory marker levels. The development of NP is associated with 
up-regulation of NMDAR on neurons that are believed to interact with microglia 
and astrocytes within the dorsal root ganglia and the dorsal horn of the spinal cord 
ipsilateral to the injured nerve23. Surprisingly, seven days following sciatic nerve in-
jury mRNA of the NMDAR subunits NR1, NR2A and NR2B are not markedly elevated 
above the levels observed in uninjured animals, despite the fact that the maximum 
measurable amount of allodynia was reached. Similar observations are described in 
2 other models of NP, where a significant NMDA receptor upregulation did not occur 
until after 14 days of NP following spinal cord injury for NR1, NR2A and NR2B24, or 
where a reduction of the NMDA receptor at peak levels of allodynia was observed25. 
In our study, ketamine treatment significantly reduces the mRNA of all the NMDA 
receptor subunits to expression levels comparable to those of naïve animals, in con-
trast to the slightly elevated levels of untreated controls. In comparison, ARA 290 has 
a significantly larger suppressive effect and markedly reduced gene expression of the 
NMDARs below expression levels observed in naïve animals. Dose-response analyses 
were not performed in this study; therefore it is uncertain whether this difference 
between ARA 290 and ketamine can be explained by potency or biological factors. 
In spite of unequal NMDAR mRNA suppression by these agents, the effect of both on 
allodynia is identical. Taken together the slightly increased expression of the NMDA 
receptor subunits with respect to the amount of allodynia and the identical effect 
of both drugs on allodynia further support the possibility that the contribution of 
NMDAR to allodynia may not be the principal determinant in the development in NP, 
which has been suggested by the results of an earlier study26.
Both ketamine and ARA 290 induce an approximately equivalent suppression of 
microglia, astrocyte and CCL2 mRNA measured within the spinal cord. The activation 
of spinal cord cells such as microglia and astrocytes is correlated to NP and reduc-
ing the numbers or activation states of these cells has shown to be of importance 
for the reduction of allodynia27. Iba1 as a marker for activated microglia and the 
suppression of its mRNA to baseline levels is consistent with significant attenuation 
of inflammation within the spinal cord and the subsequent reduction in allodynia. 
In addition to the reduction of microglia, the observed reduction of astrocytes as 
111
Ketamine and ß-common receptor
identified by GFAP mRNA may also have contributed to the anti-allodynic effect 
of both ketamine and ARA 290. Notably, CCL2 is a product of neurons within the 
effected region of the spinal cord and signals for the accumulation of microglia in 
NP28. Antagonism of the C-C chemokine receptor type 2 (CCR2), the target receptor 
of CCL2, has shown to decrease allodynia28,29. CCL2 signaling and glia cell activation 
in conjunction with NMDAR up-regulation have been considered to be hallmarks of 
central sensitization4, the observed effects of both ARA 290 and ketamine on these 
effectors is consistent with a reduction of central sensitization and with the observed 
results of these compounds on NP behavior.
Ketamine and ARA 290 have shown different effects on acute nociception that can 
be explained by the different receptor targets of the drugs. Specifically, the NMDAR, 
which mediates glutamate-dependent pain signaling arising from depolarization of 
the afferent nerve fibers, is antagonized by ketamine, but not by ARA 290. Therefore, 
blocking NMDAR activity by using 50 mg/kg ketamine results in a profound relief 
of acute nociceptive pain, whereas treatment with ARA 290 does not. Moreover, 
treatment with 50 mg/kg ketamine coincides with psychomimetic and locomotor 
side effects where mice suffer a transient period of sedation, as classified by a re-
duced activity level and subsequent explorative (stereotypical) behavior, followed 
by a hyperactive state. Treatment with ARA 290 did not induce these side effects. 
These results indicate that ketamine, but not ARA 290, interacts with the NMDAR. 
In contrast to the data on nociceptive pain, both drugs attenuate the development 
of allodynia following nerve injury in a similar manner. When administered to WT 
animals 24 h after lesion, tactile allodynia is persistently decreased in both ketamine 
and ARA 290 treated animals during the entire follow up period. In addition, the 
analgesic action of ketamine does not change during SNI status. Conversely, βcR-/- 
mice with an SNI that were treated with ketamine or ARA 290 did not benefit from 
treatment and no attenuation of allodynia was observed. However, ketamine was 
still able to induce acute antinociception in mice lacking the βcR. The βcR requires 
assembly with other receptor subunits to become a functional signaling unit. As ARA 
290 only interacts with the βcR-EPOR heteromer (IRR), it is a distinct possibility that 
the action of ketamine in this model is also mediated through the IRR. Ketamine 
possesses strong anti-inflammatory properties and is able to reduce serum TNF-α 
after sepsis in a murine laparoscopic model, an effect not readily expected from 
ketamine’s action on the NMDA receptor30. Furthermore, it has been noted in the 
SNI model that NMDA receptor blockade by MK 801 did not affect either mechanical 
or cold allodynia26.
ARA 290 has a very short plasma half-life (≈ 2 minutes31) while ketamine has a tissue 
half-life of 10–12 minutes32,33. In spite of this, both agents have sustained effects on 
pain behavior in the spared nerve model. In vivo nerve recording has demonstrated 
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that the antiallodynic effects of ketamine are maintained far longer than its NMDAR 
antagonism33. ARA 290 and ketamine administered every 48 hours for the first 5 doses 
and weekly thereafter prevent the development of allodynia and sustain this (anti-
allodynic) state in spite of chronic nerve injury. This observation is consistent with a 
modulating effect in which brief exposure to these pharmacologic agents activates a 
molecular switch, to produce long term effects through changes in gene expression. 
Previously a beneficial effect on pain behavior has been noted for treatment with 
amitriptyline extending to beyond the elimination half-life and treatment period 
in the very same model we have employed34. This effect is similar to the long-term 
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Figure 6: Neuropathic pain involves a pathway that utilizes the Innate Repair Receptor (IRR). 
Nerve injury results in microglial recruitment, increased expression of NMDAR, and proinflam-
matory cytokine production, ultimately resulting in allodynia. Activation of the IRR, e.g., by 
ARA 290, antagonizes this pathway. Ketamine also requires the IRR to reduce allodynia. This 
may be via a direct interaction with the IRR or alternatively, via modulation of intermediate 
processes that are upstream of the IRR. Additionally, ketamine interacts with NMDARs that 
mediate antinociception and psychomotor effects. ARA 290 does not interact with the NMDAR 
and therefore lacks these additional effects.
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memory and the development of NP. The observation that ketamine may affect NP 
behavior by use of a signaling pathway that includes a receptor that is a component 
of the innate immune response and repair system predicts that it may also affect 
other functions served by this receptor, such as beneficial effects on inflammation at 
multiple levels, including the recruitment of immune-competent cells and secretion 
of pro-inflammatory cytokines and chemokines (reviewed in ref.35).
In conclusion, these findings confirm the existence of a pathway in the evolution of 
NP that involves the IRR (Figure 6).
Ketamine has a distinct effect on acute nociceptive pain, but a different activity 
in common with ARA 290 on NP via a pathway that requires the βcR. Whether the 
observed effects depend upon a direct interaction of ketamine with the IRR with re-
quire further studies, e.g., receptor binding or NMDAR knockdown experiments. The 
similar effects of ketamine and ARA 290 on NP in the spared nerve model established 
through activity of the IRR, could also be true for other models of NP, as well as for 
other treatments of NP. Although the effects of ketamine on acute pain appear to 
be pharmacologically driven by interaction by the NMDA receptor, the long-term 
effects may be described as manipulating a molecular switch, altering downstream 
gene expression and subsequent detrimental effects. Finally, although ketamine 
has potent, long lasting anti-neuropathic effects, interaction with NMDARs leads to 
very significant adverse effects including abuse potential. Utilization of IRR specific 
ligands, e.g., ARA 290, avoids these undesirable effects and may point a way to 
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Corneal nerve density in painful neuropathy
Innovation
Currently, a definitive diagnosis of small fiber neuropathy (SFN) requires a skin 
biopsy that demonstrates small nerve fiber loss. However, quantifying IENFD in skin 
biopsies is an invasive, labor-intensive process that has a low sensitivity for diagnos-
ing SFN and does not correlate with the pain that patients report. Alternatively, CCM 
is a rapid non-invasive clinical ophthalmic technique for in vivo imaging of corneal 
nerve fibers. Here we show that CCM is a useful diagnostic tool to evaluate small 
fiber damage and that corneal nerve fiber density is inversely related to symptoms 
in patients with sarcoid neuropathy. This technology expands the role of CCM as a 
surrogate marker for both nerve fiber damage and pain in clinical trials of novel 
therapeutics in sarcoid and perhaps other small fiber neuropathies.
Introduction
Loss of small, unmyelinated nerve fibers, i.e., small fiber neuropathy (SFN), is an in-
creasingly recognized feature of a wide range of neuropathies1. It is a major cause of 
pain and poor quality of life with an inability to work2. SFN is characterized by spon-
taneous pain, dysesthesiae, paresthesiae, and altered thermal sensory thresholds3,4. 
Additionally loss of post-ganglionic autonomic nerve fibers leads to a wide variety 
of symptoms including anhidrosis, orthostasis, and a range of other manifestations 
depending upon the organs affected.
Routine electrodiagnostic studies, such as electromyography and nerve conduction 
studies, in conjunction with tendon reflexes and strength testing evaluate large nerve 
fibers. Consequently, these tests remain normal in small fiber neuropathy and pure 
small fiber damage is not easily evaluated. Based on data from preclinical models, 
inflammation has been suggested to be a common mechanism for the reduction in 
small nerve fibers5 and a recent study has confirmed that pro-inflammatory cytokines 
are elevated in patients with SFN and pain6.
Curative therapy for SFN is lacking. Current therapy is directed towards symptomatic 
pain relief which is generally not satisfactory1. Although reduced nerve fiber density 
as determined by skin biopsy is the hallmark of SFN, sensitivity appears suboptimal 
in sarcoidosis7, and to date no study has shown that nerve fiber density obtained 
by skin biopsy directly relates to patient symptoms, e.g., pain. Hence, no biological 
marker for pain has yet been established8,9 and therefore the outcome of clinical 




SFN is difficult to diagnose as complaints of pain and autonomic dysfunction are 
variable and standard electrophysiological testing cannot directly assess the func-
tion of the small nerve fibers involved1. Additionally, the natural history of SFN is 
poorly understood and fluctuates over time. The current diagnostic standard for 
SFN requires the presence of symptoms, a clinical examination consistent with the 
loss of small nerve fiber function, and a skin biopsy that documents reduced small, 
unmyelinated and thinly myelinated nerve fibers (Aδ and C)4. Because normative 
values have been derived for the distal leg10, this site is typically used for diagnosis.
Sarcoidosis is an inflammatory disease that is associated with SFN2. The prevalence 
of SFN in patients with chronic sarcoidosis is not precisely known, but may be as 
high a ~75%7,11. Several questionnaires (the Small Fiber Neuropathy Screening List12 
as well as an autonomic symptom assessment11) have been developed to aid in the 
diagnosis of SFN in patients with sarcoidosis. Although they are useful in screen-
ing for patients with SFN, diagnostic confirmation requires a 3 mm skin biopsy and 
immunohistochemistry to quantify IENFD13. Several recent studies have shown that 
IENFD is reduced in patients with sarcoidosis and neuropathic symptoms7,11,14.
However, SFN of sarcoidosis has been described as a non-length dependent process 
that occurs in a “patchy” distribution2 and therefore it is possible that a biopsy 
obtained from the distal leg might not reflect the presence of reduced small nerve 
fibers at other locations. Thus a majority of patients with symptoms of SFN have 
an ankle IENFD that is not below the 0.05 quantile level of normal that has been 
suggests as required for a definitive diagnosis of SFN7,11. Furthermore, skin biopsy, 
although well-tolerated with minimal potential adverse effects, is an invasive proce-
dure and sample processing requires a dedicated laboratory for fixation, sectioning, 
staining, and nerve fiber counting that is time and labor intensive and fraught with 
significant potential artifacts. Additionally, innervation of the skin is not equally dis-
tributed and follow-up biopsies cannot be taken at the exact same location. Hence, 
skin biopsies are not ideal for following the progression of disease and to assess the 
potential beneficial effects of therapeutic interventions.
The cornea has the highest density of nerve fibers of any tissue (up to 600 times 
more than the skin)15 and therefore any process that targets small nerve fibers may 
be especially prominent in the eye. Corneal nerve fibers originate from the oph-
thalmic branch of the trigeminal nerve and distribute radially towards the apex of 
the cornea parallel to the surface. Corneal innervations consists of predominantly C 
fibers, i.e., small, unmyelinated fibers that are polymodal nociceptors, that respond 
to a wide range of mechanical, thermal, and chemical stimuli15. For these reasons the 
corneal nerve fibers may be more reflective of the pain that patients report. Over 
the last decade, a confocal microscopic technique has been developed to directly, 
and non-invasively visualize nerve fibers that innervate the cornea, termed corneal 
121
Corneal nerve density in painful neuropathy
confocal microscopy (CCM)16. This technique allows direct visualization of a narrow 
slice of tissue containing nerve fibers running parallel to the surface. The utility of 
this methodology has been evaluated in a range of neuropathies including, diabetic 
neuropathy, Fabry’s disease, Charcot-Marie-Tooth disease 1A, and chemotherapy 
induced neuropathy17-20. Corneal nerve fiber number is directly related to the severity 
of neuropathy derived from a neurological examination that tests both small and 
large nerve fiber function19, as well as cooling detection thresholds, axon reflex-
mediated neurogenic vasodilatation in response to cutaneous heating by laser Dop-
pler imaging flare technique (LDIFLARE), heart rate variability (HRV)21 and IENFD22. 
It is currently unknown whether corneal confocal microscopy may aid in identifying 
nerve fiber loss and severity of pain in patients with sarcoid neuropathy.
Methods
Study Criteria and Patient Population
The results reported here are derived from a study population with chronic sar-
coidosis and debilitating symptoms of painful neuropathy (protocol NTR3575 in the 
International Clinical Trials Registry Platform). After Ethics committee approval and 
informed consent according to the Declaration of Helsinki, patients were recruited 
according to the following inclusion criteria:
• Diagnosis of sarcoidosis according to accepted international criteria23.
• Spontaneous pain level (“pain now” of the Brief Pain Inventory) ≥ 5/10 or Small 
fiber neuropathy screening list score (SFNSL) > 37/84.
• Pain defined as distal pain plus one of the following: dysesthesia, burning/painful 
feet worsening at night, or intolerance of sheets/clothes touching the legs/feet.
Exclusion criteria were:
• Clinically relevant abnormal history of physical and/or mental health.
• A semi recumbent systolic blood pressure of > 150 mmHg and/or diastolic blood 
pressure of > 90 mmHg at screening.
• History of alcoholism or substance abuse within three years prior to screening.
• Positive pregnancy test.
• Male patients habitually using more than 21 units of alcohol per week and 
female patients using more than 14 units of alcohol per week.
• Male patient unable/unwilling to use a medically acceptable method of con-
traception throughout the entire study period. Female patient not using oral 
contraceptives, or not postmenopausal.
• History of severe allergies, or an anaphylactic reaction or significant intolerabil-
ity to prescription or non-prescription drugs or food.
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• Vaccination or immunization within the last month.
• Participation in an investigational drug trial in the 3 months prior to study.
• Major surgery within three months prior to screening.
• Donation or loss of blood (> 500 mL) within 3 months prior to screening.
Thirty eight patients (18 females, 20 males) of mean age 49.5 years (range 28-65) 
satisfying inclusion criteria were evaluated (Table 1). The duration of sarcoidosis was 
8.4 ± 1.3 (SEM) years. No patient was using capsaicin topical cream that is known 
to reduce intraepidermal nerve fiber density. None had serious or progressive lung 
disease. The mean score of the Brief Pain Inventory Short Form (BPI) was 54.7 (out of 
110 total) and the mean SFNSL score was 43.4 (out of 84 total).
Clinical Testing
Quantitative Sensory Testing was accomplished according to the protocol of the 
German Pain Network24. A 6 Minute Walk Test (6 MWT) was performed according to 
published protocols25. Predicted 6 MWT distance for normal individuals as a function 
of age, gender, and height was calculated using the formula of Troosters et al.26
Table 1: Patient characteristics
Variable Value (+ SEM)
Subjects 38
Males/females 20/18
Weight (kg) 82.1+ 2.6
Age 49.5 + 1.5
Height (cm) 177.6 + 1.8
Body Mass Index 25.8 + 0.5
Years since diagnosis of sarcoidosis 8.4 + 1.3
Use of NSAIDs 14
Use of neurological/psychological drugs 11
Use of oral steroids 13
Use of opioids 7
Use of systemic anti-inflammatory drug 10
Prior use anti-TNF therapy 2
High sensitivity C-reactive protein (mg/L) 2.2 + 0.5
Angiotensin converting enzyme (normal 23-67 nmol/min/ml) 49.3 + 5.1
Elevated ACE (number) 11
SFNSL score baseline 43.4 + 2.1
BPI total pain score (range 0-40) 20.6 + 0.9
BPI pain interference (maximum 70) 34.1 + 1.7
6 Minute Walk Test (meters) 473.4 + 15.5
Predicted 6 Minute Walk Test (meters) 692.6 + 9.6
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Nerve Fiber Quantification
Skin biopsies (3 mm) were obtained from the proximal thigh (20 cm below the an-
terior superior iliac spine) and the distal leg (10 cm above the lateral malleolus) and 
processed following established guidelines13. Free floating 50 µm thick sections were 
cut and stained using rabbit anti-protein gene product 9.5 antibody (Dako Nether-
lands bv) visualized using a goat anti-rabbit Alexa fluor 488 antibody (Invitrogen, 
Life Technologies, Grand Island, NY). A minimum of 3 sections selected from the ends 
and the middle of each biopsy series was evaluated using a Leica M5500 fluorescence 
microscope (Leica Microsystems, Rijswijk, The Netherlands), magnification 1000x. The 
nerve fibers were counted manually. Images were recorded with Leica Application 
Suite, magnification 400x and epidermal lengths were measured using ImageJ (NIH, 
Bethesda, MD, USA). Normative data of nerve fiber density used for the distal leg 
was that of Lauria et al.10 and for the thigh from Umapathi et al.27
Corneal confocal microscopy was carried out using the Rostock Cornea Module with 
the Heidelberg Retina Tomograph III using established methodology28. A minimum 
of 6 images containing nerve fibers (i.e., to be within Bowman’s layer) were evalu-
ated using computer software as previously described29. Corneal nerve fiber data 
obtained from Twenty two healthy volunteers (gender (M/F-9/13), age 49.0 ± 2.7, 
height 167.3 ± 2.3, weight 71.1 ± 3.1, BMI 25.3 ± 0.9) had a mean nerve fiber den-
sity = 31.6 ± 6.4 (SD) per mm2; mean nerve fiber length = 21.7 ± 3.6 mm/mm2; and 
mean nerve branch density = 54.6 ± 23.4/mm2.
Statistics
Statistical analysis was performed using JMP (SAS, Inc, Cary, NC). Stepwise linear 
regression modeling, analysis of covariance, unpaired t-test, or Mann-Whitney U test 
were carried out where appropriate.
Results
Almost all patients had a significant reduction in the distance they could walk in 6 
minutes as estimated from the normative predictive data generated for older indi-
viduals by Troosters et al.26 which was 693 meters. The mean reduction in expected 6 
MWT distance in the sarcoidosis patients was 219 meters (95% confidence interval: 
186-253 meters).
Quantitative sensory testing showed that the majority of patients exhibited signifi-
cant small nerve fiber dysfunction as evidenced by alteration in thermal thresholds 
(Table 2). The most common abnormality was a decrease by more than 2 SD below 
the mean of normal volunteers in the cold and warm detection thresholds in ~ 80% 
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of the patients. Additionally, > 90% of the patients showed a decrease in the vibra-
tion detection threshold.
Corneal nerve fiber images of patients with sarcoidosis typically showed reduced 
corneal nerves compared to healthy controls (Figure 1A and B). Quantification 
showed that the mean corneal nerve fiber density (CNFD; patients: 21.6 fibers/
mm2 ± 5.9 SD versus controls: 31.6 fibers/mm2 ± 6.4; P < 0.0001) and Length (CNFL; 
patients: 13.2 mm/mm2 ± 4.0 versus controls; 21.7 mm/mm2 ± 3.6 P < 0.0001) of 
patients with chronic sarcoidosis were significantly reduced compared to normal 
controls (Figure 1C and D). In contrast, mean corneal nerve branch density was not 
significantly different from controls (patients: 51.2/mm2 ± 30.5 SD versus controls 
54.6/mm2 ± 23.4 SD).
The median intra-epidermal nerve fiber density of the distal leg was significantly 
reduced compared to age and gender matched normal controls (Figure 2A). The 
average difference between the normal population age and sex dependent median 
values and the patient population was 4.7 fibers/mm2 (P < 0.0001; Mann-Whitney 
Test). Stepwise linear regression modeling determined that age, height, and gender 
Table 2: Results of quantitative sensory testing. Patients showed functional impairment of both 
small nerve fibers (Aδ and C) as well as larger sensory nerve fibers (Aβ). Data are expressed as 
number of patients deviating beyond the 95% confidence interval of a sex- and age-matched 
normal populations as reported by Rolke et al24.
Variable Nerve fibers involved Change Number of patients (%)
Cold detection threshold Aδ & C Decrease 30 (79)








Paradoxical heat sensation Aδ Decrease 15 (40)
Cold pain threshold Aδ & C Increase 3 (8)




Mechanical detection threshold Aβ Decrease 21 (55)








Dynamic mechanical allodynia Aβ Increase 14 (37)
Windup ratio Aδ & C Increase 6 (16)
Vibration detection threshold Aβ Decrease 35 (92)





Corneal nerve density in painful neuropathy
were covariates of IENFD. In contrast, these variables were not covariates for IENFD 
of the proximal thigh, for which the density was also reduced approximately 50% 
compared to normal individuals (mean of patients: 11.0 fibers/mm (confidence in-





Figure 1: Nerve fibers of the sub-basal layer of the cornea are reduced in number and length in 
patients with sarcoidosis and symptoms consistent with small fiber neuropathy. A: Confocal im-
ages of a typical normal cornea. B: Confocal images cornea of a typical patient with sarcoidosis 
and neuropathic pain. Comparison illustrates an obvious reduction of nerve fibers in the patient 
(field of view is 0.4mm by 0.4 mm). These nerves are predominantly small, non-myelinated C 
fibers. C: Quantification shows that the mean corneal nerve fiber density (CNFD) is reduced in 
this patient population compared to normal individuals. D: Corneal nerve fiber length (CNFL) is 
reduced in this patient population compared to normal individuals. The heavy dashed line indi-
cates the mean, the lighter dashed lines indicate 1 SD of a normal population (n = 22). Solid hori-
zontal line indicates the mean value for the sarcoidosis patients. There was no dependence of 
corneal nerve fiber density or length upon gender, age, or height of either the patients or nor-
mal controls. Corneal nerve fiber branching density was not different from controls (not shown).
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interval 17.8-23.4)). The mean ratio of IENFD of the proximal thigh to the distal leg 
was 3.9 ± 1.5 SEM, with one patient equal to 0.9 and the others > 1.0. The patients 
in this study, therefore, had a peripheral neuropathy of a length-dependent nature. 
C
BA
Figure 2: A: The distal leg intraepidermal nerve fiber density of patients with sarcoidosis and 
symptoms of SFN is reduced compared to normal population. The horizontal lines correspond to 
the median value of each gender. The dashed line represents the age-dependent median norma-
tive value10. B: There is a significant linear relationship between CNFL and IENFD of the distal leg 
(P = 0.009). A similar finding was observed for CNFD (data not shown). C: Gender, age, height, 
and CNFL (or CNFD) are covariates for IENFD of the distal leg. A linear model constructed using 
these variables provides the relationship between CNFL and IENFD. Here, the least mean squares 
predicted values of the distal leg IENFD are plotted versus CNFL, showing that the slope of the 
relationship is the same for female (95% CI: 0.12 to 0.25) and male (95% CI: 0.16 to 0.29) patients.
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IENFD of the proximal leg was not significantly correlated to that of the distal leg 
(Pearson’s correlation coefficient = 0.20; P = 0.22).
However, the IENFD of the distal leg, which is typically employed for diagnosis of 
SFN, was significantly correlated to CNFL (Figure 2B) and to CNFD (data not shown). 
Linear regression modeling showed that age and gender were covariates and that 




Figure 3: Corneal nerve fiber length and number are correlated with patient related symptoms. 
A: CNFL is inversely correlated with the Brief Pain Inventory pain interference score (P = 0.0005) 
B: CNFD are inversely correlated with the Brief Pain Inventory pain interference score (P = 0.012, 
respectively). C: In contrast, IENFD has no relationship with the BPI pain interference score.
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Additionally, both CNFL (Figure 3A) and CNFD (Figure 3B) were negatively correlated 
with the pain interference component of the Brief Pain Inventory. Specifically, the re-
lationship between the CNFL and BPI pain interference score for individual patients 
without controlling for additional variables was described by the linear function BPI 
pain interference score = −1.38 * CNFL (mm/mm2) + 52.3 (slope 95% CI: −2.1 to −0.7; 
Pearson’s correlation coefficient of −0.54; P = 0.0005) and for CNFD: BPI interference 
score = −0.71 * CFND + 49.4 (slope 95% CI: −1.3 to −0.2; Pearson’s correlation coef-
ficient of 0.4, P = 0.012). In contrast, there was no relationship between the BPI pain 
interference score and IENFD at the ankle (Figure 3C) or proximal thigh (data not 
shown). A weaker correlation (Pearson’s coefficient −0.33; P = 0.04) was also noted 
between CNFL and the “average pain” score of the BPI, whereas no relationship was 
evident with IENFD (data not shown). No correlation was found between IENFD, 
CNFL, or CNFD with the “worst”, “least”, or “now” pain components of the BPI.
Stepwise linear regression analysis including other potential covariates of the BPI 
pain interference score showed that height, weight, and 6 MWT difference from 
expected were also inversely related to the pain interference score. Construction of 
a linear model with CNFL as the dependent variable in addition to weight, height, 
and 6 MWT deficit accurately predicted BPI pain interference (Figure 4; prediction 
formula with a slope of 1; Pearson’s correlation coefficient = −0.78; P < 0.0001).
Figure 4: Corneal nerve fiber length can be used to predict the Brief Pain Inventory pain in-
terference score. A linear model constructed with CNFL as the independent variable, with 
height, weight, and 6 MWT as covariates predicts with high accuracy the BPI interference score 
(Pearson’s correlation coefficient = 0.78, P < 0.0001).
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discussion
The main findings of this study conducted in a population of sarcoidosis patients 
having pain consistent with SFN are two-fold: Corneal nerve fiber quantification 
1) provides the same information as intra-epidermal nerve fiber densities obtained 
from the distal leg and can therefore be used for diagnosis and 2) in contrast to 
IENFD, CCM data is highly predictive of the pain that patients report. Secondary 
results show that the neuropathy documented by the skin biopsies in this population 
is of a length-dependent phenotype. The majority of the patients also appear to 
have involvement of larger nerve fibers based on an elevated vibration detection 
threshold, and in addition most patients show a significant reduction in functional 
exercise capacity, as evaluated by the 6 MWT.
Skin biopsies are an invasive procedure with a significant technical threshold of 
preparation and analysis to overcome. If a follow up biopsy is required, a differ-
ent region of the skin is examined. Additionally, as previously reported in normal 
individuals and in patients with sarcoidosis and neuropathy, age and gender are 
strong covariates of IENFD obtained from the distal leg7,10,27 and thus potentially 
complicate interpretation. These problems could potentially be avoided by utilizing 
CCM-derived corneal nerve fiber data which can be obtained repeatedly from the 
same central location of the eye.
Notably, the pattern of nerve fiber involvement in our patients was not consistent 
with a non-length dependent process as reported by some clinicians2,30. Here, both 
biopsy sites on the leg provided equivalent evidence of reduced nerve fiber densi-
ties, although the values were not significantly correlated. It should be noted that 
in diabetes, characterized by an accepted length-dependent neuropathic process, 
the much shorter corneal nerves also reflect the same pathology as the longer fibers 
innervating distal extremities19. These observations give reassurance that sampling 
corneal nerve fibers alone is sufficient to yield a diagnosis of reduced numbers of 
small nerve fiber in the setting of SFN.
There are currently no data available to explain why the corneal nerve fibers are so 
prominently affected in SFN. One important factor may be the very dense innervation 
of the cornea predominantly by C fibers. The patients in this study were selected in 
part by having pain, a primary function of the C fibers, and it is possible that processes 
that affect these fibers may cause changes more evident against a background of high 
fiber density, such as in the cornea. Another speculative hypothesis is that since there 
is no resident blood supply (corneal metabolism relies on diffusion of oxygen from the 
surrounding tear layer) the small nerve fibers are particularly prone to hypoxic and/
or inflammatory injury, similar to what has been proposed to explain the preferential 
involvement of longer fibers in many neuropathic processes such as diabetes31.
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It is notable that similar to other studies evaluating IENFD, the current study found 
no relationship between IENFD from thigh and ankle biopsies with the pain that 
patients reported. In contrast, there was a strong inverse relationship between 
corneal nerve fiber density and the extent to which the patients reported that pain 
was interfering with the activities of daily living. Current research has identified a 
prominent role for inflammation as an inducer of chronic pain states in the central 
nervous system32. Perhaps the central processes of the ophthalmic nerve are more 
direct participants in a central pain promoting processes, than fibers in the distal 
extremities that synapse centrally in the spinal cord.
The inverse relationship noted between corneal nerve fiber quantification and the 
patient reported outcome of pain interference in this study is potentially useful in 
the clinical assessment of patients reporting pain-related limitations in activities of 
daily living. The linear model that relates the pain interference score with CNFL and 
the additional covariates of height, weight, and performance on the 6 MWT allows 
an objective means by which to corroborate self reported data. Deviations from 
predicted values would alert a clinician to search for a confounding factor, e.g., pain 
reports from a malingerer.
Finally, the patients in this study had a clearly reduced functional capacity as indicated 
by the 6 MWT, in spite of the fact that none of the patients had documented signifi-
cantly reduced cardiopulmonary status. This finding has recently been observed in 
patients with chronic sarcoidosis33. Although the investigators concluded that poor 
muscle strength, fatigue, and exercise intolerance were the primary defect, it is also 
possible that a number also had SFN, as previous studies have shown a high incidence 
of SFN in the chronic sarcoidosis population11. In the present study, the patients were 
selected for having pain as well, and it is also possible that discomfort contributed 
significantly to the observed decrease in function.
One limitation of this study is that only patients with pain were evaluated. It is well 
known that SFN can be present without complaints of pain3 and it remains to be 
determined whether the corneal nerve fibers will reflect the neuropathic process in 
these patients. Additionally, the variable autonomic symptoms that accompany SFN 
often include xerophthalmia, which has been recently shown to be associated with 
a decrease in corneal nerve density34. In spite of these limitations, we anticipate that 
the results of this study showing that CCM-derived nerve fiber data reflect with good 
fidelity that obtained from skin biopsies could apply to other diseases associated 
with SFN.
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Conclusions
Corneal and cutaneous nerve fibers are reduced in the majority of sarcoidosis 
patients selected for pain and symptoms of SFN. The painful symptoms of SFN are 
inversely related to corneal nerve fiber density in this population of patients. CCM 
appears a useful, non-invasive method to quantify nerve density for the diagnosis of 
SFN. Additionally, CCM may prove to be a non-invasive, repeatable method to follow 
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Introduction
Sarcoidosis is an immune-mediated, inflammatory orphan disease of unclear etiology 
that can affect virtually any organ of the body1. In most individuals diagnosed with 
sarcoidosis the disease is mild with pulmonary and hilar lymph node involvement 
that resolves within several years whether treated by immune suppression or not. 
However, in about one third of patients, sarcoidosis evolves into a chronic, progres-
sive disease2. In these refractory cases, therapy has generally consisted of immune 
suppression which has been associated with a variable response rate3.
Recently, it has become apparent that a significant proportion of patients with 
chronic sarcoidosis report symptoms that suggest abnormal function of the small 
nerve fibers of the sensory and autonomic nervous systems4-8. Clinical evaluation by 
skin biopsy, typically of the distal leg, has shown that many of these patients have a 
demonstrable reduction in intraepidermal nerve fibers6,9. The affected nerves consist 
of unmyelinated C and lightly myelinated Aδ fibers that comprise the sensory and 
autonomic peripheral nervous systems. Patients having reduced nerve fiber densi-
ties typically complain of pain, numbness, and/or dysesthesia, as well as autonomic 
symptoms that can be extremely variable depending on the organ affected5. The 
neuropathic symptoms in these patients are frequently severe and therefore are 
major contributors to the poor quality of life of those afflicted10.
The etiology of the loss of small nerve fibers in sarcoidosis has not been definitively 
identified, but one prevalent hypothesis is that nerve fiber dropout is the end result 
of systemic and/or local inflammation11. Neuropathy arising from inflammation can 
affect both the peripheral nerve endings and the neuronal somata within the dorsal 
root ganglia of the spinal cord. At the present time, glucocorticoids and other im-
mune suppressants are the principal therapeutic approach to small fiber neuropathy 
but are often ineffective8. In addition to immune modulators as potential disease 
modifiers, treatment is generally symptomatic, consisting of the analgesics, anti-
epileptics, and antidepressants used for other painful neuropathies12. Thus, there is 
a clear need for new therapeutics in sarcoidosis-associated small fiber neuropathy.
ARA 290 is an eleven amino acid peptide derived from the structure of erythropoi-
etin (EPO) that possesses potent tissue protective and tissue repair activities13. The 
actions of ARA 290 are mediated through a receptor consisting of a complex formed 
by the EPO receptor and beta common receptor subunits14, termed the innate repair 
receptor (IRR). In preclinical models of neuropathic pain, ARA 290 has demonstrated 
beneficial effects that include IRR-dependent prevention of the development of 
allodynia in a peripheral nerve transection model15 or in an inflammatory neuritis 
model16, as well as attenuation of spinal cord inflammation. Also, EPO, and its non-
erythropoietic derivatives, e.g., ARA 290, have been shown to support the regrowth 
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of intra-epidermal nerve fibers in preclinical models of neuropathy arising from 
toxins17 or diabetes18.
An initial open label study of the effects of three intravenous doses of ARA 290 
administered over one week on neuropathic pain of patients with sarcoidosis or 
diabetes showed a 50% improvement without any safety concerns19. The results of 
a follow up trial of ARA 29020 administered intravenously three times weekly for 
4 weeks to sarcoidosis patients with symptoms of small fiber neuropathy also ap-
peared to be safe and was associated with a significant improvement in the patient 
reported outcomes of the small fiber neuropathy screening list (SFNSL21) and the 
pain and well-being components of the RAND-36.
Based on these observations, we have conducted the present study to assess the 
effects of ARA 290 on neuropathic symptoms when given as a daily subcutaneous 
injection for 28 days. Because of the association of nerve fiber loss with neuropathic 
symptoms and the potential for ARA 290 to cause nerve fiber regrowth, we hypoth-
esized that ARA 290 administration will improve symptoms and stimulate the re-
growth of small nerve fibers. To evaluate this, the nerve fiber densities in the cornea, 
proximal thigh, and distal leg were assessed. Additionally, cutaneous sensory testing 
of the face, hand, and foot were determined using quantitative sensory testing, and 
quality of life assessed with appropriate patient questionnaires. Finally, functional 
capacity, which is often reduced in chronic sarcoidosis22, was assessed using the 6 
Minute Walk Test.
Methods
Rationale for dose selection
Results of a previous study performed in sarcoidosis patients with painful small fiber 
neuropathy showed that 2 mg of ARA 290 administered intravenously (IV) three 
times weekly improved neuropathic symptoms. In the current trial we sought to 
assess the potential of subcutaneous (SC) dosing, as the IV is not practicable in the 
outpatient setting. Therefore, a crossover pharmacokinetic study was performed 
using 10 normal volunteers to compare a 2 mg IV dose that was used in the previous 
study, to 2, 4, or 6 mg of ARA 290 administered SC19. Results of preclinical and in 
vitro studies have shown that activation of the IRR requires concentrations of ARA 
290 ≥ ~1 nM (~ 1.3 ng/mL)14. Therefore, the area under the curve (AUC) of the phar-
macokinetic data was calculated using the trapezoidal rule for the period of time 
in which the plasma concentrations were > 1.3 ng/mL. The results of this crossover 
study showed the following median AUCs: 2 mg IV = 65 ng/mL*min, 2 mg SC = 23 ng/
mL*min, 4 mg SC = 59 ng/mL*min and 6 mg = 249 ng/mL*min, with only the 6 mg 
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dose differing significantly from the others (P < 0.05; Kruskal-Wallis test). Based on 
these data, the 4 mg SC group was selected for the daily dosing regimen of this trial.
Study design.
The trial, entitled “Effects of ARA 290 on the regrowth of epidermal nerve fibers in 
patients with sarcoidosis”, was an investigator-initiated, single site, double blind, 
placebo-controlled trial carried out at the Leiden University Medical Center after 
receiving Ethics Committee approval. The trial was registered with the International 
Clinical Trials Registry (NTR3575) and was assigned EudraCT number 2012-001492-37. 
All study personnel and patients remained blinded as to the treatments until the end 
of the follow up period (16 weeks from the beginning of dosing).
The primary outcomes were: 1) change in epidermal or corneal nerve fiber density at 
day 28 versus baseline; 2) change in cutaneous sensitivity of day 28 versus baseline 
using Quantitative Sensory Testing; and 3) change in visual acuity or retinal edema, 
at day 28 versus baseline. Secondary outcomes assessed were: 1) change in the Small 
Fiber Neuropathy Screening List score at day 35 versus baseline; 2) change in Brief 
Pain Inventory at day 35 versus baseline; and 3) change in distance walked in the 6 
Minute Walk Test at day 28 versus baseline.
Patients who satisfied the international consensus statement for diagnosis of sar-
coidosis23 and had symptoms suggestive of neuropathy were recruited after referral 
by sarcoidosis specialists. The Consolidated Standards of Reporting Trials (CONSORT) 
flow chart corresponding to this trial is illustrated in Figure 1. After obtaining in-
formed consent, a total of 38 patients (18 females, 20 males) of mean age 49.5 years 
(range 28-65) satisfying inclusion criteria were enrolled. These patients had a mean 
duration since sarcoidosis diagnosis of 8.4 years. The baseline characteristics of these 
patients with respect to the treatment groups are summarized in Table 1. Although 
all patients were diagnosed as having sarcoidosis, 2 patients also type 2 diabetes 
mellitus, a condition known to also be associated with SNFLD12.
Study inclusion criteria required meeting three thresholds: 1) spontaneous pain level 
(“pain now” of the Brief Pain Inventory) > 5 (scale 0-10); 2) small fiber neuropathy 
screening list score (SFNSL) > 22 (out of 84 possible), or pain < 5 and SFNSL > 37; and 3) 
pain defined as distal extremity pain plus one of the following: dysesthesia, burning/
painful feet worsening at night, or intolerance of sheets/clothes touching the legs 
or feet. Additional inclusion criteria were: age between 18 to 65 years (inclusive), 
a body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and the ability to 
read and understand the written consent form, complete study-related procedures, 
and communicate with the study staff. Exclusion criteria were: abnormal blood pres-
sure, history of alcoholism or illicit drug use, positive pregnancy test, refusal to use 
acceptable contraception throughout the study period (unless surgically sterilized 
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or post-menopausal), vaccination or surgery within the prior 3 months, or use of 
anti-TNF therapy in the prior 6 months.
Safety was assessed by questioning the patient weekly during ARA 290 administra-
tion and throughout the 12 week follow up for the occurrence of adverse events. 
Additionally, the patients were examined at three occasions during the active 
treatment phase of the study: baseline, 2 weeks, and 4 weeks at the end of dos-
ing. Additionally, blood was drawn for routine hematology and chemistry at these 
times points. Finally, serum was obtained for determination of possible anti-ARA 290 
antibodies.
Patient Questionnaires
Questionnaires were administered at the screening visit and then weekly during the 
dosing and follow-up period of 3 months (total 16 weeks). Questionnaire data were 
also obtained approximately 6 months following the end of the follow up period 
(i.e., 9 months from end of dosing) to assess durability of any effects. The Brief Pain 
Inventory Short Form, consisting of pain intensity and pain interference sections, was 
Assessed for eligibility 
(n=111) 
Excluded  (n=70) 
•Not meeting inclusion criteria 
(n=70) 
•Declined to participate (n=0) 
•Other reasons (n=0) 
Analysed  (n=21) 
•Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
•Discontinued intervention (n=0) 
ARA 290 (n=21) 
•Received allocated intervention (n=21) 
•Did not receive allocated intervention 
(n=0) 
Lost to follow-up  (n=0) 
•Discontinued intervention (n=0) 
placebo (n=20) 
•Received allocated intervention (n=18) 
•Did not receive allocated intervention 
(n=2; refused biopsy) 
Analysed  (n=17) 








Figure 1: CONSORT flow diagram.
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administered in the validated Dutch language format. The Small Fiber Neuropathy 
Screen List (SFNSL) is a questionnaire developed specifically in Dutch patients with 
sarcoidosis to assess pain and autonomic dysfunction consistent with small nerve 
fiber loss and damage21. In addition to the total score, the questionnaire was divided 
Table 1. Baseline Patient Characteristics.
ARA 290 (n = 21) Placebo (n = 17)
Years since diagnosis of sarcoidosis (mean ± SEM) 7.1 ± 1.2 9.9 ± 2.4
Concomitant medical treatment n (%)
NSAIDS 5 (23.8) 8 (47.1)
Neurological/psychological drugs 5 (23.8) 6 (35.3)
Oral corticosteroids 6 (28.6) 7 (41.2)
Opioids 6 (28.6) 2 (11.8)
Systemic immune suppressants (methotrexate or 
azathioprine)
7 (33.3) 3 (17.7)
Prior TNF-α antagonist treatment (n = yes) 2 (9.5) 0
SFNSL
Total score 43.9 ± 2.9 42.8 ± 3.2
Autonomic component 20.6 ± 2.0 20.8 ± 1.5
Pain component 23.3 ± 1.2 22.9 ± 1.2
BPI
Mean score (Pain now; range 0-10) 5.0 ± 0.4 5.3 ± 0.5
Pain interference (Maximum 70) 32.1 ± 1.9 36.5 ± 2.9
6 Minute Walk
Test actual (meters) 468 ± 18 479 ± 26
Test predicted (meters)a 700 ± 12 683 ± 15
Nerve Fiber Density
Corneal nerve fiber area (µm2) 1576 ± 94 1304 ± 104
Normal corneal nerve fiber areab 3134 ± 119
Ankle IENFD (number/mm) 5.3 ± 0.5 4.6 ± 0.4
Normal sex and age adjusted ankle IENFDc 9.9 ± 0.3 9.8 ± 0.3
Proximal thigh IENFD (number/mm) 10.8 ± 0.7 11.1 ± 0.9
Normal proximal thigh IENFDd 21.1 ± 0.2 21.0 ± 0.1
Laboratory Markers
High sensitivity C-reactive protein (mg/L) 1.5 ± 0.2 2.9 ± 1.1
Angiotensin converting enzymee 47.4 ± 6.1 53.6 ± 8.0
Number with elevated ACE n (%) 5 (23.8) 6 (35.3)
aPredicted 6 minute walk test was calculated using formula from ref32.
bdata calculated from30.
cNormal sex-age adjusted ankle IENFD is from ref26.




into an autonomic component (questions 2-5, 9, 11-16) and a pain component (ques-
tions 1, 6-8, 17-21) to assess those dimensions of the patients’ neuropathic symptoms.
Quantitative Sensory Testing
Small nerve fiber and large fiber cutaneous sensory function was assessed using 
Quantitative Sensory Testing of the face, hand, and foot using a Medoc Advanced 
Medical Systems TSA-II device (Ramat Yishai, Israel), following the published proto-
col of the German Research Network on Neuropathic Pain24. Normative data was 
Table 2: Results of baseline quantitative sensory testing. Patients in the ARA 290 and placebo 
groups showed functional impairment of both small nerve fibers (Aδ and C) as well as larger 
sensory nerve fibers (Aβ). Data are expressed as number of patients deviating beyond the 95% 
confidence interval of a sex- and age-matched normal population. Test sites of face, hand, 
and foot are pooled for calculation of percentages. “Decrease” indicates a loss of function; 
“Increase” indicates a gain in function compared to a normal population. For example, a de-
creased CDT means that a patient required a lower temperature stimulus than normal to deter-
mine that an object was cold, i.e., a decrease in sensitivity.
Variable Nerve fibers 
involved
ARA 290 (n = 21) Placebo (n = 17)
Change Number of 
patients (%)




Aδ & C Decrease 19 (91) Decrease 11 (65)
Warm detection 
threshold












Aδ Decrease 8 (38) Decrease 7 (41)
Cold pain threshold Aδ & C Increase 3 (14) - 0



























Aβ Increase 11 (52) Increase 3 (18)
Windup ratio Aβ & C Increase 4 (19) Increase 2 (12)
Vibration detection 
threshold
Aβ Decrease 20 (95) Decrease 15 (88)
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obtained from Rolke et al.24. Baseline data for each patient group is summarized in 
Table 2. To arrive at the percentages shown in this table, the three regions tested 
were pooled, i.e., each patient’s data was considered abnormal if the results were 
more than 2 standard deviations from the normative population mean in at least 
one of the locations evaluated.
Skin Biopsy
Skin biopsies were obtained at baseline and after 28 days from the proximal thigh 
(20 cm below the anterior superior iliac spine) and the distal leg (10 cm above the 
lateral malleolus) using a disposable punch biopsy (3 mm) and processed following 
established guidelines25. After fixation of the biopsy specimens, free floating 50 
µm thick sections were cut and stained using rabbit anti-protein gene product 9.5 
antibody (Dako Netherlands BV, Netherlands) and visualized using a goat anti-rabbit 
Alexa fluor 488 antibody (Invitrogen, Life Technologies, Grand Island, NY). A mini-
mum of 3 sections selected from each end and the middle of each biopsy specimen 
were evaluated using a Leica M5500 fluorescence microscope (Leica Microsystems, 
Rijswijk, The Netherlands), at magnification 1000x. The nerve fibers were counted 
manually. Images of the sections were recorded using Leica Application Suite, mag-
nification 400x and the length of the epidermal-dermal junction measured using 
ImageJ (NIH, Bethesda, MD, USA). Sex and age dependent normative data of nerve 
fiber density used for the distal leg were those of Lauria et al.26 and for the thigh 
from Umapathi et al27. All measurements and counting was performed by the same 
individual who was blinded to treatment modality. Technical problems during tissue 
preparation resulted in the loss of 2 placebo biopsies of the lower leg, one ARA 290 
biopsy of the thigh, and three placebo biopsies of the thigh.
Corneal Confocal Microscopy
Corneal nerve fiber density was determined by corneal confocal microscopy carried 
out using the Rostock Cornea Module with the Heidelberg Retina Tomograph III 
using established methodology28. Briefly, following the application of a topical 
anesthetic, the sterile objective of the confocal microscope was placed on the apex 
of the cornea as determined by the characteristic orientation of the nerve fibers in a 
superior-inferior direction. Using the automatic scan feature of the device, confocal 
images of graduated depth in the plane of the cornea were acquired. The field of 
view of each image was 0.4 mm by 0.4 mm. Images containing sensory nerve fibers 
within the sub-basal layer between Bowman’s layer and the basal epithelium were 
further analyzed. Collected images were subjected to automated analysis employing 
a custom macro written for FIJI, a public-domain image analysis program, version 
1.47e29. This macro maps all neurites in the image on the basis of their brightness 
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and tubeness. The area covered by the mapping is then expressed as a percentage 
of total image area. For each patient, the ten images with the highest nerve fiber 
density were averaged to generate a representative sample for that patient for that 
eye. Since the variation between eyes of different patients was similar to the varia-
tion between eyes of individual patients (standard deviation of the mean neurite 
area between patients = 562; standard deviation of the difference between eyes 
of individual patients = 501), each eye was treated as an independent sample. The 
automated analysis was validated by comparison of 78 randomly selected images 
in which total neurite length in each image was determined by manually outlining 
individual neurites. Linear regression analysis showed an excellent goodness of fit 
(95% confidence interval of the slope: 0.99 – 1.19; R2 = 0.76; P < 0.0001) between the 
computer-generated nerve fiber area and the manually measured total nerve fiber 
length for each image. Both the automated analyses and the manual measurements 
were performed by a researcher blinded to the treatment modality. The Shapiro-Wilk 
test showed that at baseline the corneal nerve fiber area data were not distributed 
normally, therefore non-parametric statistical analysis was performed to determine 
if a significant treatment effect was observed.
Normative data were calculated from corneal confocal data previously reported30 
obtained from 22 healthy volunteers (M/F: 9/13) age 49 ± 2.7 by determining the 
mathematical relationship between corneal nerve fiber area and corneal nerve fiber 
length. The results showed that a normal corneal nerve fiber area is 3134 ± 119 µm2.
6 Minute Walk Test
The 6 Minute Walk Test (6 MWT), the distance in meters walked in 6 minutes, was 
conducted following American Thoracic Society guideline31. Normal 6 MWT values 
were calculated using the regression equation developed from data obtained from 
a healthy, older normal Dutch population by Troosters et al.32
Ophthalmologic tests
To assess for possible retinal edema, optical coherence tomography was carried out 
to quantitate retinal thickness using the Zeiss CIRRUS1 system that includes norma-
tive values.
Visual acuity was carried out under standard uniform lighting conditions for patients 
wearing corrective lenses, if any, using a SLOAN ETDRS chart and scoring system.
Statistical analysis
Statistical analysis was performed using JMP (SAS, Inc, Cary, NC). Parametric and non-
parametric tests, linear modeling, and analysis of covariance were carried out where 
appropriate. P-values < 0.05 (two tailed) were considered to be significant.
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Results
Safety
No medically significant deviations were noted in the general blood chemistry or 
hematology assessments. There was no pain or local irritation surrounding the site 
of the injection into the upper leg or lower abdomen. No serious adverse events 
were encountered during the dosing period or within the 12 weeks of follow up. 
Three adverse events judged to be moderate were noted in the placebo group that 
resolved spontaneously (diarrhea, irritability, and light-headedness). One patient 
receiving ARA 290 suffered a moderate adverse event consisting of a long term 
weight loss of 14 kg over several months that stabilized thereafter. Verification of 
the patient’s medical history showed that the weight loss began before entering 
the study. The etiology of the weight loss was undetermined and persisted after 
administration of ARA 290 ceased. Multiple, mild adverse events were recorded, all 
of which spontaneously resolved and none were judged by the investigators as likely 
to be associated with administration of the study drug. All doses of ARA 290 were 
administered daily for the full 28 period. One placebo patient suffering from diar-
rhea discontinued dosing for the last week of the study. No anti-ARA 290 antibodies 




The baseline corneal nerve fiber area showed that the patient population exhibited 
about a 50% reduction compared to normal controls (Figure 2; Table 1). Following 
28 days of dosing, the ARA 290 group exhibited a significant increase in the me-
dian nerve fiber area over baseline of 14.5%, corresponding to an absolute median 
increase of 185 µm2 (P = 0.022; Wilcoxon signed rank test). In contrast, the placebo 
group had a non-significant decrease in median nerve fiber area over baseline of 
−5.3% and an absolute median decrease of 64 µm2 (P = 0.462). Figure 2C illustrates 
the corneal nerve density of two normal individuals compared to two ARA 290 pa-
tients who showed the best responses.
Intra-epidermal nerve fibers
Similar to the corneal nerve fiber area, at baseline the mean intra-epidermal nerve 
fiber densities of the proximal and distal leg were significantly reduced by ap-
proximately 50% in both treatment groups, compared to the median of age- and 
sex-matched normal controls (P < 0.0001; Table 1). The mean ratio of IENFD of the 
proximal thigh to the distal leg was 3.9 ± 1.5 SEM, with no patient having a ra-
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tio < 0.9. The patients in this study, therefore, suffered from a peripheral neuropathy 
characterized by a length-dependent loss of epidermal nerve fibers. IENFD of the 
proximal leg was not significantly correlated to that of the distal leg (Pearson’s cor-
relation coefficient = 0.20; P = 0.22).
Following 28 days of dosing, the ARA 290 group exhibited a mean increase in IENFD 
in the distal leg of 0.38 ± 0.48 fibers/mm (7.2% of baseline; P = ns), compared to the 
placebo group with a mean reduction of nerve fiber density of 0.06 ± 0.42 fibers/mm 
1.3% of baseline; P = ns). The thigh IENFD at 28 days showed a mean decrease of 0.49 
± 0.53 fibers/mm for the ARA 290 group (−2.3% of baseline; P = ns) and the placebo 
group had a mean decrease of 1.24 ± 0.88 fibers/mm (−5.7% of baseline; P = ns).
7 
Figure 2: ARA 290 administration is associated with an increase in corneal nerve fiber area. 
Examples of the distribution and density of corneal nerve fibers obtained via corneal confocal 
microscopy performed on two normal individuals A and B (Left panels). Examples of corneal 
nerve density obtained from two sarcoidosis patients show a decreased density at baseline 
(Middle panel: Pre-RX) and an increase when reimaged after 28 days of ARA 290 administration 
(Right panel: Post-RX).
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Cutaneous Sensitivity
Baseline QST data showed that as a group the patients with sarcoidosis and pain-
ful neuropathy exhibited findings consistent with both small fiber (Aδ and C) and 
large fiber (Aβ) dysfunction (Table 2). Most patients exhibited a reduced ability to 
determine cold (CDT; 79% of the study group) or warm temperatures (WDT; 79%), 
and to detect vibratory stimuli (VDT; 92%). Fifty five percent of the patients also 
experienced a reduced ability to detect graded mechanical stimuli elicited by von 
Frey fibers (MDT) or pain caused by graded pin prick (MPT) or to pressure (PPT). 
A minority of patients in each treatment group also exhibited abnormalities in a 
variety of the other sensory modalities tested as summarized in Table 2.
Following 28 days of daily dosing, the cold pain threshold (CPT), hot pain threshold 
(HPT), and the thermal sensory limen (TSL) significantly increased in the ARA 290 
group, as illustrated in Figure 3 which summarizes data obtained from the hand 
testing location. In contrast, there were no changes noted in the placebo group. 
Figure 3: ARA 290 administration increases the threshold for thermal pain and decreases ther-
mal sensitivity in the hand. The cold pain threshold (CPT), heat pain threshold (HPT), and ther-
mal sensitivity limen (TSL) of most patients were within normal limits at baseline (Table 1). 
Following ARA 290 administration, the mean threshold for determining a painful cold 
(P = 0.027; paired t test compared to baseline) or hot (P = 0.032) stimulus increased, whereas 
the placebo group remained unchanged (P = ns). Similarly, the thermal sensory limen (the tem-
perature threshold at which they can discriminate a hot or cold stimulus) increased in the ARA 
290 post exposure (P = 0.008). This decreased thermal sensitivity could correspond to reduced 
symptoms of temperature-induced allodynia. Post ARA 290 treatment, the CPT, HPT, and TSL 
remained within the normal range. The normative means (in oC) for CPT, HPT, and TSL were 9.7 
± 0.5, 44.8 ± 0.2, and 3.0 ± 0.1 respectively. Similar smaller changes were noted for the face, as 
well as a non-significant trend for the foot (data not shown).
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Although a decreased sensitivity was noted for these sensory modalities, the 
population means at baseline and after ARA 290 dosing remained within the normal 
range. Similar, but smaller changes were noted in the face test location, while a non-
significant trend was noted at the foot testing site (data not shown). Additionally, 
the mean cold detection (CDT) and warm detection (WDT) thresholds also decreased 
(i.e., decreased sensitivity) at the hand and face sites, but the changes were not 
quite large enough to be statistically significant (data not shown). No changes were 
observed in any other sensory modality within the QST battery.
Retinal thickness and visual acuity
Baseline average thickness of the macula and central macula, and retinal nerve fibers 
of both eyes were normal in all patients and did not significantly change over the 
28 day observation period (data not shown). Visual acuity at baseline obtained with 
corrective lenses was normal except for one patient in the ARA 290 group (data 
not shown). The visual acuity of this patient, and that of all other patients, did not 
change following ARA 290 exposure.
Secondary Endpoints
Small Fiber Neuropathy Screening List
Baseline scores of the SFNSL developed specifically for sarcoidosis patients showed 
that the treatment groups were very symptomatic and well-matched with mean 
baseline values of 43.9 and 42.8 for the ARA 290 and placebo groups respectively (not 
significantly different; t-test). When evaluated at week 5 (i.e., one week following 
the end of dosing), the ARA 290 group showed a mean reduction in the SFNSL score 
of 12.2 ± 1.9 (median of 13.0; ~ 28% reduction from baseline) compared to 3.8 ± 2.1 
(median 1.0; ~ 9% reduction from baseline) for placebo (difference between groups: 
P = 0.005; t test). Construction of proportional responders curves (Figure 4A) showed 
that the percentage of patients receiving ARA 290 having symptomatic improve-
ment in the SFNSL score was greater than the placebo group at each response level.
For example, 81% of the ARA 290 patients exhibited at least a 2 point improvement 
in the SFNSL score, compared to only 47% if patients within the placebo group. This 
response profile was substantially maintained during 12 week follow up period at 
which time the mean score reduction from baseline for the ARA 290 group was 9.7 
± 1.8 (median 11.0) and for placebo was 4.1 ± 1.9 (median 3.0; difference between 
groups: P = 0.037; t-test), in contrast to no significant change for the placebo group. 
The proportional responder curves at 16 weeks (12 weeks following the end of dos-
ing) were similar to that observed immediately following treatment (Figure 4B). Fol-
low up at 6 months after the study observation period (i.e., 9 months following the 
termination of dosing) was possible for 19/21 of the ARA 290 patients and all of the 
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placebo patients and was notable for a mean SFNSL score of 38.1 ± 3.2 SEM versus 
43.7 ± 3.2, respectively. This represented a significant improvement over baseline for 
the ARA 290 group (5.2 ± 1.9) compared to the placebo group (−0.9 ± 2.0; P = 0.036).
With respect to the autonomic component of the SFNSL, the ARA 290 group dem-
onstrated a significant improvement in the autonomic score when compared to 
the placebo group with mean improvements of 6.0 ± 1.1 and 1.2 ± 1.3 respectively 
(P = 0.009; t-test). These correspond to a 29% change from baseline for the ARA 290 
group compared to a 6% improvement in the placebo group. A significant differ-
ence was observed in the pain component with the ARA 290 group having a mean 
improvement of 6.2 ± 1.1 points (27% of baseline) compared to the placebo group 
with a mean improvement of 2.6 ± 1.3 points (12% of baseline; P = 0.032; t-test).
Brief Pain Inventory
Pain intensity
One week following the last injection (i.e., on day 35), the average Brief Pain 
Inventory pain intensity score was reduced ~ 9% from baseline in both treatment 
groups with a mean decrease of −3.4 (out of a maximum of 40). This represented 
a significant improvement for both the active and placebo arms with respect to 
baseline (P = 0.01; t-test), but with no significant difference between the treatment 
groups. The individual pain intensity scores were notable for a similar reductions in 
A B
Figure 4: Evaluation of efficacy using the Small Fiber Neuropathy Screening List shows a sus-
tained improvement in the ARA 290 treatment group compared to placebo. A: One week fol-
lowing the end of dosing a larger percentage of patients in the ARA 290 group attained a 
specified range of score improvement over a broad range of responses. B: This difference was 
largely maintained at the end of the sixteen weeks of follow-up.
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“most pain” (−1.2; P = 0.003), “average pain” (−1.1; P = 0.004), and “pain now” (−1.0; 
P = 0.03), whereas “least pain” did not change from baseline (−0.2; P = 0.54).
Pain Interference
In contrast to the mean pain intensity scores that were significantly improved in 
both groups by week 5, the mean change in the BPI pain interference score differed 
significantly between the treatment groups by the third week of dosing (P < 0.02; 
Figure 5A). Specifically, while the baseline values of the two groups were not differ-
ent, the ARA 290 group dropped from a mean score of 32.1 ± 2.3 at baseline to 20.6 
± 2.7 by the week following dosing (a 36% reduction from baseline). This compares 
to a change in the placebo group from a baseline of 36.5 ± 2.5 to 30.8 ± 3.1 (a 16% 
change from baseline). Proportional responder analysis (Figure 5B) illustrates that 
the ARA 290 group exhibited about a 20% greater proportion of responders across 
the response spectrum up to an improvement total of 20 points. At the time of 
evaluation 9 months after dosing, 2 patients in the ARA 290 group were lost to fol-
low up. For the remaining patients, the pain interference score did not significantly 
different from the baseline values. Specifically, the ARA 290 group mean was 30.0 ± 
2.2 and the placebo group was 33.9 ± 2.9.
A B
Figure 5: ARA 290 treatment improves the Brief Pain Inventory pain interference score. A: 
Weekly pain interference scores significantly decline over the 4 weeks of daily dosing for the 
ARA 290 compared to the placebo group. X = treatment with either ARA 290 or vehicle. B: A 
proportional responder display illustrates that the ARA 290 group responded to a larger extent 
at all levels of improvement.
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Six minute walk test (6 MWT)
The 6 MWT is a measure of functional exercise capacity. Both groups had approxi-
mately the same baseline 6MWT distance (Table 1), that was significantly less than 
normal. Using a normative prediction formula for a normal population with the 
same approximate age spread32, the patients in this study at baseline exhibited a 
mean reduction of 219 meters (P < 0.0001; 95% confidence interval of −186 to −253 
meters) in the actual distance walked in 6 minutes from a predicted value of 693 
meters. Following 28 days of daily dosing, the 6 MWT showed that the ARA 290 
group increased the distance walked by a mean of 18.7 meters, whereas the placebo 
group’s performance fell by a mean of −15.1 meters (difference between groups: 
P = 0.049; t test). A proportional responder analysis (Figure 6) illustrates that about 
half of the patients in both treatment groups had an improved their 6 minute walk 
distance by up to 12 meters. However, for an increase from greater than 25 meters, 
only 12% in the placebo group improved, compared to 52% of the ARA 290 group. 
Substantial percentages of the ARA 290 group exhibited even larger increases in the 
6 minute walk distance, whereas none of the placebo patients did. A 6 MWT was 
repeated at 9 months following dosing (2 ARA 290 patients and 1 placebo patient 
were lost to follow up). The mean change from baseline in the ARA 290 group was 
8.3 ± 13.3 meters and for placebo was −12.9 ± 13.9, neither of which constituted a 
significant change from baseline (P = ns; t test).
Figure 6: ARA 290 increases the distance patients can walk in 6 minutes. Similar to the results of 
symptom questionnaires, patients receiving ARA 290 performed better at all levels of response 




Sarcoidosis complicated by small fiber neuropathy is a chronic disease character-
ized by the loss of small nerve fibers with associated pain, decreased temperature 
sensitivity, thermal allodynia, and pronounced autonomic dysfunction that severely 
degrades quality of life. All patients included in this trial had painful neuropathic 
symptoms consistent with SFN that were unresponsive to the standard therapies for 
chronic sarcoidosis that they had received and many continued on immune suppres-
sion and symptom-directed therapy throughout the trial.
The principal hypothesis to be tested in this study was whether exposure to ARA 
290, a molecule demonstrating tissue protective, anti-inflammatory, and reparative 
activities in numerous preclinical models, would stimulate nerve fiber regrowth 
with associated improvements in pain and other sensory symptoms, and autonomic 
function. To accomplish this, the trial was designed to focus on the assessment of 
objective endpoints such as small nerve fiber quantification using both skin biopsy 
and corneal confocal microscopy and to relate these findings to semi-objective sen-
sory testing using QST which directly assesses the effects of potential changes in 
cutaneous innervation. The 6 MWT was also included as a simple semi-objective test 
that requires the integration of complex sensory stimuli of the lower limbs and good 
exertion by the patient. Finally, patient reported outcomes were included for sub-
jective assessments of pain and the degree to which pain interfered with activities 
of daily living, as well as symptoms of autonomic dysfunction which could also be 
potentially related to changes in nerve fiber density.
Baseline nerve fiber data from this study have been analyzed30 and these show that 
corneal nerve quantification (density and length) correlates well with the IENFD 
of the distal, but not the proximal lower limb when adjusted for the covariates of 
gender and age. Further, at baseline the corneal nerve fiber density (and length) is 
inversely related to the BPI pain interference score and therefore has relevance for 
the symptoms that the patients report. Previous work performed in patients with 
diabetes has also shown a good correspondence between corneal nerve quantifica-
tion and nerve fiber counts performed in the distal leg33, thereby confirming the 
usefulness of corneal nerve assessment in patients with symptoms of small fiber 
neuropathy.
The results of nerve fiber assessment following 28 days of dosing show that the 
corneal nerve fiber density improved significantly in the ARA 290 group when 
compared to the placebo group at the end of 28 days of dosing. In contrast, no 
change was observed in the IENFD obtained from the proximal thigh, although a 
trend was observed for the distal leg biopsy site. Notably, a recent study carried out 
in a diabetic population has reported positive effects of treatment on corneal nerve 
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fiber density, although over a longer time scale with no change in the skin biopsy 
nerve density of the distal extremity33. In this study, patients with type 1 diabetes 
were followed after curative therapy by pancreas transplantation. Twelve months 
(but not 6 months) after normalization of blood glucose concentrations, a significant 
increase in corneal nerve fiber density was documented, whereas no changes were 
observed in the IENFD of the distal leg or in the results of Quantitative Sensory 
Testing. Additionally, Boyd et al.34 were able to demonstrate a change in skin biopsy 
nerve densities following drug administration. These investigators studied type 2 
diabetic patients with small fiber neuropathy following 12 weeks of administration 
of the anti-epileptic drug topiramate and documented an increase in cutaneous 
nerve fiber length at multiple biopsy sites and in nerve fiber density in the proximal 
leg. It would be of interest to know what assessment of the corneal nerve fibers 
would have shown.
Prior study35 of re-innervation following experimental denervation using capsaicin 
application to the skin of diabetics with neuropathy or normal individuals has shown 
that the natural rate of regrowth of sensory nerve fibers is slow in normal individuals 
and very slow in patients with diabetes. In contrast, regrowth of autonomic fibers 
is appreciably faster (40-50 days to return to baseline density) than sensory fibers 
(140-160 days for normalization)36. Similar experiments have not been performed on 
corneal nerve fibers, but the results of a preclinical model shows that rapid regen-
eration (days to weeks) occurs following mechanical injury37. It is possible that the 
cornea is an especially useful location to evaluate potential nerve regrowth. Corneal 
confocal microscopy has the benefit that it is a non-invasive technique that can be 
repeated many times in the same patient and thus is well-suited for longitudinal 
interventional studies.
As a group, QST showed that the majority of the patients in this study had signifi-
cantly increased cold, warm, and vibratory detection thresholds. For patients with 
sensitivity to cold or heat, this could translate into less pain during activities of daily 
living. Previous study of patients with diabetic neuropathy has reported similar find-
ings in patients that specifically complained of pain38. Since thermal sensory function 
depends upon small fiber function, the admission criterion of neuropathic pain may 
have specifically selected patients that possess a high degree of fiber loss. This pos-
sibility was confirmed by the intra-epidermal and corneal nerve fiber assessments 
that showed a marked reduction in the mean number of small fibers innervating 
cutaneous and corneal sites compared to a normal population.
It is currently unclear what sensory changes may be associated with the axon regen-
eration that occurs during the short time frame of this clinical trial, as the results 
of few relevant studies have been reported. Clinical studies performed using nerve 
growth factor (NGF) show that a single injection into normal individuals produces 
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both mechanical and thermal hypersensitivity at the site of injection which is rapid, 
reaching a maximum by 21 days and 3 days respectively39. Hypersensitivity has been 
observed at injection site in longer term clinical trials with repeated injections car-
ried out on patients with neuropathy, e.g., diabetic polyneuropathy40. As mentioned 
above, no injection site pain was noted following ARA 290 administration in the 
current study. The observation of reduced thermal thresholds associated with ARA 
290 that occur at several sites examined that were remote to the injection site are 
suggestive a predominantly central effect in contrast to the peripheral effect previ-
ously observed for NGF.
On the basis of preclinical work it also appears that changes in responsiveness may 
occur within the time frame of the present clinical study. Tanelian and Scott37 studied 
a rabbit model in which they produced corneal nerve fiber injury by a small punch 
biopsy and subsequently used electrophysiological methods to directly determine 
the behavior of regenerating small nerve fibers to cold stimuli. Their findings docu-
ment electrophysiological changes that returned to normal by 30 days after injury. If 
similar changes occur in patients during the early period of regrowth, we would ex-
pect to observe changes in thermal thresholds to the extent that axon sprouting has 
occurred. However, no assessments were carried out during the period of dosing that 
can provide relevant information. Additionally, the questionnaires administered do 
not provide information that is helpful in determining thermal sensory thresholds. It 
will be important to add these assessments in future trials. However, it is highly likely 
that any changes that might occur in the sensory system as a result of effects of 28 
days of dosing with ARA 290 would not have reached a steady state.
The results of this study show that ARA 290 administration to patients with painful 
small fiber neuropathy is associated with a significant improvement in patient-
reported symptoms, compared to patients receiving placebo, without any evident 
adverse events attributable to the drug. The changes in level of discomfort as assessed 
by the SFNSL following 4 mg ARA 290 administered daily SC was remarkably similar 
to what was observed in the previous blinded trial in which 2 mg ARA 290 was ad-
ministered three times weekly by the IV route20. In the prior trial, approximately 80% 
of the patients in the active arm exhibited some improvement and ~ 40% showed 
improvement of ~ 50% over baseline. In contrast, while about 45% of the patients 
in the placebo arm showed some improvement, only ~ 12% showed a 50% improve-
ment. Daily administration of 4 mg ARA 290 administered subcutaneously was well 
tolerated without any evident adverse effects. Also similar to the previous blinded 
trial, a large proportion of the change in SFNSL score was attributable to questions 
that are relevant to autonomic symptoms. Finally, it is remarkable how sustained the 
response to ARA 290 appears to be. This may reflect the growth of small nerve fibers 
as the corneal confocal nerve fiber data reveals.
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Self-assessment of pain intensity using the BPI showed that similar to the first blinded 
trial20, both groups improved equally, indicating a significant placebo effect on this 
dimension. In contrast, assessment of to what extent the level of pain interfered 
with activities of daily living, mood, and enjoyment of life showed that patients 
that received ARA 290 had an immediate reduction in mean score reaching a nadir 
that was significantly different from placebo by the end of the dosing period. This 
result suggests that ARA 290 is having a complex activity that extends beyond the 
sensation of pain to include effects on activities of daily living.
The 6 minute walk test was originally developed to assess functional exercise capac-
ity (i.e., a measure of the ability to engage in physically demanding activities) in 
patients with chronic cardiopulmonary diseases. Since its introduction, the 6MWT 
has been used to evaluate functional capacity in a wide range of diseases and in 
healthy normal individuals32 and has been used as a means to assess the effects of 
therapeutic interventions. Studies evaluating patients with chronic sarcoidosis have 
observed that about 50% of these patients have a markedly impaired baseline 
6MWT22,41. In the current study, we found that all of the patients had a reduction in 
expected walk distance, some very severe. The reason for the higher prevalence in 
this patient population is not clear, but could arise from the fact that the patients 
were selected for the presence of neuropathic symptoms which involved the feet, 
which could contribute to a poor performance on a walk test due to sensory deficits 
and pain.
At the end of dosing, the ARA 290 group had improved a mean of ~19 meters while 
the placebo group had declined by ~15 meters, about a 4% improvement and 3% 
decrease of baseline respectively. Although only about half of the patients improved 
in both groups (Figure 6), the improvement in distance walked in the 6MWT was 
limited in the placebo group to less than 37 meters, whereas almost one quarter of 
the ARA 290 patients improved the distance walked by up to 75 meters. A minimally 
clinically significant difference (MCSD) has not been established for sarcoidosis pa-
tients with painful neuropathy, but for patients with cardiopulmonary disease, the 
MCSD has been determined to be as low as 25 meters42.
The most prevalent form of SFN occurs in patients with pre-diabetes or diabetes, 
and in this group retinal edema and visual acuity changes are very common. Ad-
ditionally, another major clinical manifestation of chronic sarcoidosis is ocular 
inflammation, especially uveitis that often affects the retina2. Alternatively, a recent 
study has shown that patients with neurosarcoidosis frequently have macular edema 
even in the absence of ocular symptoms43. It was of interest, therefore, to evaluate 
retinal thickness and visual acuity pre- and post-dosing. At baseline, there were no 
significant abnormalities observed in the optical coherence tomographic evaluation 
of either retinal or optic nerve head thickness. Similarly, almost all patients had good 
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visual acuity at baseline. Therefore, retinal abnormalities and visual acuity impair-
ment do not appear to be a common feature of sarcoidosis complicated by SFN.
The patients included in this trial all had longstanding sarcoidosis with mean time of 
diagnosis of 8.3 years. They all had failed existing therapy for neuropathy including 
the use of anti-inflammatory agents (NSAIDs, glucocorticoids, and methotrexate 
principally), as well as anti-epileptics and antidepressants. About 30% of the patients 
were using a variety of these drugs during the conduct of this trial. Due to the small 
numbers of patient studied it is not possible to evaluate synergistic effects with any 
of these agents. It will be interesting to assess for this possibility in future trials with 
ARA 290.
The principal limitations of this study are that only patients with pain were studied 
and these patients did not have known active sarcoid involvement of any other 
organ. Circulating markers of inflammation were not significantly elevated and 
presumptive markers of active sarcoidosis, e.g., angiotensinogen converting enzyme 
levels, where only mildly increased in a minority of patients. Small nerve fiber loss is 
also well known to occur without associated painful symptoms, e.g., in the predia-
betic state44. It will be of interest to determine whether corneal nerve fiber density is 
also abnormal in this patient group.
In conclusion, ARA 290 is the first drug that exhibits the ability to induce small nerve 
fiber regeneration in the cornea without serious side effects, showing a potential 
of true disease modification, not just symptom improvement. In addition, this trial 
design using the combination of objective and subjective endpoints offers insight 
into correlations with patient reported outcomes, and may provide a blueprint for 
superior trial design for future pain studies. Most importantly, the results of this 
study can provide some hope for sarcoidosis patients suffering from small nerve fiber 
loss and damage that ARA 290 could substantially improve their quality of life.
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Neuropathic pain is a disabling disease with a mechanism consisting of several path-
ways that ultimately converge in the development and persistence of pain. Hallmark 
symptoms are tactile and cold allodynia: mechanical and thermal stimuli that are not 
painful in healthy individuals, but that are perceived as painful in patients. Pharma-
cological treatment is often inadequate and coincides with intolerable side effects. 
New treatments are arising that may be able to target neuropathic pain more ef-
ficiently, one of which is the 11-amino acid tissue protective peptide ARA 290. This 
erythropoietin (EPO) derived peptide is devoid of hematopoietic side effects, such as 
the formation of erythrocytes, but it has anti-inflammatory properties and promotes 
cell survival and regeneration of various tissue types, including neuronal tissue. In 
chapters 2 through 4, we employed a spared nerve injury model (SNI) of chronic 
neuropathic pain, suitable for evaluating the effect of ARA 290 on behavioral and 
cellular responses after nerve injury.
In Chapter 2, we elaborated on how to induce the SNI in the rat to generate chronic 
neuropathic pain and how to quantify tactile and cold allodynia by providing a 
stepwise and detailed summary on the surgery and the behavioral tests. In this par-
ticular procedure we accessed the sciatic nerve (the large nerve running in the thigh, 
responsible for motor function and sensibility of the hind limbs) by blunt prepara-
tion, rather than making an incision through the muscle that covers the nerve as 
described in the original article of the model, thereby reducing collateral damage. 
Next, we described how to put this model to use for evaluation of neuropathic 
pain. The quantification of tactile allodynia was described by using a standardized 
method of measuring the withdrawal response to stimulation of the hind paw by 
Semmes-Weinstein monofilaments. Cold allodynia was quantified by assessing the 
withdrawal response to a spray of acetone on the hind paw. We showed that the 
SNI model was able to induce long standing neuropathic pain in the rat, making it 
suitable for evaluating chronic neuropathic pain. Finally, we assessed the effect of 
ARA 290 on neuropathic pain, of which the original results were published as a part 
of the research paper discussed in Chapter 3.
In Chapter 3, we assessed the potential of ARA 290 in the relief of allodynia follow-
ing spared nerve injury. We showed that a 10 day regimen in which 5 administra-
tions of 30 µg/kg ARA 290 were given, followed by a maintenance treatment of 
once per week, starting at 24 hours post lesion provided a long term relief of both 
tactile and cold allodynia when compared to vehicle treated animals (treatment 
effect P < 0.001). This effect was superior to treating animals for 10 days without 
maintenance. Additionally we found that the induction of an unilateral nerve injury 
resulted in the decrease of the applicable force to the contralateral hind paw as 
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well, i.e. tactile allodynia. This effect was attenuated by either regimen of ARA 290 
(P < 0.001). Contra lateral cold allodynia was observed to a small extent. Next, we 
assessed the effect of ARA 290 in mice devoid of the β-common-receptor (βcR), which 
is the receptor that couples with the EPO receptor to establish the tissue protective 
effects of EPO. Mice devoid of the βcR developed both cold and tactile allodynia 
after SNI and treatment with ARA 290 did not provide relief of their neuropathic 
pain. ARA 290 produces long-term relief of allodynia because of activation of the 
βcR. It is argued that relief of neuropathic pain attributable to ARA 290 treatment 
is related to its anti-inflammatory properties, possibly within the central nervous 
system. Because ARA 290, in contrast to erythropoietin, is devoid of hematopoietic 
and cardiovascular side effects, ARA 290 is a promising new drug in the prevention 
of peripheral nerve injury induced neuropathic pain in humans.
In Chapter 4, we established a dose-response curve for ARA 290 for doses 0, 3, 
10, 30 and 60 µg µg/kg. While animals treated with 0 µg/kg ARA 290 showed a 
rapid increase in tactile allodynia following SNI, this was attenuated by treating 
with ARA 290 for the doses 30 (P = 0.049) and 60 µg/kg (P = 0.001), lasting up to 20 
weeks postoperative. The reduction of cold allodynia was significant up to 20 weeks 
postoperative for all tested doses when compared to vehicle (P < 0.05). The effect of 
0, 10 and 30 µg/kg ARA 290 administered on days 1, 3, 6, 8 and 10 on microgliosis 
(Iba-1-immunoreactivity) and astrocytosis (GFAP-immunoreactivity) was investigated 
in animals surviving 2 or 20 weeks following lesion or sham surgery. After 2 weeks 
of survival, a significant microgliosis was observed in the L5 segment of the spinal 
cord of animals treated with 0 µg/kg ARA 290 when compared to sham operated 
(P < 0.05), while animals treated with 10 or 30 µg/kg did not show this microgliosis. 
After 20 weeks of survival, a more widespread and increased microgliosis was ob-
served for animals treated with 0 and 10 µg/kg when compared to sham operated 
animals, indicated by involvement of more spinal cord segments and higher Iba-1-
immunoreactivity. Animals treated with 30 µg/kg did not show increased microgliosis 
when compared (P < 0.05). No difference in GFAP-immunoreactivity was observed. 
The erythropoietin-analogue ARA 290 dose-dependently reduces allodynia and sup-
presses microgliosis in the dorsal horn, which is part of the mechanism of action of 
ARA 290 in producing relief of allodynia following peripheral nerve damage.
The before mentioned effects of ARA 290 closely resemble a more conventional 
drug that has been on the market for over 50 years and has been widely used as an 
anesthetic and analgesic for acute pain: ketamine. In subanesthetic doses, this drug 
has shown to be effective in relieving neuropathic pain with a pharmacodynamic 
effect that exceeds its pharmacokinetic half life. Treatment with ketamine is accom-
panied with psychomimetic side effects, such as psychosis, hallucinations, nausea and 
vomiting. It is unclear, however if the anti-neuropathic pain effect of ketamine is 
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contributed to by ketamine itself, or its active metabolite norketamine. Additionally, 
NMDA receptor antagonists that are devoid of side effects are being developed. In 
Chapter 5, we evaluated three NMDA receptor antagonists in the treatment of acute 
and neuropathic pain, as well as the severity of the side effects, or lack thereof.
In Chapter 5, we evaluated the NMDA receptor antagonists ketamine, norketamine 
and Traxoprodil in a rat model of acute antinociception (paw-withdrawal response 
to heat at increasing doses of drug), and a model of chronic neuropathic pain (spared 
nerve injury). Side effects (typical behavior, activity level) were scored and locomotor 
function of the nerve-injured paw was assessed using computerized gait analysis. In 
the chronic pain model, treatment was given 7 days following surgery, for 3-h on 
5 consecutive days. All three NMDA receptor antagonists caused dose-dependent 
antinociception in the acute pain model and relief of mechanical and cold allodynia 
for 3-6 weeks following treatment in the chronic pain model (P < 0.001). In both tests, 
ketamine was most potent with norketamine 1.5-2-times less potent and Traxoprodil 
5-8 times less potent than ketamine. Nerve-injury caused the inability to use the 
affected paw that did not improve after treatment (ketamine and Traxoprodil) or 
only showed a limited effect (norketamine for all 3 parameters, P < 0.05). Traxoprodil 
but not ketamine or norketamine, showed a clear separation between effect and 
side effect. The observation that Traxoprodil causes relief of chronic pain outlasting 
the treatment period with no side effects during treatment makes it an attractive 
alternative to ketamine in the treatment of chronic neuropathic pain.
Both ARA 290 as the NMDA receptor antagonists ketamine, norketamine and Taxo-
prodil prove to be efficient in relieving both tactile and cold allodynia in the SNI 
model. Additionally, a relatively short treatment paradigm with either type of drugs 
resulted in a long-term relief of allodynia. In Chapter 6, we compared the effects 
of ARA 290 and ketamine on spinal cord expressions of NMDA receptor subunits 
and inflammatory markers. Additionally we assessed the effects on acute and neuro-
pathic pain and side effects in similar treatment regimens in the SNI model in both 
wild-type and βcR-/- mice.
In Chapter 6, the overlapping pathways of ARA 290 and ketamine were examined 
by comparing their effects on the mRNA expression of the NMDA receptor subunits 
NR1, NR2A and NR2B, inflammatory markers Iba-1 (microglia), GFAP (astrocytes) and 
chemokine (C-C motif) ligand 2 (CCL-2). We found that that both ketamine and ARA 
290 exerted similar effects by significantly decreasing NMDA receptor subunit mRNA 
expression, as well as that of microglia, astrocytes and CCL-2, all-important con-
tributors to the development of neuropathic pain. Although the effects of ketamine 
and ARA 290 on neuropathic pain and its molecular mediators suggest a common 
mechanism of action, ARA 290 acts specifically via the innate repair receptor (IRR) 
involved in tissue protection, and has no affinity for the NMDAR. We speculated 
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therefore, that the IRR might be critically involved in the action of ketamine on 
neuropathic pain. To evaluate this, we studied the effects of ketamine and ARA 
290 on acute pain, side effects, and allodynia following a spared nerve injury model 
in mice lacking the β-common receptor (βcR), a structural component of the IRR. 
Ketamine (50 mg/kg) and ARA 290 (30 µg/kg) produced divergent effects on acute 
pain: ketamine produced profound antinociception (P < 0.001 versus vehicle and ARA 
290) accompanied with psychomotor side effects (P < 0.001 versus vehicle and ARA 
290), but ARA 290 did not, in both normal and βcR-/- mice. In contrast, while both 
drugs were antiallodynic in wild-type mice (P = 0.049 and P = 0.03 versus vehicle for 
ketamine and ARA 290, respectively), they had no effect on neuropathic pain in mice 
lacking the βcR. Together, these results show that an intact IRR is required for the 
effective treatment of neuropathic pain with either ketamine or ARA 290, but is not 
involved in ketamine’s analgesic and side effects.
Pain is a subjective outcome that can be measured by numerical rating scales (NRS), 
or questionnaires that address specific modalities correlated to, for instance, small fi-
ber neuropathy (such as the small fiber neuropathy screening list, SFNSL). Due to this 
subjectiveness, however, it is not a fully reliable measurement for diagnosing small 
fiber neuropathy (SFN), due to the inter and intra personal variability. Therefore, 
small fiber neuropathy is being diagnosed by invasive method of intra-epidermal 
nerve fiber density evaluated with (fluorescence) microscopy, which is the gold 
standard for the diagnosis of SFN. The skin, however, is not the only organ that has 
superficial small nerve fibers. The cornea has a high density of small nerve fibers that 
can be evaluated by the non-invasive method of corneal confocal microscopy.
In Chapter 7, we showed that corneal confocal microscopy (CCM) is an objective 
measure for neuropathic pain in sarcoidosis patients with symptoms of SFN that 
correlates to the symptoms patients report. Pain reported by patients with sarcoid-
osis was assessed by the brief pain inventory (BPI) and quantified by quantitative 
sensory testing (QST). The majority (~80%) of sarcoidosis patients showed altered 
(> 2 standard deviations below the mean of healthy individuals) thresholds for all 
thermal thresholds in QST, indicative of SFN. Currently, a definitive diagnosis of SFN 
requires a skin biopsy that demonstrates small nerve fiber loss. However, quantifying 
IENFD in skin biopsies is an invasive, labor-intensive process that has a low sensitiv-
ity for diagnosing SFN and does not correlate with the pain that patients report. 
Alternatively, CCM is a rapid non-invasive clinical ophthalmic technique for in vivo 
imaging of corneal nerve fibers. CCM revealed that the mean corneal nerve fiber 
density (CNFD) and corneal nerve fiber length (CNFL) was significantly decreased 
in sarcoidosis patients when compared to healthy individuals (P < 0.0001 for both 
outcomes). The IENFD was decreased in sarcoidosis patients when compared to 
healthy controls (P < 0.0001). Additionally, we found that both CNFD and CNFL, but 
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not IENFD, had a negative correlation with the pain interference score from the BPI 
(P = 0.0005 and P = 0.012). Finally, a linear model of CNFL as the dependent variable 
accurately predicted BPI interference (P < 0.0001). This technology expands the role 
of CCM as a surrogate marker for both nerve fiber damage and pain in clinical trials 
of novel therapeutics in sarcoid and perhaps other small fiber neuropathies.
Finally, in Chapter 8, we evaluated the effect of ARA 290 on nerve fiber loss and 
corneal nerve fiber density in sarcoidosis patients in a double-blind-randomized 
clinical study. Small nerve fiber loss and damage (SNFLD) is a frequent complication 
of sarcoidosis that is associated with autonomic dysfunction and sensory abnor-
malities, including pain syndromes that severely degrade the quality of life. SNFLD is 
hypothesized to arise from the effects of immune dysregulation, an essential feature 
of sarcoidosis, on the peripheral and central nervous systems. Current therapy of 
sarcoidosis-associated SFNLD consists primarily of immune suppression and symp-
tomatic treatment which, however, is typically unsatisfactory. Here we show that 
28 days of daily subcutaneous administration of ARA 290 in a group of patients 
with documented SNFLD significantly improves neuropathic symptoms. With QST 
we showed that the thermal sensory thresholds (cold pain threshold, P = 0.027 
and heat pain threshold, P = 0.032) and thermal sensitivity (thermal sensory limen, 
P = 0.008) were increased after treatment with ARA 290, while these parameters 
were unchanged after placebo treatment. Patient reported symptoms improved for 
the small fiber neuropathy screening list (SFNSL) that lasted up to 16 weeks after the 
start of treatment (P = 0.037). The brief pain inventory (BPI) also showed improved 
pain management, but the ARA 290 treatment group did not differ from the pla-
cebo treatment group. Notably, the BPI pain interference score differed significantly 
in the third week of dosing between the ARA 290 treatment group and the placebo 
group (P = 0.02). In addition to improved patient-reported symptom based outcomes, 
ARA 290 administration was also associated with a significant increase in corneal 
small nerve fiber density (P = 0.022 for ARA 290 versus P = 0.462 for placebo), and an 
increased exercise capacity as assessed by the 6 minute walk test (6MWT) on the final 
day of dosing (P = 0.049). On the basis of these results and of prior studies, ARA 290 
is a potential disease modifying agent for treatment of sarcoidosis-associated SNFLD.
Conclusion
The data collected in this thesis show that:




• A part of the mechanism of the relief of neuropathic pain of ARA 290 is through 
suppression of microglia in the dorsal horn of the spinal cord
• Astrocytes are not crucial for neuropathic pain states at 2 and 20 weeks postop-
erative
• Ketamine, its active metabolite norketamine and the NR2B selective N-methyl-
D-aspartate receptor antagonist Traxoprodil are effective in relieving both acute 
and neuropathic pain
• The NR2B subunit of the N-methyl-D-aspartate receptor is not involved in the 
induction of side effects by N-methyl-D-aspartate receptor antagonists
• Ketamine and ARA 290 have overlapping pathways in the relief of neuropathic 
pain by suppression of spinal cord inflammation
• The β-common-receptor is pivotal in the treatment of neuropathic pain, but not 
in acute pain
• Sarcoidosis patients have decreased nerve fiber densities in both the epidermis 
and the cornea
• Corneal confocal microscopy, but not intraepidermal nerve fiber density is 
related to patient reported symptoms in sarcoidosis patients with small fiber 
neuropathy
• Treatment of sarcoidosis patients with symptoms of small fiber neuropathy with 
ARA 290 results in improvement of pain related outcomes
• Treatment of sarcoidosis patients with symptoms of small fiber neuropathy with 








Neuropathische pijn is een invaliderende ziekte met een mechanisme dat bestaat 
uit verschillende “pathways”, die uiteindelijk convergeren in het ontstaan en on-
derhouden van pijn. Karakteristieke symptomen zijn tactiele en koude allodynie: 
mechanische en thermale stimuli die niet pijnlijk zijn in gezonde individuen, maar als 
pijnlijk worden door patiënten. Farmacologische behandeling is vaak ontoereikend 
en gaat gepaard met onverdraagbare bijwerkingen. Nieuwe behandelingen worden 
ontwikkeld die neuropathische pijn op een effectievere manier kunnen bestrijden, 
waarvan het uit 11 aminozuren bestaande peptide ARA 290 er een is. Dit peptide 
afgeleid van erythropoietine (EPO) heeft geen hematopoietische bijwerkingen zoals 
de aanmaak van erytrocyten, maar het heeft wel anti-inflammatoire eigenschappen 
en het stimuleert celoverleving en regeneratie van verscheidene soorten weefsel, 
waaronder zenuwweefsel. In hoofdstuk 2 tot en met 4 hebben we het “spared nerve 
injury” voor chronische neuropathische pijn gebruikt om het effect van ARA 290 te 
testen op gedragsmatig en cellulair niveau na zenuw schade.
In Hoofdstuk 2 beschreven we hoe het SNI model te induceren in de rat om zo chro-
nische neuropathische pijn te genereren en tactiele en koude allodynie te kunnen 
kwantificeren door een stapsgewijze gedetailleerde beschrijving te geven van de 
operatie en de gedragsmatige testen. In deze specifieke procedure benaderden we 
de nervus ischiadicus (de grote bovenbeenzenuw die zorgt voor de motoriek en 
het gevoel van de achterpoten) door middel van stompe preparatie in plaats van 
deze te benaderen door een snede te maken in de spier die deze zenuw bedekt, 
zoals beschreven staat in het originele artikel dat dit model beschrijft, waardoor 
bijkomende schade beperkt bleef. Vervolgens beschreven we hoe dit model gebruikt 
kon worden voor het evalueren van neuropathische pijn. Het kwantificeren van 
tactiele allodynie werd beschreven met het gebruik van een gestandaardiseerde me-
thode van het meten van de terugtrekrespons bij stimulatie van de achterpoot met 
Semmes-Weinstein monofilamenten. Koude allodynie werd gekwantificeerd door 
middel van het meten van de terugtrekrespons ten gevolge van een spray aceton op 
de achterpoot. We lieten zien dat het mogelijk was door middel van het SNI model 
om langdurig aanwezige neuropathische te induceren, waardoor dit model geschikt 
was om chronische neuropathische pijn te vervolgen. Tenslotte onderzochten we het 
effect van ARA 290 op neuropathische pijn, de resultaten werden gepubliceerd als 
onderdeel van het onderzoeksartikel beschreven in Hoofdstuk 3.
In Hoofdstuk 3 hebben we de effectiviteit van ARA 290 om allodynie na spared 
nerve injury the verlichten onderzocht. We vonden dat een doseerschema van 10 
dagen waarin 5 toedieningen van 30 µg/kg ARA 290, beginnend 24 uur na de lesie, 
een langdurige verlichting gaf van zowel tactiele als koude allodynie wanneer dit 
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werd vergeleken met een placebo behandeling (behandeleffect P < 0.001). Dit effect 
was superieur vergeleken met een 10-daagse behandeling zonder onderhoudsbe-
handeling. Daarbij vonden we dat het induceren van een unilaterale zenuwlesie 
resulteerde in een afname van de uit te oefenen kracht op de contra laterale ach-
terpoot (tactiele allodynie). Ook dit effect was verminderd door een behandeling 
met ARA 290, hetzij met of zonder onderhoudsdosering (P < 0.001). Contra laterale 
koude allodynie werd niet geobserveerd. Vervolgens bestudeerden we het effect 
van ARA 290 in muizen welke geen β-common-receptor (βcR) hebben, de receptor 
welke koppelt met de EPO receptor om de weefselbeschermende effecten van EPO 
te bewerkstelligen. Muizen zonder de βcR ontwikkelden zowel tactiele als koude 
allodynie na SNI en behandeling met ARA 290 resulteerde niet in de verlichting van 
neuropathische pijn. ARA 290 bewerkstelligt langdurige verlichting van allodynie 
door activatie van de βcR. Het verlichtende effect van ARA 290 zou het effect kun-
nen zijn van de anti-inflammatoire eigenschappen van dit middel, mogelijk binnen 
het centrale zenuwstelsel. Omdat ARA 290, in tegenstelling tot EPO, geen hemato-
poietische en cardiovasculaire bijwerkingen vertoont, is dit een veelbelovend middel 
in de behandeling van perifere neuropathische pijn in mensen.
In Hoofdstuk 4 construeerden we een dosis-respons curve voor de doses 0, 3, 10, 30 
en 60 µg/kg ARA 290. Dieren behandeld met 0 µg/kg ARA 290 vertoonden een snelle 
toename van tactiele allodynie door SNI, dat werd verminderd door behandeling 
met 30 (P = 0.049) en 60 µg/kg (P < 0.001), durend tot tenminste 20 weken na de 
operatie. De reductie van koude allodynie was significant tot temminste 20 weken 
na de operatie voor alle geteste doses (P < 0.05) wanneer vergeleken met 0 µg/kg. 
Het effect van 0, 10 en 30 µg/kg ARA 20- toegediend op dag 1, 3, 6, 8 en 10 op mi-
crogliose (Iba-1-immunoreactiviteit) en astrocytose (GFAP-immunoreactiviteit) werd 
onderzocht in dieren die 2 of 20 weken overleefden na de inductie van de lesie of de 
sham operatie. Na 2 weken overleving was een significante microgliose zichtbaar in 
ruggenmerg segment L5 van dieren doe 0 µg/kg ARA 290 ontvingen (P < 0.05), terwijl 
dieren die behandeld werden met 10 en 30 mg/kg deze microgliose niet toonden. Na 
20 weken van overleving werd een uitgebreider en toegenomen microgliose gezien 
in dieren behandeld met 0 en 10 µg/kg ARA 290 vergeleken met sham geopereerde 
dieren, wat zich openbaarde in een toename van het aantal ruggenmergsegmenten 
dat microgliose vertoonde en een hogere Iba-1-immunoreactiviteit. Dieren behan-
deld met 30 µg/kg ARA 290 vertoonden deze toename van microgliose niet (P < 0.05). 
Er werd geen veranderingen in GFAP-immunoreactiviteit gezien. Het erytropoietine 
analoog ARA 290 verminderde dosisafhankelijk allodynie en microgliose in de dor-
sale hoorn, wat deel is van het werkingsmechanisme van ARA 290 waardoor het 
verlichting van allodynie na perifere zenuwschade bewerkstelligt.
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De eerder genoemde effecten van ARA 290 vertonen een opvallende vergelijking 
met een meer conventioneel middel dat al meer dan 50 jaar op de markt is en uit-
gebreid gebruikt is als anestheticum and als analgeticum voor acute pijn: ketamine. 
In subanesthetische doses is dit middel tevens effectief gebleken in het verlichten 
van neuropathische pijn met een farmacodynamisch profiel dat zicht uitbreid verder 
dan de farmacologische halfwaardetijd. De behandeling van ketamine gaat gepaard 
met psychomimetische bijwerkingen, zoals psychoses, hallucinaties, misselijkheid en 
braken. Het is onduidelijk echter, of aan het anti-neuropathische pijn effect van 
ketamine wordt bijgedragen door ketamine zelf, of het actieve metaboliet nor-
ketamine. NMDA receptor antagonisten die deze bijwerkingen niet vertonen zijn in 
ontwikkeling. In Hoofdstuk 5 hebben we 3 NMDA receptor antagonisten vergeleken 
voor de behandeling van acute en neuropathische pijn, de ernst van de bijwerkingen 
of de afwezigheid van bijwerkingen.
In Hoofdstuk 5 hebben we de NMDA receptor antagonisten ketamine, norketamine 
en Traxoprodil onderzocht in een rat model van acute antinociceptie (terugtrek res-
pons van de poot bij hitte stimulatie bij toenemende doses van het geneesmiddel), 
en een model van chronische neuropathische pijn (spared nerve injury). Bijwerkingen 
(stereotype gedrag en mate van activiteit) werden gescoord en locomotor functie 
van de aangedane poot werd onderzocht met behulp van computergestuurde 
looppatroon analyse. In het chronische pijn model werd de behandeling gestart 7 
dagen na de operatie, 3 uur per dag op 5 opeenvolgende dagen. Alle drie de NMDA 
receptor antagonisten veroorzaakten dosisafhankelijke antinociceptie in het acute 
pijnmodel en verlichting van tactiele en koude allodynie gedurende 3-6 weken na 
de behandeling in het chronische pijnmodel (P < 0.001). In beide testen was ketamine 
het meest potent, met norketamine 1,5-2 maal minder potent en Traxoprodil 5-8 
maal minder potent dan ketamine. De zenuwlesie veroorzaakte een beperking in 
het gebruik van de aangedane poot welke niet verbeterde met behandeling (ke-
tamine en Traxoprodil) of slechts een beperkt effect (norketamine voor alle 3 de 
parameters, P < 0.05). Traxoprodil, maar niet ketamine of norketamine toonde een 
duidelijke scheiding tussen werking en bijwerking. De observatie dat behandeling 
met Traxoprodil leidt tot een periode van verlichting van chronische pijn die langer 
duurt dan de behandelingsperiode zelf, zonder bijwerkingen gedurende de behan-
deling, maakt het een aantrekkelijk alternatief in de behandeling van chronische 
neuropathische pijn.
Zowel ARA 290 als de NMDA receptor antagonisten ketamine, norketamine 
en Traxoprodil hebben getoond effectief te zijn in de verlichting van zowel tac-
tiele als koude allodynie in het SNI model. Een relatief korte behandelperiode met 
beide typen medicatie resulteerde in een langdurige verlichting van allodynie. In 
Hoofdstuk 6 hebben we de effecten van ARA 290 en ketamine op de expressie van 
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NMDA receptor subunits en ontstekingsmarkers vergeleken. We vergeleken tevens 
de effecten op acute en chronische pijn en de bijwerkingen in gelijke behandelings-
schema’s in het SNI model in zowel wild-type als βcR-/- muizen.
In Hoofdstuk 6 onderzochten we de overlappende pathways van ARA 290 and 
ketamine door de effecten op de mRNA expressie van de NMDA receptor subunits 
NR1, NR2A en NR2B, ontstekingsmakers Iba-1 (microglia), GFAP (astrocyten) en 
chemokine (C-C) motif ligand 2 (CCL-2). We vonden dat zowel ketamine als ARA 
290 gelijksoortige effecten bewerkstelligden door zowel significant de expressie van 
mRNA van de NMDA receptor subunits te verminderen als de mRNA expressie van 
microglia, astrocyten en CCL-2, die allen een belangrijke bijdrage leveren aan de 
ontwikkeling van neuropathische pijn. Hoewel de effecten van ketamine en ARA 
290 op neuropathische pijn en diens moleculaire mediatoren de suggestie wekken 
van een gezamenlijk mechanisme, werkt ARA 290 specifiek op de “innate repair 
receptor” (IRR) welke is betrokken bij weefselbescherming en ARA 290 heeft geen 
interactie met de NMDA receptor. We speculeerden eerder dat de IRR belangrijk 
zou kunnen zijn in de werking van ketamine op neuropathische pijn. Om dit te 
onderzoeken hebben we de effecten van ketamine en ARA 290 op acute pijn, bij-
werkingen en allodynie in het SNI model in muizen die de β-common-receptor (βcR) 
missen, een structurele component van de IRR. Ketamine (50 mg/kg) en ARA 290 (30 
µg/kg) hadden divergente effecten op acute pijn. Ketamine zorgde voor duidelijke 
antinociceptie (P < 0.001 vergeleken met placebo en ARA 290) en psychomotore 
bijwerkingen (P < 0.001 vergeleken met placebo en ARA 290), terwijl ARA 290 dit 
niet had, in zowel normale als βcR-/- muizen. In tegenstelling, beide middelen waren 
effectief in het verlichten van allodynie in wildtype muizen (P = 0.049 en P = 0.03 
versus placebo voor respectievelijk ketamine en ARA 290), maar waren niet effectief 
in muizen zonder de βcR. Samengenomen laten deze resultaten zien dat een intacte 
IRR nodig is voor een effectieve behandeling van neuropathische pijn met zowel 
ketamine als ARA 290, maar dat deze receptor niet is betrokken in ketamine’s anal-
getische werking en bijwerkingen.
Pijn is een subjectieve uitkomstmaat die gemeten kan worden met behulp van 
een numerieke score (numerical rating scale, NRS), of vragenlijsten die specifieke 
aspecten kunnen meten die gecorreleerd zijn aan, bijvoorbeeld, kleine vezel neu-
ropathie (zoals de kleine vezel neuropathie screening lijst, SFNSL). Doordat deze 
manieren subjectief zijn, is zo een meting niet volledig betrouwbaar om kleine vezel 
neuropathie (SFN) te diagnosticeren, vanwege de inter- en intrapersoonlijke variabi-
liteit. Daarom wordt de diagnose kleine vezel neuropathie gesteld met de invasieve 
methode van intra-epidermale zenuwvezel dichtheid bepaald met (fluorescentie) 
microscopie, wat de gouden standaard is voor de diagnose van SFN. De huid is echter 
niet het enige orgaan met oppervlakkige kleine zenuwvezels. De cornea heeft een 
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hoge dichtheid van kleine zenuwvezels welke onderzocht kunnen worden met de 
niet-invasieve methode cornea confocale microscopie.
In Hoofdstuk 7 lieten we zien dat cornea confocale microscopie (CCM) een objectieve 
maat is voor neuropathische pijn in sarcoidose patiënten met symptomen van SFN 
dat correleert met de symptomen die de patiënten rapporteren. Pijn gemeld door 
patiënten werd in onderzocht door middel van de “brief pain inventory” (BPI) en 
gekwantificeerd door middel van “quantitative sensory testing” (QST). De meerder-
heid (~80%) van de sarcoidose patiënten vertoonden veranderde (> 2 standaard de-
viaties onder het gemiddelde van gezond individuen) voor alle drempelwaarden van 
de temperatuur drempelwaarden in de QST dat wijst op SFN. Op dit moment is een 
huidbiopt nodig om verlies van zenuwvezels aan te tonen om tot een diagnose van 
SFN te komen. Echter, het kwantificeren van IENFD in huidbiopten is een invasief, 
arbeidsintensief proces dat een lage sensitiviteit heeft om SFN te diagnosticeren en 
niet correleert met de symptomen die door de patiënten gerapporteerd worden. Als 
alternatief is CCM een snelle niet invasieve klinische oogheelkundige techniek voor 
de in vivo beeldvorming van cornea zenuwvezels. CCM toonde dat de gemiddelde 
cornea zenuwvezeldichtheid (CNFD) en cornea zenuwvezel lengte (CNFL) significant 
verminderd waren in sarcoidose patiënten vergeleken met gezonde individuen 
(P < 0.0001 voor beide uitkomstmaten). De IENFD was verminderd in sarcoidose pati-
enten vergeleken met gezonde individuen (P < 0.0001). Daarbij vonden we dat CNFD 
en CNFL, maar niet IENFD, een negatieve correlatie hadden met de pijn interferentie 
score van het BPI (P = 0.0005 en P = 0.012). Tenslotte voorspelde een lineair model 
met de CNFL als afhankelijke variabele accuraat de BPI pijn interferentie (P < 0.0001). 
Deze technologie vergroot de rol van CCM als een surrogaat marker voor zowel 
zenuwvezel schade als pijn in klinische studies van nieuwe therapieën in sarcoidose 
en misschien andere kleine vezel neuropathiën.
Uiteindelijk onderzochten we in Hoofdstuk 8 het effect van ARA 290 op het verlies 
van zenuwvezels en de zenuwvezeldichtheid in de cornea in sarcoidose patiënten 
in een dubbelblind gerandomiseerde klinische studie. Kleine zenuwvezel verlies 
en schade (small nerve fiber loss and damage, SNFLD) is een frequente complicatie 
van sarcoidose welke is geassocieerd met autonome dysfunctie en sensore afwij-
kingen, inclusief pijnsyndromen, die een negatieve invloed hebben op de kwaliteit 
van leven. Van SNFLD wordt gedacht dat dit veroorzaakt door een disregulatie 
van het immuunsysteem, een belangrijke eigenschap van sarcoidose, die hun 
weerslag hebben op het centrale en perifere zenuwstelsel. De huidige therapie van 
sarcoidose-gerelateerde SNFLD bestaat in de eerste plaats uit onderdrukking van het 
zenuwstelsel en symptomatische behandeling, welke vaak niet tot een bevredigend 
resultaat leidt. Hier tonen we dat een behandeling van 28 dagen met een dagelijkse 
dosis van subcutaan ARA 290 significant de neuropathische symptomen verbetert 
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in patiënten met een vastgestelde SNFLD. Met behulp van QST laten we zien dat 
de temperatuur gevoelige detectiegrenzen (detectiegrens voor koude pijn, P = 0.027 
en detectiegrens voor hittepijn, P = 0.032) en de temperatuurgevoelszin (P = 0.008) 
significant werden verbeterd na behandeling met ARA 290, terwijl deze parameters 
niet waren veranderd voor placebo behandeling. Patiënt gemelde symptomen ver-
beterden voor de small fiber neuropathy screening list (SFNSL) welke aanhielden tot 
16 weken na het starten van de behandeling (P = 0.037). De brief pain inventory (BPI) 
toonde tevens een verbetering van de pijn in de met ARA 290 behandelde groep, 
maar dit effect verschilde niet van placebo behandelde groep. De BPI pain inter-
ference score verschilde significant tijdens de derde week van de dosering tussen 
de ARA 290 groep en de placebo groep (P = 0.02). In toevoeging tot de verbeterde 
patiënt gerapporteerde symptoom gebaseerde uitkomstmaten was de behandeling 
van ARA 290 geassocieerd met een toename van de kleine vezel dichtheid in de 
cornea (P = 0.022 voor ARA 290 in vergelijking met P = 0.462 voor placebo) en een 
toegenomen uithoudingsvermogen zoals onderzocht met de 6 minuten looptest 
(6 minute walk test, 6MWT) op de laatste dag van ARA 290 dosering (P = 0.049). 
Gebaseerd op deze resultaten en de resultaten van voorgaande studies blijkt dat 
ARA 290 een potentieel ziekte modificerend medicijn is voor de behandeling van 
sarcoidose geassocieerde SNFLD.
Conclusie
De data verzameld in dit proefschrift laat zien dat
• ARA 290 effectief is in het verlichten van neuropathische pijn na zenuwschade 
en dat dit de β-common-receptor vereist
• Een deel van het mechanisme van het verlichten van neuropathische pijn door 
ARA 290 wordt bewerkstelligd door suppressie van microgliose in de dorsale 
hoorn van het ruggenmerg
• Astrocyten zijn niet cruciaal voor neuropathische pijn op 2 en 20 weken post-
operatief
• Ketamine, de actieve metaboliet norketamine en het NR2B selectieve N-methyl-
D-aspartaat receptor antagonist Traxoprodil zijn effectief in het verlichten van 
acute en neuropathische pijn
• De NR2B subunit van de N-methyl-D-aspartaat receptor is niet betrokken bij de 
inductie van bijwerkingen door N-methyl-D-aspartaat antagonisten
• Ketamine en ARA 290 hebben overlappende pathways in de verlichting van 
neuropathische pijn door suppressie van ruggenmerg inflammatie
177
Samenvatting en conclusie
• De β-common-receptor is essentieel in de behandeling van neuropathische pijn, 
maar niet voor acute pijn.
• Sarcoidose patiënten hebben verminderde zenuwvezeldichtheid in de epidermis 
en de cornea
• Cornea confocaal microscopie, maar niet intra epidermale zenuwvezel dichtheid 
is gerelateerd aan de symptomen die gerapporteerd worden door sarcoidose 
patiënten met kleine vezel neuropathie.
• Behandeling van saroidose patiënten met symptomen van kleine vezel neuropa-
thie met ARA 290 resulteert in verbeterde uitkomsten gerelateerd aan pijn
• Behandeling van saroidose patiënten met symptomen van kleine vezel neuropa-
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